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Abstract 
 
β-dystroglycan is a ubiquitously expressed protein that forms adhesion complexes 
in various cell and tissue types. In skeletal muscle it is part of the dystrophin -
associated glycoprotein complex, which is lost from the sarcolemma in the 
pathology of Duchenne muscular dystrophy, as well as other muscular dystrophies. 
The loss of β-dystroglycan from the surface membrane is a key step in the 
pathology of muscular dystrophies and yet, little is known about the mechanisms 
governing this process. Before, it was thought that β -dystroglycan is held at the 
membrane by scaffolding proteins, but recent findings reported in the literature 
challenge this view. In light of these findings it was hypothesized that the 
phosphorylation of a single residue, tyrosine 890, prompts the internalization of β -
dystroglycan. This process was investigated using H2k
b
 ts-A58 murine skeletal 
myoblasts, an established in vitro model of skeletal muscle satellite cells. The 
internalization of β-dystroglycan from the surface membrane in response to 
tyrosine 890 phosphorylation is described in this thesis. The internalization of β -
dystroglycan appears to be critically dependent on this modification, as the 
unmodified form of the protein remains at the plasma membrane. Tyrosine 890 
phosphorylation is also linked to the monoubiquitylation of β -dystroglycan 
although the exact function of this modification in the internalization process is 
uncertain. An examination of several common endocytic routes reveals no pathway 
for the internalization of β-dystroglycan. These findings are supported by data 
from the Dag1
Y890F/Y890F
: mdx mouse, suggesting that the mechanism described in 
H2k
b
 myoblasts is also present in vivo. These findings have profound implications, 
not only for the understanding of β -dystroglycan, but for the pathology of muscular 
dystrophies and the development of new therapies.  
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1.1.1 The Dystroglycan Subunits 
The dystroglycan gene, DAG1, is evolutionarily conserved across mammals 
(Ibraghimov-Beskrovnaya et al., 1993 ; Yotsumoto et al., 1996) and other phyla of 
the animal kingdom including nematodes (Grisoni  et al., 2002), arthropods 
(Yatsenko et al., 2009) and chordates (Deyst et al., 1995). In mammals, the gene 
comprises two exons separated by a single intron and it is strongly conserved 
between mouse and man (Ibraghimov-Beskrovnaya et al., 1993). The gene encodes 
a single polypeptide that is post-translationally cleaved to form two subunits, α- 
and β-dystroglycan (Ibraghimov-Beskrovnaya et al. 1992 ; Deyst et al., 1995). 
Dystroglycan is ubiquitously expressed in mammalian tissues and together the two 
subunits form a transmembrane adhesion complex (Ibraghimov-Beskrovnaya et al., 
1993 ; Durbeej et al., 1998). α-dystroglycan binds to components of the 
extracellular matrix (ECM): most notably laminin-α1 and –α2 (Ervasti et al., 1993 
; Sunada et al., 1994 ; Durbeej et al., 1999), but also biglycan (Bowe et al., 2000), 
agrin (Deyst et al., 1995 ; Moll et al., 2001), heparin (Gee et al., 1993) and 
perlecan (Peng et al., 1998 ; Hochenester et al., 1999). β -dystroglycan contains a 
single transmembrane domain and binds to both α-dystroglycan (Yoshida et al., 
1994 ; Sciandra et al., 2001) and various cytoskeletal linker proteins (Ervasti et al., 
1993 ; Rybakova et al., 1996 ; Cerecedo et al., 2005 ; Rezniczek et al., 2007 ), via 
an extracellular and an intracellular domain respectively. In this way, the 
dystroglycan subunits mediate a physical link between the internal cytoskeleton of 
cells and the surrounding extracellular milieu. A diagrammatic representation of 
this, as well as an annotated sequence, is shown below. 
 
 
 
 
 
Figure 1: (A) The two subunits of dystroglycan arise from a post -translational 
cleavage event. α-dystroglycan is extracellular and mediates various contacts with 
the extracellular matrix. β-dystroglycan is composed of an ectodomain, a 
transmembrane domain and a cytoplasmic domain, which mediates interactions 
with intracellular proteins. All artwork provided as a generous gift by Sarah 
Palmer. (B) The amino acid sequence of the mature murine β -dystroglycan protein. 
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1.1.2 Dystroglycan is an Essential Adhesion Protein  
In vitro estimates of the interaction between α- and β-dystroglycan predict a Kd of 
approximately 15µM, suggesting that the interaction is weaker and more dynamic 
than expected for two molecules acting as a mechanical anchor for cells (Sciandra 
et al., 2001). However, from in vivo findings it is clear that dystroglycan is a 
component of adhesion complexes (Ervasti et al., 1991 a), and has a critical role in 
the both the development and stability of various tissues.  The deletion of Dag1 
results in embryonic lethality in mice, due to a number of defects (Williamson et 
al., 1997). Although a role for dystroglycan in the correct formation of b asement 
membranes has been proposed (Henry et al., 1998), it is more likely that 
dystroglycan is involved in the clustering and organization of laminins alongside 
the integrins, as is evidenced by findings in chimeric DAG1
-/-
 mice and 
morpholino-treated zebrafish embryos (Cote et al., 1999 ; Cote et al., 2002 ; 
Parsons et al., 2002). The essential role of dystroglycan is even observed in 
invertebrates, with dystroglycan gene deletion causing oocyte arrest in D. 
melanogaster (Yatsenko et al., 2009) and muscle weakness in C. elegans (Grisoni 
et al., 2002).  
Beyond early development, similar scenarios are encountered within various 
tissues where dystroglycan-mediated adhesion is critical  for further development 
and growth. Specific examples include: in the development of specific structures 
within the kidney (Durbeej et al., 1995), in filopodia branching and process 
formation in differentiating oligodendria (Eyermann et al., 2012), in the formation 
of the myelin sheath (Nodari et al., 2008), in the repair of pro state lumenal 
epithelia (Esser et al., 2010), in the formation of the neuromuscular and 
myotendinous junctions in skeletal muscle (Cote et al. 1999, Goody et al., 2012), 
and in the maintenance and survival of muscle fibers (Brown et al., 1999 ; Cote et 
al., 2002 ; Lagenbach et al., 2002 ). Furthermore, alterations in the levels of α - and 
β-dystroglycan are linked to the process of tumourigenesis, with decreased protein 
levels correlating to the emergence of metastasis and reduced chances of patient 
survival (Sgambato et al., 2007 ; Cross et al., 2008 ; Shen et al., 2011 ; Parberry-
Clark et al., 2011). 
Consequently, it is unsurprising to find that few examples of dystroglycan 
mutations are reported in the literature, given the essential nature of this protein  in 
development. A patient with a heterozygous deletion of chromosome 3, which 
encompasses the DAG1 region, presented symptoms that included facial hypotonia, 
oral-motor dyspraxia, mild myopathy and white matter abnormalities (Frost et al., 
2010). However, whether this is specifically due to the observed reduction in 
dystroglycan protein levels (approximately 40%) or the deletion of the 62 protein 
coding genes and 3 miRNAs in this locus is uncertain. Another patient , who 
presents with mild dystrophy and cognitive impairment, has been reported with a 
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homozygous T192M mutation in the DAG1 gene (Hara et al., 2011). In this 
patient, the mutation impaired the glycosylation of α-dystroglycan, preventing 
normal binding to laminin-α2, and mice harboring the equivalent mutation also 
exhibited impaired synaptic plasticity and laminin binding (Hara et al., 2011). 
With this example, one can see both the essential nature of the adhesion mediated 
by dystroglycan, and how strongly the function of this protein is evolutionarily 
conserved. 
 
1.1.3 Dystroglycan in the Dystrophin-associated Glycoprotein 
Complex 
The important effects of dystroglycan adhesion are not mediated by the protein 
alone. Rather, it is the concerted action of a multitude of binding proteins, which 
scaffold around the dystroglycan adhesion axis, that enable the key functionality of 
dystroglycan in a variety of situations. In this way, one can draw an important 
parallel to the multiple effects of adhesion mediated by integrins, which influence 
the many systems of cellular biology through a large interactome (Zaidel-Bar et 
al., 2007 ; Sen et al. 2011). A complete exploration of the multiple dystroglycan 
complexes that have been described to date is beyond the scope of this thesis. 
However, one can draw many useful inferences and a detailed understanding from 
an examination of the best characterized example, the dystrophin -associated 
glycoprotein complex (DGC) (Figure 2). 
Early purifications of the DGC from rabbit skeletal muscle describe a tight 
interaction between the various components. Dystrophin is only dissociated from 
β-dystroglycan by high molar potassium iodide or alkaline treatments, and 
chemical cross-linking experiments strongly suggest the existence of a tightly-
bound complex (Yoshida et al., 1990 ; Ervasti et al. 1991a). The extraction of some 
components by alkaline treatment in the absence of detergent demonstrates that not 
all components of this complex are integral membrane proteins (Ohlendieck et al., 
1991b). However, immunohistochemical staining reveals a strong sarcolemmal 
localization, despite not all components being present within the membrane, 
furthering the argument for a tightly bound complex (Ervasti et al. 1991 b). 
Detergent treatment of the purified DGC with n-octyl β-D-glucoside separates the 
components into subcomplexes, but the persistence of these sub -complexes 
reiterates the notion of a complex held together by strong intermolecular forces 
(Yoshida et al., 1994). Twenty years after these pioneering experiments, it is now 
possible to describe a more precise model of the DGC and the protein interactions 
responsible in the formation of this complex, and it is this that is explored next.  
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Figure 2: A diagrammatic representation of the dystrophin-associated glycoprotein 
complex. With dystroglycan at the core, the various components of the DGC 
enable a mechanical link between the ECM and the cell cytoskeleton, in addition to 
scaffolding numerous signalling proteins. Note that the organiza tion and 
stoichiometry of the complex is not exactly as shown, owing to the variable nature 
of binding by the α-dystrobrevins and syntrophins. In addition, the syntrophins 
may scaffold any of the associated binding partners at any part of the complex; the 
organization depicted above is merely for simplicity.  All artwork provided as a 
generous gift by Sarah Palmer. 
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As is summarized in Figure 2, the recruitment of the many proteins associated with 
this complex is enabled via interactions with the cytoplasmic domain of β -
dystroglycan. The cytoplasmic domain of β -dystroglycan contains several protein-
protein interaction motifs and has a high polyproline content (see Figure 1).  The 
flexibility of this domain enables the binding of a wide range of proteins and 
indeed, numerous examples exist in the literature of this versatility (Yang et al., 
1995a ; Huang et al., 2000 ; James et al., 2000 ; Illsey et al., 2001 ; Zhan et al., 
2005 ; Batchelor et al., 2006 ; Higginson et al., 2008). This binding system is 
analogous to, and even shares components with, the interactome centred around the 
cytoplasmic tails of the integrins (Zovein et al., 2010). In the case of the DGC, the 
majority of interactions are mediated by the sarcoglycans and dystrophin, which 
recruits several key proteins. However, one should note that in other complexes, 
and particularly in other tissues where these proteins are not expressed, this is not 
always the case. Hence, either directly, or through additional factors, the 
cytoplasmic domain of β-dystroglycan scaffolds numerous proteins. It is these 
numerous proteins that the text now describes in detail.  
Dystrophin was first identified as the gene that is mutated in Duchenne and Becker 
muscular dystrophies, and the full-length form of this gene is expressed in skeletal 
and cardiac muscle only (Kingston et al., 1984 ; Hoffman et al., 1987 ; Koenig et 
al., 1987). Dystrophin is part of the spectrin family of proteins, which arose from a 
common α-actinin ancestor, and, like the other members of this family, it is 
comprised of an N-terminal actin binding domain, a rod domain (comprised of 24 
spectrin-like repeats), a cysteine-rich domain and a C-terminal domain (Hammonds 
et al., 1987 ; Koenig et al., 1988 ; Hoffman et al., 1989 ; Koenig et al., 1990). The 
N-terminal actin-binding domain provides a physical link to the actin cytoskeleton 
(Ervasti et al., 1993 ; Corrado et al., 1994 ; Rybakova et al., 1996 ; Rybakova et 
al., 2000), whereas the cysteine-rich and C-terminal domains mediate binding to β -
dystroglycan via an atypical WW domain interaction (Suzuki et al. 1992 ; Suzuki 
et al., 1994 ; Jung et al., 1995 ; Rentschler et al., 1999). Owing to the high 
homology to α-actinin, it was initially proposed that dystrophin functions as an 
anti-parallel dimer, but subsequent studies have suggested that it is more likely 
that dystrophin functions as a monomer (Hammonds et al., 1987 ; Rybakova et al., 
1996 ; Thomas et al., 1997). Whilst dystrophin is a minor component of s keletal 
muscle tissue, it is exclusively present at the sarcolemma, where, through 
dystroglycan, it mediates a physical link between the ECM and the costameric 
actin cytoskeleton (Ohlendieck et al., 1991 b ; Ervasti et al., 1993 ; Rybakova et al., 
2000). 
Early purifications of dystrophin identified the presence of several proteins that 
co-elute with dystrophin and form a strongly associated complex (Yoshida et al., 
1990 ; Ervasti et al., 1990 ; Ervasti et al., 1991b ; Matsumara et al., 1992a). This 
complex can be divided into what would be later identified as the dys troglycan and 
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sarcoglycan sub-complexes, which are membranous, as well as several other 
intracellular proteins (Ervasti et al., 1991a ; Roberds et al., 1993a ; Yoshida et al., 
1994 ; Lim et al., 1995). The sarcoglycan complex (SGC) is comprised of four 
subunits in skeletal muscle: α-, β-, γ- and δ-sarcoglycan (Roberds et al., 1994 ; 
Nigro et al., 1995 ; Lim et al., 1995 ; McNally et al., 1996). These four subunits 
are strongly associated and, whilst these proteins are expressed from separate 
genes and are processed independently, the loss of one subunit results in the 
complete loss of all subunits from the sarcolemma (Jung et al., 1996 ; Duclos et 
al., 1998 ; Holt et al., 1998a ; Araishi et al., 1999 ; Hack et al., 1999). The SGC 
can be thought of as having two distinct, although not exclusive , functions. The 
first function of the SGC is to strengthen the association of α - and β-dystroglycan 
with the DGC, potentially through electrostatic interactions (Roberds et al., 1993b ; 
Metzinger et al., 1997 ; Duclos et al., 1998 ; Holt et al., 1998 b ; Araishi et al., 1999 
; Yoshida et al., 2000 ; Matsumara et al., 2005). The second function of the SGC is 
to provide a scaffold for sarcospan and the α -dystrobrevins. 
Sarcospan co-purifies with the DGC and is expressed as either a full -length 
isoform in skeletal and cardiac muscle, or as a truncated isoform in other tissues 
(Crosbie et al. 1997). Upon dissociation of the DGC, sarcospan specifically co -
sediments with the SGC due to direct binding to the subunits of this complex 
(Araishi et al., 1999 ; Crobie et al., 1999 ; Miller et al., 2007). Sarcospan has a 
high degree of sequence similarity to the tetraspannin proteins and, like the 
tetraspannins,  sarcospan oligomerizes and exhibits a membranous localization 
(Crosbie et al., 1997 ; Miller et al., 2007). Owing to the similarity to tetraspannins, 
it is postulated that sarcospan oligomers promote the clustering of DGCs, leading 
to the formation of membrane micro-domains and signalling platforms (Miller et 
al., 2007). In support of this, there is a growing body of evidence to suggest that 
sarcospan levels modulate Akt signalling, although exactly how this occurs is 
currently unclear (Marshall et al., 2012 a ; Marshall et al., 2012b). In a similar vein, 
the α-dystrobrevins can bind to the SGC and regulate the signalling capabilities of 
the DGC (Metzinger et al., 1997 ; Yoshida et al., 2000). 
The α-dystrobrevin gene was originally identified by its sequence homology with 
an 87kDa post-synaptic protein isolated from T. Californica, and this gene has a 
similar gene organization to dystrophin, despite a low level of sequence similarity 
(Blake et al., 1996 ; Ambrose et al., 1997). Three different protein isoforms, 
termed α-dystrobrevin 1-3, arise from a single transcript in skeletal muscle , which 
is post-transcriptionally regulated (Ambrose et al., 1997). Indeed, the sequence of 
the α-dystrobrevins is further modified by additional alternative splicing events 
and the removal of variable regions (Ambrose et al. 1997), and transcripts from the 
skeletal muscle promoter undergo both developmental and spatial regulation 
(Newey et al., 2001). All 3 isoforms are expressed in skeletal muscle, but only α-
dystrobrevin-3 is skeletal muscle specific (Nawrotzki et al., 1998). α -dystrobrevin-
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1 and -2 contain dystrophin binding sites and are thought to bind to dystrophin, 
whereas α-dystrobrevin-3 lacks this site and is proposed to bind to the SGC 
(Nawrotzki et al., 1998 ; Yoshida et al., 2000). The α-dystrobrevins, along with 
dystrophin, recruit the syntrophins to the DGC, the signalling function of which is 
described below. All three α-dystrobrevins contain a constitutive syntrophin 
binding site, but α-dystrobrevin-1 and -2 can also contain an additional syntrophin 
binding site as a result of further alternative splicing (Newey et al., 2000 a). This 
exquisite regulation permits the fine alteration of the signalling capabilities of the 
DGC, as and where it is required. A notable example of the essential role of α-
dystrobrevins is in the maturation of, but not the formation of, the neuromuscular 
junction in skeletal muscle (Grady et al., 2000). 
The syntrophins are PDZ-containing proteins which, through interactions with 
dystrophin and the dystrobrevins, recruit a multitude of signalling molecules to the 
DGC. The three syntrophins, α-, β1- and β2-syntrophin are encoded by three 
separate genes (Adams et al., 1993). Multiple sites within the C-terminus of 
dystrophin bind the syntrophins in vitro (Yang et al., 1995 ; Suzuki et al., 1995) 
and, as stated above, the dystrobrevins also have constitutive and alternatively 
spliced syntrophin binding sites (Yang et al., 1995 ; Newey et al., 2000 a). The 
importance of these interactions is underlined by the loss of syntrophin staining at 
the sarcolemma when the dystrophin binding site is lost (Roberts et al., 1992), or 
in α-dystrobrevin null mice (Grady et al., 2000). The syntrophins are proposed to 
bind to a wide range of signalling and scaffolding molecules including nitric oxide 
synthase (Brenman et al. 1996), sodium and potassium channels (Gee et al., 1998), 
the microtubule associated serine/threonine kinase (MAST), (Lumeng et al., 1999) 
and Grb2 (Oak et al., 2001). That these interactions are functionally important is 
evidenced by reports of dystrophic patients with deletions in the syntrophin genes 
(Roberts et al., 1992). Hence, the syntrophins permit the association of signalling 
molecules with the DGC with important functions beyond adhesion alone. 
Finally, there are additional proteins that, despite not co-purifying with the 
complex in earlier studies (Ervasti et al., 1990), have been shown to interact with 
members of the complex and are considered to be part of the functional complex. 
Neural nitric oxide synthase (nNOS) can associate with the DGC via the 
syntrophins, or via dystrophin, and is thought to regulate calcium homeostasis and 
the hypertrophic response (Lai et al., 2009 ; Ito et al., 2013 b ; Lai et al., 2013). 
Syncoilin, a protein associated with intermediate filaments, interacts with α -
dystrobrevin-1, extending the adhesive capability of the DGC beyond the actin 
cytoskeleton (Newey et al., 2001). In addition, various kinases associate with the 
DGC and are regulated through this interaction (Lagenbach et al., 2002 ; Spence et 
al., 2004 ; Batchelor et al., 2006). Hence, the function of the DGC extends beyond 
an immediate, mechanical link to the actin cytoskeleton, to a complex with links to 
various components of cell adhesion and signalling. 
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Hence, from the example of a single complex involving dystroglycan, one can 
draw several important inferences. Whilst adhesion is critically dependent on α- 
and β-dystroglycan, cytoskeletal linkers, such as dystrophin and syncoilin, enable 
full linkage between the internal and external environments. Sub-complexes, in 
this example the SGC and sarcospan, strengthen the adhesive capability of 
dystroglycan whilst defining the membrane microdomain. Signalling adaptor 
proteins, chiefly the dystrobrevins and syntrophins, control the number and types 
of signalling molecules and ion channels associated with the complex. Finally,  
additional proteins, with perhaps more transient interactions, extend the 
functionality of the DGC even further. Whilst the proteins specifically associated 
with dystroglycan in complexes vary between tissues, and even specific membrane 
domains (for example, the NMJ in skeletal muscle fibres), the se general features of 
complexes involving dystroglycan are the same. However, an understanding of the 
sarcomeric complex alone does not adequately describe why dystroglycan is so 
essential in development. Therefore, it is necessary to briefly examine the protein 
in the context of other tissues and complexes. 
 
1.1.4 Dystroglycan in Other Complexes 
The utrophin-associated glycoprotein complex (UGC), which is one example of an 
“other” dystroglycan complex,  is similar to the DGC in organization, but the 
cytoskeletal linker protein in this case is utrophin.  This complex is found in both 
skeletal muscle and other tissues (Thi Man et al., 1995 ; Deconinck et al., 1997 a ; 
Durbeej et al., 1999).  Utrophin has a high level of amino acid homology and 
similar gene structure to dystrophin, and therefore it is predicted that utrophin 
arose due to gene duplication before vertebrate radiation (Pearce et al., 1993). 
Utrophin has a widespread tissue distribution and is up-regulated during the earlier 
stages of mammalian development (Khurana et al., 1990). Utrophin is also  up-
regulated in necrotic and regenerating muscle fibres (Takemitsu et al., 1991), but 
upon maturation of the muscle fibre and expression of dystrophin, the expression 
of utrophin is normally restricted to NMJs and myotendinous junctions (MTJs) 
(Khurana et al., 1991 ; Gramolini et al., 1997 ; Gramolini et al., 1998). Agrin, 
which is a ligand of α-dystroglycan and defines NMJs (through acetylcholine 
receptor clustering), also induces the expression of utrophin , thus allowing site-
specific expression (Cohen et al., 1997 ; Gramolini et al., 1998 ; Gramolini et al., 
1999).  
Functionally, utrophin is comparable to dystrophin: the N-terminal domain is also 
responsible for actin binding (Winder et al., 1995) and a similar region binds to β -
dystroglycan (Chung et al., 1999 ; James et al., 2000). Indeed, the similar nature of 
the two proteins is verified by the fact that increased utrophin expression can 
compensate for the loss of dystrophin (Tinsley et al., 1996 ; Tinsley et al., 1998 ; 
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Rafael et al., 1998). However, two important distinctions should be drawn between 
the two proteins. First, utrophin does not have the same essential nature as 
dystrophin: utrophin-null mice exhibit no severe developmental defects and exhibit 
only small changes to the structure of tissues (Deconinck et al., 1997a). Second, 
the promoter region of utrophin is altered with respect to dystrophin: a CpG island 
permits constitutive expression (Pearce et al., 1993) and an N-box motif boosts 
expression in response to factors downstream of agrin and heregulin, such as the 
transcription factor AP-1 (Gramolini et al., 1998 ; Gramolini et al., 1999).  Thus, 
utrophin is expressed in a wide variety of tissues, whereas dystrophin expression is 
restricted by promoter elements specific for skeletal and cardiac muscle tissue. 
The UGC is also found in tissues other than skeletal muscle and involves 
homologues of the proteins involved in the DGC, which also do not show skeletal 
muscle specific expression. The presence of a UGC, containing utrophin and 
dystroglycan, has been reported in kidney cell lines and epithelia (Kachinsky et al., 
1999 ; Durbeej et al., 1999), as well as in the myelin sheath of the peripheral 
nervous system (Matsumara et al., 1993). Interestingly, in the case of the complex 
present in lung smooth muscle, the presence of a sarcoglycan sub-complex is 
observed that is associated with the UGC (Durbeej et al., 1999). In this instance, ε -
sarcoglycan, the ubiquitously expressed homolog of α -sarcoglycan, functions in 
place of α-sarcoglycan (Ettinger et al., 1997 ; McNally et al., 1998 ; Durbeej et al., 
1999 ; Imamura et al., 2005). Indeed, other components of the UGCs, which are 
not expressed in skeletal muscle, substitute for the factors in the DGC described 
earlier. For example, ζ-sarcoglycan replaces γ-sarcoglycan (Shiga et al., 2006) and 
β-dystrobrevin replaces the α-dystrobrevins (Blake et al., 1998). Like dystrophin 
and utrophin within the muscle fibre, the presence of complexes involving these 
homologues within a tissue is not mutually exclusive, as evidence by the presence 
of complexes  containing α- and β-dystrobrevin  in renal endothelial and epithelial 
cells respectively (Loh et al., 2000).  The differences in the composition of these 
complexes are likely to reflect specific , local requirements different from that of 
the costameric DGC in skeletal muscle. In support of this  idea, a differential 
association of the syntrophins is observed in the various complexes containing α - 
or β-dystrobrevin in kidney tissue (Loh et al., 2000).  
Interestingly, there are several reports in the literature of dystroglycan complexes 
without the presence of a cytoskeletal linker, such as full -length utrophin or 
dystrophin. In some cases this is due to the expression of apo -dystrophins, 
transcripts from the dystrophin gene generated by alternative splicing or 
transcription initiation sites (Blake et al., 1992 ; Tinsley et al., 1993 ; Schofield et 
al., 1994). These apo-dystrophins lack the N-terminal actin binding domain, but 
can bind both β-dystroglycan and the other members of the complex. Therefore, 
complexes involving apo-dystrophins are thought to have signalling and 
developmental roles, as full adhesion is not possible (Matsumara et al., 1993 ; 
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Schofield et al. 1994 ; Loh et al., 2000 ; Cerecedo et al.,  2005 ;  Judge et al., 
2006). Interestingly, there are no apo-utrophins (Man et al., 1995), although an 
evolutionarily conserved homologue of utrophin and dystrophin, dystrophin related 
protein 2 (Drp2) has been identified (Roberts et al., 1996). Despite h aving a low 
homology to utrophin and dystrophin, Drp2  forms a complex with dystroglycan 
and periaxin in the peripheral nervous system, which is involved in Cajal band 
formation and myelination (Sherman et al., 2012). Finally, there are reports in the 
literature of membranous dystroglycan complexes formed in the absence of 
dystrophin, the dystrophin homologues or apo-dystrophins (Matsumara et al., 
1992a ; Deconinck et al., 1997b ; Durbeej et al., 1999). In these instances, other or 
unknown cytoskeletal linkers may bind β-dystroglycan, such as plectin 1f 
(Rezniczek et al., 2007). These complexes may also contain other, unknown 
associated proteins, permitting further, diverse functions for the adhesion complex. 
Indeed, the presence of dystroglycan in adhesive structures and other regions of 
the cell, distinct from that of the costameric DGC of surface membranes, have been 
reported in multiple systems. This is made possible by the binding of proteins that 
are not part of the α-actinin family. For example, the cytoplasmic tail of β-
dystroglycan can also bind to Grb2 in vivo and the proposed binding site overlaps 
with that of dystrophin (Yang et al., 1995 b ; Russo et al., 2000). However, the 
estimated Kd of the Grb2 interaction is higher than that of dystrophin  and utrophin, 
suggesting that only non-DGC β-dystroglycan would form this complex (Russo et 
al., 2000). Nonetheless, the presence of β -dystroglycan in a functional complex 
with Grb2 and dynamin in cortactin-positive membrane ruffles has been 
demonstrated (Zhan et al., 2005). β-dystroglycan has also been reported in 
complexes with ezrin in both filopodia and the cleavage furrow (Cerecedo et al., 
2005 ; Batchelor et al., 2007 ; Higginson et al., 2008), and with Tsk5 in podosomes 
(Thompson et al., 2008), where β-dystroglycan is proposed to scaffold additional 
factors required for the specific function of these structures. In the case of focal 
adhesions, it has been observed that β -dystroglycan is not only present in these 
structures, but binds and recruits components associated with integrin-mediated 
adhesion (Kramarcy et al., 1990 ; Yoshida et al. 1998 ; Thompson et al., 2008). 
That there is synergy between the two systems of adhesion involving integrins and 
dystroglycan is confirmed by the modulation of adhesion to fibronectin (an 
integrin ligand) in response to dystroglycan levels, and the reciprocal regulation 
between dystroglycan and integrin expression (Brown et al. 2004 ; Thompson et 
al., 2010 ; Liu et al., 2011). Furthermore, dystroglycan is observed in , or is 
proposed to form complexes with, components of various signalling pathways 
including: RhoA and Rac1 (Chockalingam et al., 2002 ; Oak et al., 2003), ERK and 
MAPK (Spence et al., 2004), c-Src (Sotgia et al., 2001), FAK (Yoshida et al., 1998 
; Thompson et al., 2008) and Pak1 (Oak et al., 2003). Hence, through the many 
potential interacting partners of β -dystroglycan, dystroglycan can be involved in a 
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wide range of complexes with differing signalling capabilities, beyond those 
defined by the presence of dystrophin or related proteins thereof. 
 
1.1.5 Dystroglycan Complex Formation in Response to the 
Extracellular Matrix 
Shifting the focus from the interactions of the cytoplasmic domain of β -
dystroglycan, one finds an additional layer of complexity and regu lation in 
dystroglycan complexes from the interactions between α-dystroglycan and 
components of the ECM. The mature α-dystroglycan protein is extensively 
glycosylated and this glycosylation is essential for ligand binding (Ervasti et al., 
1991a ; Gee et al., 1993 ; Sunada et al., 1994). Disrupting the glycosylation of α -
dystroglycan in mice produces a dystrophic phenotype, due to impaired laminin -α2 
binding (Grewal et al., 2001). Whilst the dystrophic phenotype may have a 
mechanical basis, due to the loss of linkage between the actin cytoskeleton and the 
ECM, studies on cell lines suggest this may also have a signalling basis. The 
blockade of laminin-α2 binding by α-dystroglycan leads to an increased apoptosis 
of myotubes, due to decreased anti-apoptotic signalling via the Akt pathway 
(Lagenbach et al. 2002). Furthermore, blockade of the same interaction in 
myoblasts negatively impacts the differentiation process, resulting in reduced 
myotube size, myofibril disorganization and the loss of contractile activity (Brown 
et al., 1999). Conversely, engagement of laminin-α2 is proposed to have an 
inhibitory effect on ERK-MAPK signalling, due to the sequestering of MEK2 by β-
dystroglycan (Spence et al., 2004). In these examples one sees a situation 
reminiscent of the “outside-in” signalling mediated by integrins: binding to the 
extracellular α-dystroglycan directly changes the partners bound by the 
cytoplasmic domain of β-dystroglycan, which affects the maturation, survival and 
signalling pathways of muscle tissue. 
A better characterized example of this phenomenon is found in the agrin -dependent 
formation of NMJs. Treatment of muscle cultures with agrin causes a redistri bution 
and clustering of acetylcholine receptors and UGCs, which is dependent on 
tyrosine phosphorylation (Cohen et al., 1997). In addition to binding α -
dystroglycan, agrin stimulates the activation of MuSK and transcription of 
utrophin from nearby myonuclei (Nawrotzki et al., 1998 ; Gramolini et al., 1998). 
Furthermore, agrin treatment also promotes the recruitment of α-dystrobrevin-1 to 
NMJs, and α-dystrobrevin-1 co-immunoprecipitates with utrophin, suggesting that 
these proteins exist in a specialized, agrin-defined UGC (Nawrotzki et al., 1998). 
The recruitment of α-dystrobrevin-1 is dependent on tyrosine phosphorylation, like 
the clustering of UGCs (Cohen et al., 1997 ; Nawrotzki et al., 1998), and in the 
absence of α-dystrobrevin-1 acetylcholine receptor clusters fragment upon removal 
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of agrin (Grady et al., 2000). Here, the “outside -in” signalling is extended by a 
subsequent “inside-out” signalling event: agrin treatment specifies the type of 
dystroglycan complex present at nascent NMJs, but the presence of components of 
these dystroglycan complexes are required for further maturation of the synapse.  
Returning to the glycosylation of α-dystroglycan, one can find further examples of 
how subtle changes to the ligand binding capacity of this prot ein impacts the 
formation of dystroglycan complexes. The binding of biglycan by α -dystroglycan 
is dependent on the presence of chondrotin sulphate linkages (Bowe et al., 2000), 
and results in the formation of complexes containing utrophin, β2 -syntrophin, and 
nNOS (Mercardo et al., 2006 ; Amenta et al., 2011). These findings may be 
criticised on the basis that it is equally plausible that biglycan is exerting these 
effects on dystroglycan complex formation via another membranous receptor , and 
that biglycan being an α-dystroglycan ligand is purely coincidental. Nonetheless, 
assuming that the same kind of process is occurring as is found in the more defined 
pathways of agrin and NMJ formation, one can conclude that biglycan also 
influences the formation of dystroglycan complexes.  In addition, a minor 
glycoform of α-dystroglycan, which only binds to β-dystroglycan and no other 
typical complex components (UGC or DGC), has been described in skeletal muscle 
(McDearmon et al., 2001).  One can postulate that this will influence the formation 
of another, specific type of dystroglycan complex, but no evidence exists to 
describe the components involved. Together, the examples of laminin-α2, agrin, 
biglycan and atypical glycoforms of α-dystroglycan underline an important feature 
of dystroglycan complexes: that the type of interaction with the ECM is as 
important as the availability and localization of intracellular binding partners in 
the definition of the complex. 
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1.1.6 Summary: Why Dystroglycan is an Essential Protein  
Upon molecular examination of the DGC, as well as the other adhesion and 
signalling complexes that dystroglycan is a component of, it is clear how mutations 
in DAG1 have such severe effects in mice and why these are rarely observed in 
humans. Whilst α- and β-dystroglycan may have a primary function in adhesion, 
the plethora of proteins associated with dystroglycan complexes, permit a 
definition of function beyond this role alone. In this manner, dystroglycan can 
contribute to a wide range of processes in cellular biology. A summary of these 
interacting proteins is given in Figure 3. Furthermore, by acting as an interface 
between the extracellular matrix and the cellular microenvironment, dystroglycan 
has a critical role in not only defining the different complexes it is observed in, but 
enabling dynamic, regiospecific specialization of the cell. From focal to basement 
membrane adhesion, and from growth signalling to synaptic function, dystroglycan 
plays a key role in a multitude of cellular processes and hence, one is able to 
appreciate why the disruption of the DAG1 gene has such a profound and negative 
impact on a wide range of species. It is not surprising then to find that human 
diseases where this protein is mislocalized, such as DMD, are of a chronic and 
debilitating nature. What is known about the pathology of this disease, as well as 
the implications this has for the cellular biology of β -dystroglycan, shall form the 
following section of this chapter. 
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Figure 3: A simplified schematic of the proteins that bind the cytoplasmic tail of β-
dystroglycan. Rapsyn (blue), binds to the juxtamembrane region and is thought to 
specify the neuromuscular junction membrane domain. Similarly, ezrin (red) binds 
to the juxtamembrane region and specifies the β -dystroglycan complex found at the 
cleavage furrow. The adaptor protein Grb2 (purple) also binds the cytoplasmic tail 
to permit the establishment of signalling complexes, such as that containing Sos 
and JNK1. The signalling kinases ERK and FAK (green) have been shown to have 
a direct and functional interaction with the cytoplasmic domain. Finally, the 
adaptor proteins utrophin, dystrophin and dystrophin related protein 2 bind the C -
terminus of the protein and provide mechanical linkage to the cytoskeleton.  
Ezrin: Formation of the 
cleavage furrow complex 
Kinases: Cellular
signalling 
Cytoskeletal Adaptors: 
Mechanical linkage and 
signalling 
Rapsyn: Specification of 
membrane microdomain 
(above) 
Adaptor Proteins: 
Formation of larger 
complexes 
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1.2.1 Duchenne Muscular Dystrophy  
DMD is an X-linked disease with an incidence rate of 1 in 3500 male births 
(Kingston et al., 1984 ; Moser et al., 1984). The disease is primarily characterized 
by progressive dystrophy of the skeletal muscles and eventual respiratory or heart 
failure. Clinical manifestations begin between the ages of 3 to 5 years, with a 
progressive loss of muscle strength that result in a loss of ambulance by the age of 
12 years, and death by the age of 20 years (Emery et al., 2003 ; McDonald et al., 
2010). Mutations in the DMD gene, which codes for dystrophin (see Section 1.1.3), 
cause DMD, as well as the milder, Becker muscular dystrophy (BMD) (Koenig et 
al., 1987). BMD patients present with a range of symptoms, which are similar to 
those of DMD, but less severe: the onset of symptoms occurs between 8 and 12 
years of age and, whilst there is progressive muscle weakness, patients can remain 
ambulatory without assistance to the age of 40 and beyond (Emery et al., 2003). 
 The DMD gene is the largest known gene in humans, spanning over 2.3Mb of 
genomic DNA, and as such, the gene has a considerably higher mutation rate  
(mutations/gene unit) than average (Aartsma-Rus et al., 2006). There is a 
correlation between disease severity and type of mutation , which is broadly 
explained by the hypothesis proposed by Monaco et al., (1988) . “Monaco’s Rule” 
predicts that in-frame mutations produce decreased expression of truncated 
dystrophins and BMD, whilst out-of-frame and premature stop mutations cause 
abortive nonsense-mediated decay of the DMD transcript and the lack of 
dystrophin expression typical of DMD patients (Hoffman et al., 1987 ; Bonilla et 
al., 1988 ; Koenig et al., 1989). However, numerous examples exist that refute this 
simple explanation.  
Chiefly, there is a differential importance in the domains of dystrophin that can be 
lost due to mutation: large deletions of the rod domain typically result in BMD, 
whereas small deletions of either the actin binding or the β -dystroglycan binding 
domains cause DMD (Beggs et al., 1991 ; Helliwell et al. 1992 ; Aartsma-Rus et 
al., 2006). In fact, estimates from the Leiden DMD mutation database suggest that 
as many as 9% of BMD/DMD patients do not genetically confo rm to “Monaco’s 
Rule”. In addition to the factors described above, this can be attributed to a variety 
of post-transcriptional events that are either generated or altered by mutation 
(Aartsma-Rus et al., 2006 ; Beroud et al., 2007). Consequently, “Monaco’s Rule” 
only applies for the majority of BMD/DMD patients when the site of mutation is 
examined at the RNA level. However, one cannot rule out other genetic factors that 
modulate the severity of the disease, as evidenced by the reported variation in 
symptoms manifested by patients from a family with the same deletion (Melis et 
al., 1998). 
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The loss of functional dystrophin expression in the DMD disease state results in 
several changes to the muscle fibre. First, there is a large reduction in both the 
sarcolemmal localization and protein levels of components of the DGC, including 
α- and β-dystroglycan (Matsumara et al., 1992a ; Ohlendieck et al., 1993 ; 
Campbell et al., 1995). This loss is specific as the overall levels of other 
sarcolemmal glycoproteins are unaltered in the absence of dystrophin (Ohlendieck 
et al., 1991a ; Ohlendieck et al., 1993). In the absence of the DGC, the sarcolemma 
ruptures, presumably due to an inability to dissipate the lateral forces generated 
during muscle contraction. When compared to healthy muscle, muscles fibres from 
DMD patients have a reduced diameter and are permeable to small dyes such as 
procion yellow and Evans blue, and also large molecules such as IgM (Bradley et 
al., 1978 ; Straub et al., 1997 ; Kinali et al., 2011). In this instance, the release of 
enzymes from the permeable muscle fibres results in elevated serum aldolase and 
creatine kinase levels, which can be used as a diagnostic marker of the disease 
(Dreyfus et al., 1953 ; Kinali et al., 2011). As a consequence of this damage , 
dystrophic fibres undergo continual cycles of degeneration and regeneration, as 
evidenced by the presence of necrotic and centrally nucleated fibres respectively 
(Ohlendieck et al., 1993). Interstitial fibrosis is evident at early stages of the 
disease, but the reduction in large, healthy fibres and eventual expansion of the 
connective tissue leads to progressive fibrosis of the muscle tissue (Ohlendieck et 
al., 1993). In this manner the distal, followed by the proximal, skeletal muscles 
become progressively weakened, until respiratory failure and death occ urs, due to 
the combined weakening of the diaphragm and cardiac tissue (Emery et al., 2003). 
The full pathology of DMD is currently uncertain. Genetic studies highlight the 
importance of the mechanical link between dystroglycan and the actin cytoskeleton 
formed by the respective binding domains of dystrophin (Beggs et al., 1991 ; 
Helliwell et al., 1992 ; Aartsma-Rus et al., 2006). Furthermore, attempts at 
molecular therapy in mouse models have demonstrated the necessity of these 
domains for amelioration of the disease (Cox et al., 1993 ; Cox et al., 1994 ; 
Phelps et al., 1995 ; Rafael et al., 1998 ; Judge et al., 2006). Finally, reports of 
patients with reduced expression of dystrophin suggest that as little as 30% 
expression is required to protect against dystrophy (Neri et al., 2007 ; Anthony et 
al., 2011). Collectively, these studies suggest that when the linkage between the 
actin cytoskeleton and ECM drops below a critical threshold, the extent of 
myofibrillar necrosis becomes too high, leading to progressive fibrosis and 
weakness. Indeed, dystrophic muscle tissue tries to overcome this problem by up-
regulating the expression of utrophin and reconstitution of the mechanical link. 
Analyses of muscle biopsies from DMD patients reveal both an extra -junctional, 
sarcolemmal localization of utrophin as well as increased levels of protein (Voit et 
al., 1991 ; Man et al., 1995 ; Taylor et al., 1997). Whilst utrophin expression is 
dominant in regenerating muscle fibres (Khurana et al., 1991 ; Takemitsu et al., 
1991), a partial protection of the mature muscle fibre is enabled through 
 19 
maintenance of the extra-junctional UGC in the dystrophic state, as evidenced by 
the inverse correlation between utrophin up-regulation and disease severity 
(Mizuno et al., 1993 ; Taylor et al., 1997). However, what happens when these 
protective mechanisms fail, as is the case for DMD patients, is still unknown. As 
such, no curative therapy exists for DMD to date, however further insights into the 
pathological mechanism have emerged from studies of murine models of Duchenne 
and other muscular dystrophies and it is these that the next section describes.  
 
1.2.2 The mdx Mouse and Other Models 
The mdx mutation arose spontaneously in the C57 B1/10 ScSn colony of mice and 
was later shown to correspond to a missense mutation in the mouse DMD gene that 
results in premature termination and nonsense-mediated decay of the DMD 
transcript (Bulfield et al., 1984 ; Hoffman et al. 1987 ; Sicinski et al., 1989). 
Despite a similar genetic origin, the pathology of the mdx mouse is different to that 
of DMD patients. Mdx mice display no histological differences in muscle tissue 
architecture, compared to control mice, until 3 weeks of age, whereupon extensive 
necrosis occurs, leaving very few intact fibres and phagocyte infiltration (Dangain 
et al., 1984). Following this peak in necrosis , continual cycles of necrosis and 
regeneration are evident, yet these are not accompanied by the progressive fibrosis 
observed in DMD patients (Coulton et al. 1988). Furthermore, whilst the 
variability in fibre diameter does increase, the mean fibre diameter size does not 
change in the mdx mouse, unlike in DMD patients (Coulton et al., 1988). The mdx 
mouse lives until at least one year of age and has increased serum creatine and 
pyruvate kinase levels, which is a consequence of ruptured or permeable 
sarcolemma (Coulton et al., 1988). Mdx skeletal muscles exhibit a decreased 
specific force and an increased fatigue in response to repeated contraction, despite 
an increased muscle mass (Dangain et al., 1984 ; Sacco et al., 1992). The increase 
in muscle mass observed in mdx mice has been suggested to be due to an Akt-
dependent hypertrophic protection mechanism, which is not observed in DMD 
patients (Peter et al., 2006). In a similar vein, the disruption of skeletal muscle 
tissue architecture in the mdx mouse in not uniform across all muscle groups; 
proximal limb, pelvic and shoulder girdle muscles show a large uptake of Evans 
blue dye (a marker of membrane permeability), whereas distal limb muscles, such 
as the tibialis anterior show little or no uptake, suggesting that these muscle groups 
are protected against sarcolemmal rupture (Straub et al., 1997).  
The above findings, when partnered with the comparatively long lifespan and 
viability of the mdx mouse, suggest that the protective mechanisms activated in the 
absence of dystrophin in mice are more significant than in humans. Indeed, mdx 
muscle fibres show the same compensatory up-regulation of utrophin and retention 
of dystrophin associated proteins, including dystroglycan, at the sarcolemma , as is 
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observed in humans (Khurana et al., 1991 ; Ohlendieck et al., 1991a). Whilst not 
all dystroglycan is associated with utrophin in UGCs, that functional UGCs are 
formed is also evident from co-sedimentation analysis (Ohlendieck et al. 1991 c ; 
Matsumara et al., 1992). In fact, it has been proposed that a stronger up-regulation 
of this compensatory pathway in the mdx mouse is the cause of the protection of 
cardiac and distal muscle tissue from sarcolemmal rupture (Matsumara et al., 1992 a 
; Straub et al., 1997). In support of this, an increase in both utrophin and β-
dystroglycan protein levels, relative to proximal muscles, is observed in the tibialis 
anterior muscle of mdx mice (Dowling et al., 2002 ; Dowling et al., 2003). In 
addition, alternative cytoskeletal linkers that bind β -dystroglycan, such as plectin 
1f, are also up-regulated in mdx muscle tissue (Rezniczek et al., 2007). Thus, 
relatively speaking, there is a greater pool of proteins compensating for the loss of 
dyrtophin in mice than in humans. In turn, there is an  enhanced restoration of 
dystroglycan complexes to the sarcolemma and adhesion to the ECM. This  
ameliorates the dystrophy caused by the loss of dystrophin  expression in the mdx 
mouse. However, with an examination of the dko model it becomes apparent that 
dystroglycan-dependent adhesion, and not merely dystrophin expression, is a 
requirement to protect against dystrophy. 
In the dko mouse, both the utrophin and dystrophin genes are disrupted. The 
resulting dystrophic phenotype is far more severe than that of the mdx mouse, with 
necrosis and fibrosis of muscle tissue by postnatal day 6, and death due to 
respiratory failure by 20 weeks of age (Deconinck et al., 1997 b). In this instance, 
the dko mouse more closely resembles the pathology of DMD patients, however 
important exceptions still remain. Despite death by respiratory failure, this is due 
to weakening of the diaphragm and dko mice do not exhibit any cardiomyopathy, 
unlike DMD patients (Deconinck et al., 1997a ; Crisp et al., 2011). Furthermore, 
the same protection of distal muscle groups against sarcolemmal rupture is 
observed, and the extent of degeneration and regeneration is no different to that of 
the mdx mouse. However, one should note that extra-junctional, sarcolemmal 
dystroglycan is still observed in the dko mouse, making the retention of 
dystroglycan, potentially via cytoskeletal linkage enabled by alternative proteins, a 
possible cause for the protection of murine muscle fibres in the absence of both 
dystrophin and utrophin (Deconinck et al., 1997b). In other words, the presence of 
sarcolemmal dystroglycan prevents the pathology of these dystrophic diseases in 
mice. However, the notion of the singular importance of dystroglycan can be 
challenged by other features of the dystrophic pathology of both dko and mdx 
mice. 
As mentioned earlier, there is an increase in Akt protein levels and signalling in 
the mdx mouse, with selective downstream activation of p70S6K, suggesting a 
protective, hypertrophic response (Peter et al., 2006). That this is the case is 
confirmed by studies using transgenic, inducible Akt in mdx mice, as enhanced Akt 
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signalling and consequent hypertrophy partially ameliorates muscular dystrophy 
(Peters et al., 2009). However, an important corollary of this study is that utrophin 
expression is also up-regulated by inducible transgenic Akt signalling; a finding 
corroborated by studies in transgenic mdx mice that overexpress sarcospan, an 
activator of the Akt/p70S6K pathway (Marshall et al., 2012a ; Marshall et al., 
2012b). As utrophin up-regulation occurs downstream of Akt signalling, the 
hypertrophic protection may only occur as a consequence of enhanced 
dystroglycan restoration. Both mdx mice and DMD patients also exhibit rare 
revertant muscle fibres, where dystrophin expression is restored due to exon 
skipping of nonsense mutations (Takemitsu et al., 1991 ; Helliwell et al., 1992 ; 
Fall et al., 2006 ; Van Deutekom et al. 2007). In these fibres, the internally 
truncated dystrophin mediates the restoration of DGC components and there is an 
expansion of these fibres in mdx muscle with age (Arechavala-Gomeza et al., 
2010). As there is no similar expansion of revertant fibres in DMD patients, one 
could propose that this expansion is another protective mechanism in the mdx 
mouse. However, this mechanism also ultimately results in the restoration of 
sarcolemmal dystroglycan, suggesting that dystroglycan localization is critically 
important in DMD and mdx pathology (Arechavala-Gomeza et al., 2010). 
Alternatively, up-regulation of the integrin adhesion system may be the cause of 
protection observed in the mdx mouse. Mice lacking both dystrophin and α7-
integrin exhibit a considerably shortened lifespan and increased muscle necrosis 
and regeneration, relative to their single knock out littermates, suggesting that 
these two adhesion system exert a synergistic effect (Rooney et al., 2006). Indeed, 
in other mouse models an inverse relationship between β -dystroglycan and α7-
integrin expression has been reported (Cote et al., 2002 ; Allikian et al., 2004) and 
in other muscular dystrophies, both β1-integrin and α-dystroglycan levels inversely 
correlate with disease severity (Brown et al., 2004). Furthermore, transgenic 
expression of α7-integrin on the dko mouse background increases lifespan and 
ameliorates the features of dystrophic pathology (Burkin et al., 2001), although 
this finding is called into question on the basis that β1 -integrin levels determine 
the amount of functional, sarcolemmal α7-integrin protein (Liu et al., 2011). 
However, a recent trial of α7-integrin overexpression as a therapy for the mdx 
mouse demonstrated little or no improvement in dystrophic pathology (Heller et 
al., 2013). Moreover, the up-regulation of integrins does not ameliorate the 
dystrophic features of Dag1 null chimeric mice (Cote et al., 1999 ; Cote et al., 
2002). Thus, whilst the integrin system of adhesion may attempt to compensate for 
the loss of dystroglycan-dependent adhesion, it is unlikely to be the protective 
mechanism in the mdx mouse, owing to the incomplete functional overlap between 
these two systems of adhesion (Boppart et al., 2006 ; Sen et al., 2011).  
Finally, one cannot ignore the involvement of other members of the DGC and 
UGC, which are also lost from the sarcolemma in DMD, mdx and dko pathology. A 
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good example of this is nNOS, which is recruited by binding to either syntrophin 
or dystrophin (see Figure 2 and Section 1.1.3). In addition to a loss of sarcolemmal 
localization, nNOS expression is decreased in mdx mice and DMD patients (Vaghy 
et al., 1998 ; Barton et al., 2005 ; Amenta et al., 2011) and nNOS levels also 
inversely correlate with disease severity in DMD patients (Anthony et al., 2011). 
Transgenic overexpression of nNOS on the mdx background ameliorates features 
of dystrophic pathology, and this has been proposed to be due to the modulation of 
intracellular calcium handling (Wehling et al., 2001 ; Ito et al., 2013b). In support 
of this proposal, alterations in calcium homeostasis have been proposed to 
contribute to the necrosis of muscle fibres in dystrophic pathology (Kämper et al., 
1992 ; Collet et al., 1999 ; Dowling et al., 2003 ; Batchelo r et al., 2006 ; 
Goonaserka et al., 2011). However, these alterations are proposed to occur 
downstream of sarcolemmal rupture, and hence probably reflect the later stages of 
pathology (Collet et al., 1999 ; Tinsley et al., 2011). Furthermore, nNOS activity  
also causes activation of the Akt/p70S6K pathway, which causes an up-regulation 
of utrophin expression (Marshall et al., 2012 a ; Marshall et al. 2012b). Moreover, 
nNOS-null mice do not exhibit any symptoms of dystrophic pathology, suggesting 
that the loss of nNOS activity is not causative in mdx pathology. (Wehling et al., 
2001). Thus, the importance of nNOS activity and calcium homeostasis in 
dystrophic pathology may be viewed as secondary, when compared to the presence 
of correctly localized dystroglycan and a functional link to the ECM.  
 
1.2.3 Dystroglycan Disruption and Other Muscular Dystrophies 
Whilst an examination of the mdx and dko mouse models provides evidence for and 
against the importance of β-dystroglycan in dystrophic aetiology, several other key 
experiments and observations bring the importance of this protein into sharp focus. 
As mentioned previously, Dag1-null mice die during embryogenesis (Williamson 
et al., 1997), yet chimeric Dag1-null mice, which continue to live after birth,  have 
been reported (Cote et al., 1999). These chimeric mice are highly dystrophic and 
have reduced amounts of DGC proteins including: dystrophin, the SGC, nNOS and 
α-dystrobrevin-2. The basement membranes and ECM components of surrounding 
muscle fibres appear to be unaltered, but the dystrophic phenotype partnered with 
the loss of many DGC components re-affirms the key role of α and β-dystroglycan 
in both the function and integrity of the DGC (Cote et al., 1999 ; Cote et al., 2002). 
Given that β-dystroglycan binds dystrophin, and the other components of the DGC 
through dystrophin, one can infer that the presence of sarcolemmal β -dystroglycan 
is critical for the correct localization of the complex.  
This inference is further supported by observations from the conditional loss of 
dystroglycan, which appears to serve as a master -switch in the formation of the 
complex.  The conditional disruption of dystroglycan expression in mature skeletal 
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muscle leads to a familiar loss of the DGC, partnered with the onset of dystrophic 
necrosis, yet later, re-expression restores the DGC and facilitates regeneration 
(Cohn et al., 2002). The fact that not all DGC components exert this pivotal effect, 
as evidenced by the retention of DGC components at the sarcolemma in sarcospan
-
/-
 and dy/dy (Laminin α2-/-) mice (Marshall et al., 2012a ; Ohlendieck et al. 1991a), 
only serves to strengthen the idea that dystroglycan is a central scaffold in several 
adhesion complexes. Indeed the subset of limb-girdle muscular dystrophies that are 
caused by the loss of any one of the sarcoglycans also exhibit reduced levels of 
sarcolemmal β-dystroglycan, despite only slight reductions in the levels of 
dystrophin (Vainzof et al., 1996 ; Metzinger et al., 1997 ; Duclos et al., 1998). 
These muscular dystrophies, amongst many others, have a common loss of 
dystroglycan from the sarcolemma, implicating it as a key player in the integrity of 
the complex. Thus, in addition to the dystrophic pathology of mdx and dko mice, 
the loss of β-dystroglycan is common to other dystrophies, as one would expect 
from the critical dependence of the DGC on the presence of this protein. 
 
1.2.4 Summary: The Loss and Restoration of β-Dystroglycan in 
DMD Pathology and Therapy 
From the findings described above, one can come to several important conclusions. 
Whilst it is not the cause of DMD, BMD, mdx or dko pathologies, the secondary 
loss of β-dystroglycan from the sarcolemma in these diseases is of importance. 
Levels of sarcolemmal β-dystroglycan correlate with disease severity as much as 
that of dystrophin or utrophin (Neri et al., 2007 ; Anthony et al., 2 011) and, 
whereas dystrophin can be functionally replaced with other proteins in the mdx and 
dko mouse models (Cox et al., 1993 ; Rafael et al., 1998 ; Tinsley et al., 1998 ; 
Rezniczek et al., 2007), β-dystroglycan can not be functionally replaced, even by 
the integrins, which share functions and binding partners with dystroglycan 
complexes (Yoshida et al., 1998 ; Cote et al., 2002 ; Thompson et al., 2010 ; Heller 
et al., 2013). Furthermore, genetic and molecular studies both point to the critical 
nature of the binding between dystrophin and β -dystroglycan, and if this link is 
lost then dystrophic pathology ensues (Beggs et al., 1991 ; Cox et al., 1994 ; Judge 
et al., 2006 ; Aartsma-Rus et al., 2006). This idea is supported by the fact that 
almost all trialled therapies for DMD to date involve the restoration of β -
dystroglycan to the sarcolemma as a marker of efficacy (Gilbert et al., 1998 ; 
Wakefield et al., 2000 ; Wang et al., 2000 ; Wehling et al., 2001 ; Gregorevic et 
al., 2006 ; Van Deutekom et al., 2007 ; Peter et al., 2009 ; Yin et al., 2010 ;  Cirak 
et al., 2011 ; Goemans et al., 2011 ; Tinsley et al., 2011 ; Goyenvalle et al., 2012 ; 
Taniquiti et al., 2012 ; Miller et al., 2012).  
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In light of this, there is still a large gap in the understanding of β -dystroglycan 
function: how is this protein lost from the surface membrane? One might postulate 
that it is merely the loss of binding to sub-membranous scaffolding proteins, such 
as utrophin or dystrophin, which results in a destabilization of dystroglycan a t the 
surface membrane, but this hypothesis alone cannot explain why membranous 
dystroglycan complexes exist that are not associated with these proteins. One can 
argue that in complexes other than the UGC or DGC, other, poorly-characterized 
proteins scaffold β-dystroglycan at the surface membrane. Certainly, from an 
examination of complexes involving β-dystroglycan in non-muscle tissues and cell 
lines this is likely to be the case. However, recent studies have demonstrated the 
involvement of direct, post-translational modification in the localization of β -
dystroglycan (Sotgia et al., 2001 ; Sotgia et al., 2003 a). These studies, discussed in 
detail later, strongly suggest that a single residue, Y890, is critical  to β-
dystroglycan localization. However, they do not discern what effect, if any, this 
has in the internalization process. 
In this thesis the role of this tyrosine residue in the internalization of β -
dystroglycan is described. This study was performed in parallel with work in the 
Winder lab examining the therapeutic potential of knock-in mutagenesis of Y890 
to a phospho-null form on the mdx background. To substantiate and expand the in 
vivo data from this project, several in vitro approaches with a muscle cell line were 
used for the experiments presented in this thesis. Thus, this introduction concludes 
with a description of this system, the H2K
b
-tsA58 myoblast cell line. 
 
1.3.1 The H2K
b
-tsA58 Myoblast Cell Line 
The H2K
b
-tsA58 myoblast cell line (hereafter referred to as H2K myoblasts) is a 
conditionally immortal cell line derived from the H2K
b
-tsA58 mouse (Morgan et 
al., 1994). H2K mice are derived from embryos implanted with the H2Kb -tsA58 
construct: a temperature sensitive form of the SV40 transforming antigen (tsA58) 
coupled to a major histocompatibility complex promoter (H2Kb) (Jat et al. 1991). 
The H2Kb promoter permits widespread expression in a manner inducible with 
interferon-γ (Jat et al., 1991), whereas the tsA58 prote in drives conditional 
immortality, but only at permissive temperatures (Jat et al., 1989). Definitive 
experiments with murine embryonic fibroblasts demonstrated that shifts to the non -
permissive temperature accompany degradation of the tsA58 protein and a switch 
to differentiation, rather than proliferative growth (Jat et al., 1989). Primary 
myoblasts were isolated from H2Kb mice in vitro, prior to demonstration of these 
cells to maintain proliferation by injection into mouse muscle, and re -isolation of 
myogenic clones (Morgan et al., 1994). Growth at non-permissive conditions 
induces differentiation in vitro and in vivo, with induction of myogenin, a factor 
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regulating myogenesis, at 12 hours, and dystrophin at later time points (Wright et 
al., 1989 ; Morgan et al., 1994). 
The advantage of using this cell line over other muscle cell lines, such as C2C12  
cells, is that other cell lines are permanently transformed (Morgan et al., 1992). 
This transformation impairs the capacity for differentiation of these cell lines, as 
evidenced by the numerous discrepancies between differentiated C2C12 myotubes 
and adult skeletal muscle described in the literature. For example, caveolin-3 is 
expressed in primary myoblasts and embryonic mouse muscle tissue, where it is 
proposed to have a role in the development of the t -tubule system (Parton et al., 
1997), yet caveolin-3 expression is only detected in differentiated C2C12 
myotubes (Song et al., 1996). Further inconsistencies are observed in the C2C12 
system with flotillin-1 and -2 (Volonte et al., 1999), and utrophin expression 
(McDearmon et al., 2001). Whilst these inconsistencies do not prevent the use of 
the C2C12 system, the unconditional immortality of these cell lines no doubt has 
an impact on in vitro differentiation, and hence the regulation of expression of 
certain proteins, which reduces the utility of any experimental observations 
obtained. On the basis that H2K myoblasts are not tumourigenic (Morgan et al., 
1994), one can assume that the expression of proteins in these  cells more closely 
mimics the in vivo state, making H2K myoblasts a preferential model of choice.  
One important caveat of the H2K myoblast system is that, assuming that the 
differentiation process mimics the development of skeletal muscle tissue, H2K 
myoblasts do not express full-length dystrophin. Nonetheless, utrophin, which is 
up-regulated in developing and regenerating skeletal muscle tissue (Khurana et al., 
1990 ; Pearce et al., 1993) is expressed in H2K myoblasts (Thompson et al., 2008). 
Furthermore, in keeping with the functional similarity between utrophin and 
dystrophin, utrophin and β-dystroglycan co-localize in adhesion structures in H2K 
myoblasts, suggesting that the two proteins form a functional adhesive complex, as 
observed in skeletal muscle tissue (Matsumara et al., 1992a ; Thompson et al., 
2008). The H2K myoblast system has also been extensively used to study the 
function of β-dystroglycan in cellular adhesion, suggesting that this system is a 
good approximation of the adhesive complexes that contain dystroglycan in vivo 
(Thompson et al., 2008 ; Thompson et al., 2010). As this the sis chiefly investigates 
how β-dystroglycan is internalized in cells, a process potentially linked to the loss 
of adhesion in dystrophic pathology, one can conclude that the H2K myoblast 
system is a justified in vitro model. Owing to the similar nature of the adhesive 
complexes involved, albeit without the costameric DGC found in skeletal muscle 
fibres, these data can be further tested by in vivo experimentation. 
 
 
 26 
1.4.1 Chapter Summary  
β-dystroglycan, together with α-dystroglycan, is part of an essential adhesion 
receptor. This receptor is evolutionarily conserved and forms complexes with 
various cellular proteins and components of the ECM. β -dystroglycan is present in 
a wide range of tissues and fulfils signalling and adhesion functions through its 
interactions with a large number of ubiquitous and tissue -specific proteins. The 
DGC is a notable example of a β-dystroglycan complex as it exemplifies the many 
features of dystroglycan-dependent signalling and adhesion. The essential nature 
of these features is evidenced by the chronic and degenerative nature of the disease 
DMD, which is characterized by the loss of this complex from the sarcolemma. 
Molecular studies, whilst indicating the contribution of various processes to the 
dystrophic state, underline the singular importance of the loss of sarcolemmal β -
dystroglycan as a key step in dystrophic pathology. Relatively little is known about 
the mechanisms governing the sarcolemmal localization of β -dystroglycan yet, as 
evidenced by the therapeutic effect of sarcolemmal restoration, an understanding 
of these mechanisms may provide a target for future intervention, as well as extend 
the current understanding of this protein. In this thesis the role of Y890 in this 
regard is examined. The work presented here was performed in parallel with a 
study of the DAG1
Y890F/Y890F 
knock-in mouse. As such, the H2K myoblast cell line 
was chosen as an experimental model, to more closely mimic studies performed in 
vivo. Through the combination of these approaches the mechanism governing β-
dystroglycan localization, as well as the importance of this mechanism in 
dystrophic pathology could be investigated. 
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Chapter 2: 
Materials and Methods 
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Please note that all buffer formulations are given in full upon first mention in the 
text, but for ease of reference all buffer formulations are also given in Table 2.6.1.  
 
2.1 Bacterial Methods 
 
2.1.1 Preparation of Competent Bacteria 
E.coli DH5α or BL21(DE3) were taken from a frozen glycerol stock and plated on 
to solid (+4% (w/v) agarose) 2xYT media (1% (w/v) Yeast Extract, 1.6% (w/v) 
Tryptone, 0.5% (w/v) NaCl) containing no antibiotic. The plated E.coli were 
placed in an incubator and grown at 37°C overnight. The following morning single, 
isolated colonies were picked with a sterile pipette tip and used to inoculate 10ml 
of sterile 2xYT media. This starter culture was placed in a rotating incubator set at 
37°C and 175rpm and left to grow overnight. The following morning, 200µl of the 
overnight culture were used to inoculate 20ml of sterile 2xYT media. This culture 
was placed in a rotating incubator set at 37°C and grown until the OD 600 reached 
0.6 AU. The bacteria were pelleted by centrifugation at 700 x g for 10 minutes at 
4°C. The supernatant was removed and the pellet was resuspended in 10ml of ice -
cold, sterile 0.1M CaCl2. The resuspended cells were incubated on ice for 2 hours, 
before centrifugation as before. The supernatant was removed and the pellet was 
resuspended in 2ml ice-cold sterile 0.1M CaCl2. Glycerol stocks of competent 
bacteria were made by addition of glycerol to a final concentration of 10% (v/v) 
prior to freezing and storage at -80°C. 
 
2.1.2 Plasmid Purification 
E.coli DH5α, which had been successfully transformed with the desired plasmid, 
were used to produce all the DNA used in this study. DNA was purified using 
either Mini or Maxi kits (QIAGEN) using the manufacturer’s protocol. Purified 
DNA was re-suspended in sterile distilled water and assayed by A260 measurement 
using a quartz 1cm path-length cuvette (Unico) and a 7315 spectrophotometer 
(Jenway). Once the concentration of DNA had been determined, aliquots were 
either stored at 4°C for 6 weeks or less, or stored at -20°C for 6 weeks or more. 
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2.1.3 Transformation of Competent Bacteria 
A glycerol stock aliquot of competent E.coli DH5α (for DNA purification) or 
E.coli BL21(DE3) (for protein purification) bacteria was removed from storage at -
80°C and thawed on ice. 0.5µg of plasmid DNA were added to the E.coli and the 
mixture was vortexed briefly, before incubation for 20 minutes on ice. The E.coli 
were then transformed by incubation at 42°C for 1 minute, before incubation for a 
further 20 minutes on ice. 100µl of sterile 2xYT media were added to the 
transformed E.coli and the mixture was vortexed briefly before incubation at 37°C 
for 1 hour. Following incubation, the cells were plated on to solid YT + agar 
containing the appropriate antibiotic for selection of the plasmid DNA and placed 
in an incubator set at 37°C to grow overnight. Following incubation, and checking 
for the presence of single, isolated colonies, the plates were used immediately for 
DNA or protein purification, or were stored at 4°C for future use.  
 
2.2 Protein Methods 
 
2.2.1 Growth and Induction of Recombinant Proteins 
E.coli BL21(DE3), which had been successfully transformed with the desired 
plasmid, were used to produce all the recombinant proteins used in this study. 
Plates of transformed E.coli were scraped into 1l of sterile 2xYT media containing 
kanamycin or ampicillin, at a concentration of 30µg/ml or 100µg/ml respectively, 
to maintain selection during growth. The inoculated media was placed in a rotating 
incubator set at 37°C and 175rpm and grown until the OD600 reached 0.6 AU. 
Isopropyl β-D-1-thiogalactopyranoside was then added to the media to a final 
concentration of 1mM and the E.coli were returned to the rotating incubator for 
induction. The time period for induction varied between the different recombinant 
proteins expressed, so preliminary induction curves were generated prior to the 
purifications described here. In general, all recombinant proteins in this study were 
induced for 4 hours or less at 37°C. Following induction, the E.coli were 
centrifuged at 12,000 x g for 15 minutes. The supernatant was removed and the 
pellet was stored at -20°C for future purification. 
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2.2.2 WW Domain GST Fusion Purification 
Pellets of induced E.coli BL21(DE3) were thawed on ice before resuspension in 
20ml of chilled PBS (0.8% (w/v) NaCl, 0.02% (w/v) KCl, 0.144% (w/v) Na 2HPO4, 
0.024% (w/v) KH2PO4, pH 7.4) . Following the addition of protease inhibitors 
(1mM sodium orthovanadate, 100nM Calyculin A, 1mM 
phenylmethanesulfonylfluoride, 10µM tosyl phenylalanyl chloromethyl ketone, 
10µM leupeptin, 1µM pepstatin, 10µg/ml aprotinin, 10µg/ml benzamidine), cells 
were lysed by sonication on ice and thoroughly vortexed, before centrifugation at 
21,000 x g for 45 minutes at 4°C. The supernatant was mixed with 0.5ml 
glutathione-Sepharose (GE Healthcare), which had been pre-equilibrated in PBS. 
The slurry was mixed on a roller for 1 hour at 4°C, prior to transfer to a co lumn in 
a cold-room. Once settled on the column, the beads were washed with 10ml chilled 
PBS containing 1% (v/v) Triton-X, then 10ml chilled high salt buffer (150mM 
NaCl, 50mM Tris (pH 7.4), 1mM dithiothreitol and 1mM EDTA). GST-tagged 
proteins were then eluted from the beads with 1ml of chilled elution buffer (10mM 
reduced glutathione in 50mM Tris (pH 8)). 100µl fractions were collected on ice 
and used for subsequent experiments or stored at -20°C. The peak elution fractions 
were determined by SDS-PAGE and Coomassie staining, prior to pooling of the 
peak fractions and determination of final protein concentration by Bradford assay.  
 
2.2.3 Multi-Dsk Protein Purification 
Purification was similar to the protocol used above, but with the modifications 
made by Wilson et al. (2012), owing to the expression of the protein in inclusion 
bodies. Pellets were resuspended in 20ml chilled STE buffer (10mM Tris pH 8, 
1mM EDTA, 100mM NaCl) with 100µg/ml lyzosyme and incubated on ice for 15 
minutes. Dithiothreitol and N-lauryl sarcosine were added to final concentrations 
of 5mM and 1.5% (v/v) respectively and the mixture was sonicated gently on ice. 
Following sonication and further mixing, the mixture was filtered through 
cheesecloth and Triton-X was added to the filtrate at a final concentration of 3% 
(v/v). The filtrate was mixed with 0.5ml glutathione-Sepharose (GE Healthcare), 
which had been pre-equilibrated in STE buffer. The slurry was mixed on a roller 
for 3 hours at 4°C, prior to transfer to a column in a cold -room. Once settled on the 
column, the beads were washed with 50ml chilled wash buffer 1 (450mM NaCl, 
10% glycerol (v/v), 0.1mM EDTA, 0.1% Triton-X (v/v) and 2mM DTT in PBS), 
followed by 25ml chilled wash buffer 2  (50mM NaCl, 10% glycerol (v/v), 1mM 2 -
Mercaptoethanol, 0.2% Triton-X (v/v) in 50mM KPhos buffer (40.1mM K2HPO4, 
9.9mM KH2PO4, pH 7.4)). The beads were then resuspended in chilled PBS with 
1mM sodium azide and stored at 4°C. 
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2.2.4 Bradford Assay  
Duplicate aliquots of 0, 2.5, 5, 7.5 and 10µg of BSA in 100µl of 0.15M NaCl were 
prepared. The solutions to be assayed were also prepared in duplicate at 1:10, 
1:100 and 1:500 dilutions in 0.15M NaCl. 1ml of Coomassie brilliant blue solution 
(0.1mg/ml Coomassie brilliant blue G-250, 4.5% ethanol (v/v), 8.5% phosphoric 
acid (v/v)) was added to each of the aliquots before vortexing and incubation at 
room temperature for 2 minutes. The solutions were transferred to 1 -cm pathlength 
polystyrene cuvettes and the A595 for each solution was measured using a 
spectrophotometer (7315 model, Jenway). After correcting for baseline 
absorbance, the A595 values for the control samples were used to generate a 
standard curve, from which the concentration of the unknown samples could be 
interpolated. In the event of the unknown samples having corrected A595 values 
outside the standard curve range, the assay was repeated with different dilutions of 
the test solution. 
 
2.2.5 Sodium Dodecyl Sulphate Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) 
For SDS-PAGE analysis, an equal volume of 2x Laemmli buffer (20% (v/v) 
glycerol, 100mM Tris (pH 6.8), 4% (w/v) SDS, 0.2% (w/v) bromophenol blue, 2% 
(v/v) 2-mercaptoethanol) was added to the samples. The samples were vortexed 
and then incubated at 95°C for 5 minutes. After cooling, the samples were 
vortexed and run on SDS-PAGE mini-gels. Mini-gels (10cm x 1cm x 1cm) were 
run using the Bio-Rad mini-gel system. Mini-gels were either prepared 
individually using the Bio-Rad casting system or were purchased pre-poured 
(Mini-protean TGX, Bio-Rad). The mini-gels comprised of 10% or 12% resolving 
gels with 5% stacking gels (Table 2.6.3). The mini -gels were run in Bio-Rad 
chambers filled with SDS running buffer (200mM glycine, 25mM Tris, 0.1% (w/v) 
SDS) according to the manufacturer’s instruction. After loading of the sample, 
mini-gels were run at the fixed voltages of 100V through the stacking gel, and 
150V through the resolving gel.  
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2.2.6 Electroblotting of Proteins 
For western blotting, proteins were electroblotted from SDS-PAGE mini-gels to 
PVDF (polyvinylidene fluoride) membrane (Immobilon-P, Millipore) using the 
Bio-Rad Mini Trans-Blot system. Prior to transfer, gels were soaked in Towbin 
transfer buffer (25mM Tris, 192mM Glycine and 20% methanol (v/v)) for at least 5 
minutes. The PVDF membrane was wetted in methanol and then immersed in the 
Towbin transfer buffer with the gel, so that all components of the blot were in 
chemical equilibrium. Finally, chromatography paper (Whatman) was also 
immersed in the equilibrated Towbin transfer buffer. All components were 
assembled into the Bio-Rad Mini Trans-Blot system and the chamber was filled 
with equilibrated Towbin transfer buffer, as per the manufacturer’s instructions. 
Membranes were blotted at a fixed voltage of 100V for 75 minutes. Following 
blotting, membranes were removed from the blotting stack and immediately 
immersed in TBSTw (50mM Tris (pH 7.5), 150mM NaCl, 0.5% (v/v) Tween).  
 
2.2.7 Western Blotting 
Electroblotted membranes were blocked with 5% (w/v) skimmed milk powder 
(Tesco) in TBSTw for 1 hour at room temperature. Membranes were then 
incubated with a primary antibody at the appropriate dilution (Table 2.6.2) in 
TBSTw with 5% (w/v) skimmed milk powder for either 2 hours at room 
temperature, or overnight at 4°C. Following primary antibody incubation, 
membranes were washed 4 times for 15 minutes with TBSTw at room temperature 
and then incubated with secondary antibody at the appropriate dilution (Table 
2.6.2) in TBSTw with 5% (w/v) skimmed milk powder for 1 hour at room 
temperature. Following secondary antibody incubation, membranes were washed 3 
times for 10 minutes with TBSTw at room temperature. A chemiluminescent signal 
was generated by incubating the membranes with freshly mixed ECL solut ion 
(100mM Tris (pH 8.5), 1.25mM luminol, 0.2mM p-Coumaric acid, 0.02% (v/v) 
H2O2) for 30 seconds. The membranes were then transferred to the Bio -Rad 
Chemidoc XRS system, where the chemiluminescent signal was recorded for up to 
30 minutes.  
Please note that for western blots using extravidin-peroxidase as a secondary 
antibody 5% (w/v) bovine serum albumin was used as a blocking agent instead of 
skimmed milk powder. 
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2.2.8 Peptide Arrays 
Peptide arrays representing the entire cytoplasmic domain of β -dystroglycan, as 15 
residue oligomers with a single residue step, were purchased from Intavis AG. 
Arrays were wetted with analytical grade ethanol prior to three washes in TBSTw. 
The arrays were blocked with 5% (w/v) skimmed milk powder in TBSTw for 30 
minutes at room temperature, and then incubated with purified protein at 20µg/ml 
and 5% (w/v) skimmed milk powder in TBSTw overnight at 4°C. Following 
protein incubation, arrays were rinsed three times in TBSTw and then washed a 
further three times in TBSTw for 5 minutes per wash. Arrays were incubated with 
anti-GST at a dilution of 1:5000 in 5% (w/v) skimmed milk powder in TBSTw for 
2 hours at room temperature. Following primary antibody incubation, arrays were 
rinsed three times in TBSTw and then washed a further three times in TBSTw for 5 
minutes per wash. Arrays were then incubated with anti -rabbit IgG-HRP at a 
dilution of 1:10000 in 5% (w/v) skimmed milk powder in TBSTw for 1 hour at 
room temperature. Following secondary antibody incubation, arrays were rinsed 
three times in TBSTw and then washed a further three times in TBSTw for 5 
minutes per wash. Arrays were drained of excess TBSTw and a chemiluminescent 
signal was generated and recorded as described for western blotting (section 2.2.7).  
 
2.3 Cell Culture and Assays 
 
2.3.1 Growth of H2K Myoblasts 
H-2K
b
-tsA58 myoblasts (Jat et al., 1991; Morgan et al., 1994) were maintained in 
DMEM Glutamax
TM
 (+4.5g/L D-glucose, -pyruvate) media (Gibco BRL), 
supplemented with 20% (v/v) foetal bovine serum (Gibco BRL), 2% (v/v) chick 
embryo extract (Sera Lab), 2% (v/v) penicillin-streptomycin (Gibco BRL), and 
20U/ml Interferon-γ. Myoblasts were maintained in an  incubator (Galaxy S, 
Biohit) at 33°C and 10% CO2. Myoblasts were passaged using 1% (v/v) trypsin -
EDTA (Sigma), followed by centrifugation (11030 rotor, Sigma) at 80 x g for 3 
minutes and resuspension in growth media. Myoblasts were then re -seeded at 
dilutions suitable for further growth or specific experimental requirements.  
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2.3.2 Preparation of Lysates 
For all experiments, dishes of H2K myoblasts were placed on ice, washed once 
with chilled PBS, then lysed with RIPA buffer (50mM Tris (pH 7.5), 150mM 
NaCl, 1mM EGTA, 1mM EDTA, 1% (v/v) Triton-X, 0.5% (w/v) sodium 
deoxycholate, 0.1% SDS (w/v), 1mM azide) supplemented with protease and 
phosphatise inhibitors (1mM sodium orthovanadate, 100nM Calyculin A, 1mM 
PMSF, 10µM TPCK, 10µM leupeptin, 1µM pepstatin, 10µg/ml aprotinin, 10µg/ml 
benzamidine). A cell scraper was used to ensure complete lysis and collection o f 
sample. Following collection, lysates were centrifuged at 18,000 x g for 15 
minutes at 4°C. 
 
2.3.3 Immunoprecipitation  
H2K myoblast lysates were sonicated for 10 seconds on ice, before centrifugation 
at 18,000 x g and 4°C for 15 minutes. The supernatant was incubated with either 
protein A Sepharose or protein G Sepharose, pre-equilibrated as a 50% slurry in 
RIPA buffer, at a ratio of 100µl/1000µl sample. The mixture was incubated for 1 
hour at 4°C on a roller. Protein A or G Sepharose was removed by centrifugation at 
10,000 x g for 1 minute at 4°C. The supernatant was incubated with primary 
antibody at the appropriate dilution (Table 2.6.2) and placed on a roller overnight 
at 4°C. The supernatant was then incubated with either protein A Sepharose or 
protein G Sepharose, pre-equilibrated as a 50% slurry in RIPA buffer, at a 
concentration of 50µl/1000µl sample. The mixture was incubated for 1 hour at 4°C 
on a roller. Following centrifugation at 10,000 x g for 1 minute at 4°C the 
supernatant was removed and stored on ice and the beads were washed 3 times in 
10 volumes of chilled RIPA buffer. Finally, pellet and supernatant samples were 
mixed with equal volumes of 2x Laemmli buffer (see section 2.5.2) and were 
incubated for 5 minutes at 95°C. After cooling to room temperature, samples were 
either processed immediately, or stored at -20°C for future use. 
 
2.3.4 Orthovanadate Treatment of H2K Myoblasts 
H2K myoblasts were incubated with serum-free growth media containing 1mM 
sodium orthovanadate and 2% (v/v) H2O2 for 30 minutes at 33°C. Following 
incubation, H2K myoblasts were brought to ice and lysed in RIPA buffer as 
described in section 2.3.2. 
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2.3.5 Biotinylation Assay 
H2K myoblasts were seeded on to dishes and allowed to adhere in the growth 
incubator overnight. The dishes were removed from the incubator and placed on 
ice and washed 3 times with chilled PBS before incubation with chilled 
biotinylation buffer (0.5 mg/ml EZ-link Sulfo-NHS-ss-biotin (Pierce) in PBS) for 
30 minutes. The dishes were then washed once with chilled PBS and twice with 
chilled serum-free growth media containing 0.2% (w/v) BSA. The dishes were 
returned to the incubator, to allow endocytosis to occur, for varying amounts of 
time. After this, dishes were removed from the incubator and placed on ice. The 
dishes were washed 3 times for 20 minutes with chilled stripping buffer (50mM 
Tris (pH 8.6), 100mM NaCl, 1mM EDTA, 100mM MesNa and 0.2% (w/v) BSA). 
The dishes were then washed once for 10 minutes with 100mM iodoacetamide in 
chilled PBS, before 3 washes in chilled PBS and lysis in RIPA buffer as described 
(see section 2.3.2). To each lysate, 50µl of streptavidin -Sepharose (50% slurry, 
preequilibrated in RIPA) was added and the mixture was incubated for 1 hour on a 
roller at 4°C. Following centrifugation at 10,000 x g for 1 minute at 4°C the 
supernatant was removed and stored on ice and the beads were washed 3 times in 
10 volumes of chilled RIPA buffer. Finally, pellet and supernatant samples were 
mixed with an equal volume of 2x Laemmli buffer (see section 2.5.2) and were 
incubated for 5 minutes at 95°C. After cooling to room temperature, samples were 
either processed immediately, or stored at -20°C for future use. 
 
2.3.6 Transferrin Uptake Assay 
Transferrin uptake experiments were performed in a manner similar to the method 
of Semerdjieva et al. (2008). H2K myoblast cells were seeded onto 13mm 
coverslips in dishes and left to adhere overnight. On ice, the growth media was 
removed from the dishes and replaced with chilled growth media containing Texas 
Red transferrin (Invitrogen) at a final concentration of 10µg/ml. The dishes were 
returned to the incubator, to allow endocytosis to occur, for various times. 
Following this incubation, the dishes were returned to ice and washed once in 
chilled PBS, followed by a wash in chilled transferrin stripping buffer (50mM 
glycine (pH 3.0), 2M urea and 100mM NaCl) for 5 minutes. Coverslips were then 
processed for microscopy as described in “Preparation of Cells For Microscopy”.  
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2.3.7 Cholera Toxin Uptake Assay 
Cholera toxin uptake assays were performed as described in Marks et al. (2005). 
H2K myoblast cells were seeded onto 13mm coverslips in dishes and left to adhere 
overnight. On ice, the growth media was removed from the dishes and replaced 
with growth media containing Alexa fluor 594-cholera toxin B subunit (Invitrogen) 
at a final concentration of 1µg/ml and the dishes were returned to the incubator to 
allow endocytosis to occur for various times. Following this incubation, the dishes 
were returned to ice and washed once in chilled PBS, followed by 3 washes in 
chilled stripping buffer (500mM glycine (pH 2.2)) for 30 seconds each. Coverslips 
were then processed for microscopy as described in “Preparation of Cells For 
Microscopy”. 
 
2.3.8 Lysotracker
TM 
Staining and Ammonium Chloride 
Treatment 
Lysotracker staining was performed in a manner similar to the method of Gotink et 
al. (2011). H2K myoblast cells were seeded onto 13mm coverslips in dishes and 
left to adhere overnight. On ice, the growth media was removed from the dishes 
and replaced with chilled growth media containing Lysotracker
TM
 Red DND-99 
(Molecular Probes) at a final concentration of 500mM and the dishes were  returned 
to the incubator for 15 minutes. Following this incubation, the dishes were 
returned to ice and washed once in chilled PBS. The coverslips were then 
processed for microscopy as described in “Preparation of Cells For Microscopy”. 
For experiments using ammonium chloride treatment, the protocol followed was 
exactly the same except that H2K myoblasts were pre -treated with growth media 
containing 50mM NH4Cl for 2 hours prior to the experiment. 
 
2.3.9 H2K Myoblast Transfection 
For all transfections of H2K myoblasts the Neon
TM
 Transfection System 
(Invitrogen) was used, as described by the manufacturer’s instructions pertaining 
to adherent cells. H2K myoblasts were trypsinized with 1% (v/v) trypsin -EDTA 
(Sigma) and centrifuged at 80 x g for 3 minutes, before resuspension in growth 
media and counting using an improved Neubauer haemocytometer (Weber). The 
myoblasts were washed in sterile PBS twice, before resuspension in sterile PBS at 
a concentration of 2x10^6 cells/ml. Plasmid DNA (see section 2.1.2) was a dded to 
the suspended cells at a final concentration of 75µg/ml and the mixture was gently 
inverted before incubation at room temperature for 5 minutes. The myoblast/DNA 
mixture was transferred to a 100µl Neon
TM
 tip before electroporation with a single 
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1400V pulse for 30ms. The electroporated myoblasts were seeded onto dishes 
containing antibiotic-free growth media (see section 2.3.1). The dishes were 
returned to the incubator and the transfected myoblasts were left to adhere and 
express recombinant proteins for 24 hours prior to further processing. 
 
2.4 Microscopy Techniques 
 
2.4.1 Preparation of Cells for Microscopy 
H2K myoblast cells on 13mm coverslips were placed on ice and carefully washed 3 
times with chilled PBS. The coverslips were then removed from ice and gently 
immersed in fixative solution (3.7% (v/v) formalin in PBS) for ten minutes at room 
temperature. Following fixation, the coverslips were immersed in permeabilizing 
solution (0.05% (w/v) saponin in PBS) for 1 minute at room temperature. The 
coverslips were washed with PBS three times at room temperature before blocking 
by inverting the coverslips onto 20µl of blocking buffer (5% (v/v) FBS, 3% (w/v) 
BSA, in PBS) on parafilm. The inverted coverslips were placed in a dark, humid 
chamber and blocked for 1 hour at room temperature. Primary antibody solutions 
were prepared by mixing primary antibody at the appropriate dilution (Table 2.6.2) 
in blocking buffer. The coverslips were removed from the humidity chamber, 
drained of excess blocking buffer, and inverted onto 20µl of primary antibody 
solution on parafilm. The inverted coverslips were returned to the dark, humid 
chamber and incubated for 1 hour at room temperature or overnight at 4°C. 
Secondary antibody solutions were prepared by mixing secondary antibody at the 
appropriate dilution (Table 2.6.2) in blocking buffer. Following primary antibody 
incubation, the coverslips were removed from the parafilm and washed by gentle, 
triplicateimmersions in PBS, before draining of excess PBS and inversion onto  
20µl of secondary antibody solution on parafilm. The inverted coverslips were 
returned to the dark, humid chamber and incubated for 1 hour at room temperature. 
Following the secondary antibody incubation, the coverslips were removed from 
the parafilm and washed by gentle, multiple immersions in PBS, before draining of 
excess PBS and mounting on to glass slides using a preservative mounting solution 
(2.5% (w/v) 1,4-diazabicyclo[2.2.2]octane (Sigma) and 100ng/ml 4’,6 -diamidino-
2-phenylindole (Sigma) in Hydromount
TM
 (National Diagnostics)). The coverslips 
were allowed to set in a dry, dark, chamber for 2 hours at room temperature and 
were then either used immediately or stored at 4°C in the dark.  
 
 
 38 
2.4.2 Epifluorescence Microscopy 
Slides were viewed using a Leica DMIRE2 inverted fluorescent microscope 
powered by a Leica CTRMIC controller. Images were obtained with a Leica HCX 
PL 63X/1.32 oil-immersion objective lense, with a 50W Osram mercury 
illumination source and an Ebq isolated lamp power supply. Leica narrow pass 
filters were used to prevent bleed-through: A4, DAPI, blue (excitation at 360nm, 
emission at 400nm); L5 FITC/GFP, green, (excitation at 480nm, emission at 
505nm); N2.1, rhodamine/Texas Red/Alexa fluor-594, red (excitation at 515-
560nm, emission at 580nm). Images were acquired using the Leica QFluoro 
software package running on a Leica Q550FW Pentium II computer, supported by 
Microsoft Windows 2000 Professional.  
 
2.4.3 Confocal Microscopy 
Slides were viewed using a Leica TCS SP confocal microscope, f itted on to a Leica 
DMRE upright stand with a motorised stage, under the control of Microsoft 
Windows 7. Confocal images were obtained using a 63X PL Apo oil -immersion 
objective lens with a 50W HBO ACL1 illumination source, and Scan Electronics 
Argon-ion 100mW gas laser, emitting lines at 458, 477, 488 and 514nm, and a 
25mW Kryton-ion gas laser emitting light at 568nm in conjunction with Leica 
Confocal Suite software. 
 
2.5 Computer Aided Analysis of Data 
 
2.5.1 Gel and Blot Analysis 
All gels and blots were analyzed for densitometry using Image J v.1.47 (Schneider 
et al., 2012). Densitometry was performed as described in Ferreira et al., (2012), 
but is described here in brief. Following manual definition of lanes (Analyze > 
Gels > Select First Lane/Select Next Lane), the signal intensities were plotted as a 
function of vertical distance (Analyze > Gels > Plot Lanes). Using the straight line 
tool, the baseline intensity was defined for each plotted signal intensity peak. The 
wand tool was then used to find the integrated area under each peak and this 
number was recorded used for further analysis.  
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All gels and blots were analyzed for molecular weight estimation, using the “Image 
Lab” (Bio-Rad) software package, v.3.0. For molecular weight estimation, lanes 
were manually defined and bands were detected automatically. Following 
definition of the protein markers, the “Report” function was used to estimate the 
molecular weight of bands.  
 
2.5.2 Image Processing 
Adobe Photoshop CS (Adobe Inc.) and ImageJ  were used fo r the production of all 
figures and images. Single channel images were first converted to monochrome 8 -
bit images using Image J (Image > Type > 8-bit). The images were then scaled 
(Analyze > Set Scale), cropped (Selection, Image > Crop) and depicted with scale 
bars (Analyze > Tools > Scale Bar). The processed monochrome images were then 
saved as TIFF files. False colour merged images were then generated (Image > 
Color > Merge Channels), converted to RGB format (Image > Type > RGB Colour) 
and saved as TIFF files. Single channel and false colour merged TIFFs were 
opened in Adobe Photoshop CS2 (Adobe) and manually adjusted for intensity 
levels and gamma settings, without addition or subtraction of visual data. The 
final, processed images are presented in this thesis. 
 
2.5.3 Co-localization Analysis 
All co-localization analysis was performed using the JaCoP plug-in for Image J 
(Bolte et al., 2006). Following manual thresholding, the manders coefficients (M1 
and M2) were calculated for each pair of images (Manders  et al., 1993). The mean 
manders coefficient (defined as M1+M2/2) was calculated for each pair of images 
within a data set. After calculation of the mean manders coefficient for a set of 
data, the data set was subjected to statistical analysis (described b elow) prior to 
graphical presentation within the thesis. Where appropriate, the mean of individual 
manders coefficients (M1 or M2) are used, as stated in the text.  
 
2.5.4 Statistical Analysis 
All statistical testing was performed using the statistical soft ware “Minitab” v.15 
(Minitab Inc.). Where appropriate, the normality of data sets was confirmed using 
the Anderson-Darling test or histographical analysis. Data sets which were of a 
normal distribution were tested parametrically, whereas data sets of a non -normal 
distribution were tested non-parametrically. Graphs were generated using “Prism” 
v.5 software (Graphpad Software). 
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2.6 Tables 
 
2.6.1 Buffers and Solutions  
Buffer/Solution Name Components Solvent and 
Notes 
Relevant Section 
Biotinylation Buffer 0.5 mg/ml EZ-link 
Sulfo-NHS-ss-
biotin 
PBS Cell Culture and 
Assays 
Blocking Buffer 
(Immunofluorescence) 
5% (v/v) FBS, 3% 
(w/v) BSA 
PBS Microscopy 
Techniques 
Blocking Buffer 
(western blotting) 
5% (w/v) skimmed 
milk powder 
TBSTw Protein Methods 
ChTxB Stripping 
Buffer 
500mM glycine-
HCl (pH 2.2) 
Distilled 
Water 
Cell Culture and 
Assays 
Coomassie Brilliant 
Blue/Bradford 
Reagent 
0.1mg/ml 
Coomassie 
brilliant blue G-
250, 4.5% ethanol 
(v/v), 8.5% 
phosphoric acid 
(v/v) 
Distilled 
Water 
Protein Methods 
ECL Solution 100mM Tris (pH 
8.5), 1.25mM 
luminol, 0.2mM p-
Coumaric acid, 
0.02% H2O2 
Distilled 
Water 
Protein Methods 
Elution Buffer 10mM reduced 
glutathione in 
50mM Tris-HCl 
(pH 8) 
Distilled 
Water 
Protein Methods 
Fixative Solution 3.7% (v/v) 
formalin 
PBS Microscopy 
Techniques 
High Salt Buffer 150mM NaCl, 
50mM Tris-HCl 
(pH 7.4), 1mM 
DTT and 1mM 
EDTA 
Distilled 
Water 
Protein Methods 
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H2K Myoblast 
Growth Media 
20% (v/v) foetal 
bovine serum, 2% 
(v/v) chick 
embryo extract, 
2% (v/v) 
penicillin-
streptomycin, 
20U/ml Interferon-γ 
DMEM 
Glutamax
TM
 
(+4.5g/L D-
glucose, -
pyruvate) 
Cell Culture and 
Assays 
50mM KPhos Buffer 
(pH7.4) 
40mM K2HPO4, 
10mM KH2PO4 
Distilled Water Protein Methods 
Laemmli Buffer (2x) 20% (v/v) 
glycerol, 100mM 
Tris (pH 6.8), 4% 
(w/v) SDS, 0.2% 
(w/v) bromophenol 
blue, 2% (v/v) 2-
mercaptoethanol 
Distilled Water Protein Methods, 
Cell Culture and 
Assays 
PBS 0.8% (w/v) NaCl, 
0.02% (w/v) KCl, 
0.144% (w/v) 
Na2HPO4, 0.024% 
(w/v) KH2PO4, pH 
7.4 
Distilled Water All 
Permeabilizing 
Solution 
0.05% (w/v) 
saponin 
PBS Microscopy 
Techniques 
Preservative 
Mounting Solution 
2.5% (w/v) 
DABCO, 100ng/ml 
DAPI 
Hydromount
TM
 Microscopy 
Techniques 
RIPA Buffer 50mM Tris (pH 
7.5), 150mM 
NaCl, 1mM 
EGTA, 1mM 
EDTA, 1% (v/v) 
Triton-X, 0.5% 
(w/v) sodium 
deoxycholate, 
0.1% SDS (w/v), 
1mM azide 
Distilled Water Protein Methods, 
Cell Culture and 
Assays 
SDS Running Buffer 200mM glycine, 
25mM Tris, 0.1% 
(w/v) SDS 
Distilled Water Protein Methods 
STE 10mM Tris-HCl 
(pH 8), 1mM 
EDTA, 100mM 
NaCl 
Distilled Water Protein Methods 
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TBSTw 50mM Tris (pH 
7.5), 150mM 
NaCl, 0.5% (v/v) 
Tween 
Distilled 
Water 
Protein Methods 
Towbin Transfer 
Buffer 
25mM Tris, 
192mM glycine, 
20% MeOH 
Distilled Water Protein Methods 
Transferrin 
Stripping Buffer 
50mM glycine (pH 
3.0), 2M urea and 
100mM NaCl 
Distilled Water Cell Culture and 
Assays 
Wash Buffer 1 450mM NaCl, 10% 
glycerol (v/v), 
0.1mM EDTA, 
0.1% Triton-X 
(v/v), 2mM DTT 
Distilled Water Protein Methods 
Wash Buffer 2 50mM NaCl, 10% 
glycerol (v/v), 
1mM 2-
Mercaptoethanol, 
0.2% Triton-X 
(v/v) 
50mM KPhos 
buffer (pH7.4) 
Protein Methods 
2xYT 1% (w/v) Yeast 
Extract, 1.6% 
(w/v)Tryptone, 
0.5% (w/v) NaCl 
Distilled water 
 
Bacterial and 
Protein Methods 
 
 
 
 
 
 
 
 
 
 
 43 
2.6.2 Antibodies 
Antibody Name Protein Target Source Species Dilution Used 
WB IF IP 
MANDAG2 Beta-
dystroglycan 
Thi Man & 
Morris (gift) 
Mouse 1/100 1/10 1/10 
1709 Beta-
dystroglycan 
(pY890 form) 
In house Rabbit 1/500 1/150 1/30 
Anti-EEA1 
610456 
EEA1 BD 
Biosciences 
Mouse N/A 1/100 N/A 
Anti-Nedd4 
(#2740S) 
Nedd4 Cell 
Signalling 
Rabbit 1/100 N/A N/A 
Anti-α-Tubulin 
(T5168) 
α-Tubulin Sigma Mouse 1/2000 N/A N/A 
Anti-GFP 
(11814460001) 
GFP Roche Mouse 1/1000 N/A N/A 
Anti-GST 
(1011/1012) 
GST VASCAM Rabbit 1/5000 N/A N/A 
Transferrin 
Receptor (236-
15375) 
Transferrin 
Receptor 
Invitrogen Mouse 1/5000 N/A N/A 
Anti-Clathrin 
Heavy Chain 
Clathrin 
Heavy Chain 
Philipe 
Feraria (gift) 
Mouse N/A 1/10 N/A 
Anti-
Ubiquitin(P4D1) 
Ubiquitin Enzo Life 
Sciences 
Mouse 1/100 N/A N/A 
Biotinylated 
Concanavalin A* 
Various (α-D-
mannosyl and 
α-D-glucosyl 
groups) 
Vector Labs N/A 1/4000 N/A N/A 
Texas Red Anti-
mouse 
Mouse IgG Vector Labs Goat N/A 1/100 N/A 
Texas Red Anti-
rabbit 
Rabbit IgG Vector Labs Goat N/A 1/100 N/A 
FITC Anti-mouse Mouse IgG Vector Labs Goat N/A 1/100 N/A 
FITC Anti-rabbit Rabbit IgG Vector Labs Goat N/A 1/100 N/A 
HRP Anti-mouse 
(A4416) 
Mouse IgG Sigma Goat 1/10000 N/A N/A 
HRP Anti-rabbit 
(A0545) 
Rabbit IgG Sigma Goat 1/10000 N/A N/A 
HRP Extravidin 
(E2886) 
Biotin Sigma Goat 1/20000 N/A N/A 
*Please note that this is technically a lectin, and not an antibody. It is used in the 
same way, so it is presented here. 
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2.6.3 Gel Formulations  
 Separating Gel   Stacking Gel 
        10%                   12% 5% 
30% Acrylamide 
Gel Stock 
Water 
TEMED 
10% Ammonium 
Persulfate 
Bromophenol Blue 
     1.675ml             2.075ml 
     1.875ml             1.875ml 
     1.425ml             1.000ml 
       2.5µl                 2.5µl 
         
        50µl                  50µl 
          (-)                     (-) 
0.8ml 
0.625ml 
3.525ml 
15µl 
 
50µl 
(+) 
Seperating Gel Stock: 1.5M Tris (pH 8.8), 0.4% (v/v) SDS 
Stacking Gel Stock: 0.5M Tris (pH 6.8), 0.4% (v/v) SDS  
2.6.4 Plasmids  
Construct 
Name 
Plasmid 
Backbone 
Selection Other Notes Reference 
WW Domain 
Plasmids 
 
pHH0013 
(derivative 
of pGEX) 
Ampicillin GST- and His-
tagged, cloned 
for bacterial 
expression 
Haiming Huang, 
personal 
communication 
Lamp1-
mcherry 
 
pcDNA3-
EGFP 
Kanamycin Cloned for 
mammalian 
expression 
Jim Norman, 
personal 
communication 
Sialin-GFP 
 
pcDNA3-
EGFP 
Kanamycin Cloned for 
mammalian 
expression 
Jim Norman, 
personal 
communication 
HA-UQ 
 
pcDNA3.1 Ampicillin Cloned for 
mammalian 
expression 
http://www.addgen
e.org/18712/ 
Dystroglyca
n GFP 
 
pcDNA3-
EGFP 
Kanamycin Cloned for 
mammalian 
expression 
Chen et al., 2002 
Dystroglyca
n 
(Y890E) 
GFP 
pcDNA3-
EGFP 
Kanamycin Cloned for 
mammalian 
expression 
Winder lab, 
unpublished 
Dystroglyca
n 
(Y890F) 
GFP 
pcDNA3-
EGFP 
Kanamycin Cloned for 
mammalian 
expression 
Winder lab, 
unpublished 
Beta-
dystroglycan 
(cytoplasmic 
only) 
Pinpoint
TM
 
Xa-1 
Vector 
Ampicillin Biotin-tagged, 
cloned for 
bacterial 
expression 
Thompson et al., 
2008 
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Chapter 3: 
Phosphorylation of Y890 and 
-the Internalization of β-
Dystroglycan 
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3.1.1 Introduction 
To understand the importance of the c-terminus, and in particular Y890, in the 
localization of β-dystroglycan it is first necessary to return to the interaction with 
dystrophin described in the introduction (see Chapter 1, Section 1.1.3). As 
previously described (see Chapter 1, Sections 1.2.1-1.2.4), this interaction is lost 
in Duchenne muscular dystrophy (DMD), causing the loss of β -dystroglycan from 
the sarcolemma.  
 
3.1.2 The Importance of the Interaction Between β-
dystroglycan and Dystrophin 
Within the DGC, the interaction between the c -termini of β-dystroglycan and 
dystrophin is critical for the stability of the complex as a whole and as such, is 
well defined and evolutionarily conserved. In vitro binding assays map the 
interaction of dystrophin to a region between residues 3026-3264 and residues 
3265-3442, which together largely encompass the cysteine -rich region (Suzuki et 
al., 1992 ; Suzuki et al., 1994). The first region, which encompasses a WW domain 
binds to the c-terminal 15 amino acids of β-dystroglycan, whilst the second region, 
which contains EF hand and ZZ domains stabilizes this interaction (Jung et al., 
1995 ; Rentschler et al., 1999). This mode of binding extends to other dystrophin-
family proteins, including utrophin and α-dystrobrevin, and these regions not only 
show high homology, but high conservation between species (Koenig et al., 1988 ; 
Chung et al., 1999). This interaction is central to a large number of complexes 
containing β-dystroglycan. A crystal structure of the WW domain of dystrophin 
bound to the c-terminus of β-dystroglycan reveals the biochemical reasons for this: 
both the C-terminal PPPY motif, which contains Y890, and R887 of β-
dystroglycan are pivotal in binding and the EF hand and ZZ domains of dystrophin 
support this interaction and provide specificity (Huang et al., 2000). These in vitro 
data are further confirmed by in vivo studies. Not only can the binding domains of 
dystrophin and utrophin immunoprecipitate β-dystroglycan from skeletal muscle 
preparations (Jung et al., 1995 ; Chung et al., 1999), but confocal 
immunofluorescence microscopy and freeze-fracture electron microscopy reveal a 
close association (≤10nm) between the c -termini of dystrophin and β-dystroglycan 
(Cullen et al., 1998 ; Stevenson et al., 1998).  
The potential of truncated dystrophins and utrophins in therapies for DMD 
underlines the importance of the interaction with the c-terminus of β-dystroglycan. 
Transgenic or adenoviral-mediated expression of truncated versions of dystrophin, 
which retain the β-dystroglycan and actin binding domains, ameliorate dystrophic 
pathology and restore the DGC in both the mdx and dko mouse models of DMD 
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(Phelps et al, 1995 ; Rafael et al., 1998 ; Gregorovic et al., 2006). It is of interest 
to note that these studies are based on the observation that patients with the milder, 
Becker muscular dystrophy (BMD) often express truncated dystrophins of a similar 
nature, although the relationship between mutation and phenotype is not as 
consistent in humans as it is in mice (Aartsma-Rus et al., 2006). These findings 
have are also replicated with adenoviral and peptide delivery of utrophins, which 
are truncated in a similar manner (Rafael et al., 1998 ; Gilbert et al., 1998 ; 
Wakefield et al., 2000 ; Sonnemann et al., 2009). However, it is important to 
reiterate that these truncated proteins all retain the actin -binding regions of 
dystrophin and utrophin. Transgenic overexpression of Dp71, an isoform of 
dystrophin lacking the actin-binding region, results in a restoration of DGC 
components to the sarcolemma with little improvement in mdx pathology (Cox et 
al., 1994 ; Straub et al., 1997). Here, one can distinguish between the importance 
of a functional link to the cytoskeleton in dystrophic aetiology, and the 
stabilization of β-dystroglycan and the DGC at the sarcolemmal membrane 
mediated by the cysteine-rich regions of dystrophin and utrophin.  
Finally, unusual patients and revertant expression of truncated dystrophins provide 
evidence for the importance of the interaction with the c -terminus of β-
dystroglycan. Severe DMD patients have been described in the literature with in -
frame deletions of the cysteine-rich region of dystrophin (Bies et al., 1992 ; 
Aartsma-Rus et al., 2006 ; Beroud et al., 2007). Despite correct sarcolemmal 
localization of dystrophin, the inability of this protein to bind the C-terminus of β-
dystroglycan leads to a severe pathology. In addition, an analysis of 17 BMD 
patients expressing various levels of truncated dystrophin, which all maintain the 
cysteine-rich domain, demonstrates a correlation between the levels of dystrophin 
and β-dystroglycan present at the sarcolemmal membrane (Anthony et al., 2011). 
In addition, biopsies from DMD patients containing revertant fibres, which 
produce similar, truncated dystrophins, also exhibit correct sarcolemmal 
localization of β-dystroglycan and α-sarcoglycan (Arechavala-Gomeza et al., 
2010).  
The summation of these findings leads to the established view of the sarcolemmal 
localization of β-dystroglycan: that it is dependent on the presence of dystrophin, 
or proteins containing similar binding domains, to scaffold β -dystroglycan. 
However, the molecular analysis of dystrophic pathology, as well as other 
evidence, can also be used to propose that the residues within the c -terminus of β-
dystroglycan are critical for its stabilization at the membrane, and that the same 
residues may play a pivotal role in its loss. In this instance, the interaction with 
dystrophin and related proteins retain the importance suggested by numerous 
studies to date, but instead this interaction serves to protect, rather than scaffold, 
the c-terminus of β-dystroglycan. Thus, one can postulate that these proteins only 
scaffold β-dystroglycan because they block internalization.  
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3.1.3 The Effect of Y890 Phosphorylation 
Despite the extensive characterization of the interaction with dystrophin, the loss 
of β-dystroglycan from the plasma membrane can not be explained by any model 
that solely deals with this interaction, or interactions of a similar nature , exerting a 
scaffolding function. Biopsies from limb-girdle muscular dystrophy 2C-F patients, 
who lack the SGC, exhibit reduced levels of β -dystroglycan at the plasma 
membrane despite near normal levels of sarcolemmal dystrophin (Metzinger et al., 
1997). An early characterization of the mdx mouse demonstrated the existence of 
dystroglycan complexes that were not associated with utrophin or other proteins in 
the DGC (Matsumara et al., 1992), and even when utrophin is significantly up-
regulated in the mdx disease state, there is no strict correlation between the levels 
of utrophin and sarcolemmal β-dystroglycan (Dowling et al., 2002). Furthermore, 
there is significant data to suggest the existence of membranous dystroglycan in 
other tissues lacking these cytoskeletal linker proteins (Durbeej et al., 1999 ; Loh 
et al., 2000) and at the sarcolemma of mice lacking both utrophin and dystrophin 
(Deconinck et al., 1997a). Whilst it is not possible to rule out the action of other, 
uncharacterized proteins acting in the place of dystrophin and utrophin, as is 
exemplified by the substituting role of plectin 1f in the mdx disease state 
(Rezniczek et al., 2007), there could to be an additional factor controlling the 
localization of β-dystroglycan to membranous complexes. The phosphorylation 
state of Y890 is a candidate in this regard, as Y890 is part of the PPPY motif 
bound by the WW domains of dystrophin and utrophin.  
The phosphorylation of Y890 is also linked to an altered localization of β-
dystroglycan within a separate, intracellular compartment. This non -sarcolemmal 
distribution is also observed in murine skeletal muscle and β -dystroglycan with 
this post-translational modification is separate from that found at the plasma 
membrane (Sotgia et al., 2001 ; Sotgia et al., 2003 a). Interestingly, phosphorylation 
at this residue also blocks the interaction with dystrophin and utrophin, 
presumably due to disruption of the WW domain binding site (James et al., 2000 ; 
Illsey et al., 2001). A caveat of this and earlier work is that phosphorylation of this 
residue was not measured directly and may be caused by artefacts of the 
experimental systems used, such as the overexpression of c -Src (Sotgia et al., 
2001). However, phosphorylation of this tyrosine has been reported in other cell 
lines in response to adherence, and in the association with Tsk5 (James et al., 2000 
; Thompson et al., 2008), which, along with the presence of intracellular puncta in 
muscle fibres, suggests that this is a normal, physiological process (Sotgia et al., 
2003a).  As well as abrogating the interaction with dystrophin or utrophin, the 
phosphorylation of Y890 would itself be blocked by the binding of these proteins 
(Jung et al., 1995 ; Huang et al., 2000) and hence, Y890 phosphorylation could 
have a role in dystrophic pathology by acting as a molecular switch in the function 
of β-dystroglycan. 
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This idea is not without precedent: phosphorylation of the cytoplasmic tail of β -
dystroglycan, albeit at different residues, also changes the signalling properties of 
this molecule, by altering the kinases bound by this protein (Spence et al., 2004). 
Accounting for this also provides an explanation for why some β -dystroglycan 
remains at the plasma membrane in the absence of dystrophin, utrophin or both 
these proteins: presumably because phosphorylation is a requirement for the 
initiation of internalization (Deconinck et al., 1997 a ; Sotgia et al., 2003a). Given 
the unstructured nature of the cytoplasmic domain of β-dystroglycan, which is 
largely attributable to a high proline content, a post -translational modification such 
as phosphorylation can have a large impact on the molecular activity of this 
protein by the generation, or removal, of binding sites fo r other proteins. Thus, it 
would seem that Y890 phosphorylation may be crucial for a model describing the 
loss of β-dystroglycan from the plasma membrane. 
 
3.1.4 Hypothesis: Y890 Phosphorylation is Required for the 
Internalization of β-Dystroglycan in H2K Myoblasts 
Given that Y890 phosphorylation prevents the interaction with cytoskeletal linker 
proteins found in cell adhesion structures, is only possible in the absence of 
binding by dystrophin or utrophin, and could promote the recruitment of other 
binding proteins, it was hypothesized that this modification would play a key role 
in the loss of β-dystroglycan from the plasma membrane. Also, given the exclusive 
separation of β-dystroglycan with this modification from membranous β-
dystroglycan, it seemed logical that this modification would exclusively drive 
internalization, whereas the unmodified form would remain at the plasma 
membrane. Experiments were performed in H2K myoblasts, which have been 
previously demonstrated to be amenable for the molecular study of β -dystroglycan 
(Thompson et al., 2008 ; Thompson et al., 2010) as well as providing an ideal 
compromise between a cell line and skeletal muscle tissue (see Chapter 1, Section 
1.3.1).  
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3.1.5 1709 and MANDAG2: Specific Information on the 
Antibodies Used in This Study 
The study of the phosphorylation of Y890 and how this affects β -dystroglycan was 
made possible by the use of two antibodies available in the Winder lab. Owing to 
the similar nature of the epitopes, and the important nature of the antibodies in the 
analyses of the following data, a brief, detailed explanation of the two antibodies is 
given here. Both antibodies are raised against the last 15 residues at the c -terminus 
of β-dystroglycan, KNMTPYRSPPPYVPP, and hence, recognize exactly the same 
region. However, 1709 was raised against a peptide containing an additional 
phosphate on Y890, or KNMTPYRSPPPpYVPP. Hence the two epitopes for these 
antibodies are not identical. Both antibodies have been demonstrated to bind their 
target epitopes on peptide arrays (Figure 1) and do not recognize their cognate 
phosphorylated or unphosphorylated epitopes. One can draw a useful parallel here 
between the binding of MANDAG2 and the WW domain of dystrophin/utrophin, 
which is also abrogated upon phosphorylation of this residue. Consequently, 1709 
and MANDAG2 can be thought of as specific sensors for the phosphorylation state 
of Y890. Importantly, β-dystroglycan that is phosphorylated on tyrosines outside 
of this region is also detected by these antibodies, but the implications of this will 
be discussed later. 
 
 
 
 
 
 
 
 
 
Figure 1: Peptide arrays (Invatis) representing the cytoplasmic domain of β -
dystroglycan and a phospho-peptide of the last 15 amino acids were probed with 
the two antibodies used in this study. In triplicate, MANDAG2 bound the sequence 
KNMTPYRSPPPYVP whereas 1709 bound the sequence KNMTPYRSPPPpYVPP. 
Importantly, both antibodies are specific for the two phosphorylation states  of 
Y890. All experiments performed by Dr. Chris Moore and data is reproduced with 
permission 
 51 
3.2.1 Phosphorylation of Y890 is Linked to a Change in the 
Cellular Localization of β-Dystroglycan 
To begin, a brief examination of the localization of β-dystroglycan in H2K 
myoblasts was conducted. Following on from the results of Sotgia et al. (2003), if 
the hypothesis that phosphorylation of Y890 causes internalization of β -
dystroglycan was correct, then this would be reflected by a difference in the 
cellular staining pattern of Y890-phosphorylated β-dystroglycan when visualized 
by immunofluorescence. H2K myoblasts were co-stained with MANDAG2 
(unphosphorylated form) and 1709 (pY890 form) antibodies. Figure 2 contains 
representative epiflourescent images showing a distinct punctuate staining pattern 
of pY890 β-dystroglycan. Owing to the limited resolution of epifluorescence 
microscopy, it is not possible to conclude that the 1709 stain is internal, however it 
does show a clear separation from the unphosphorylated form and the punctuate 
nature of the stain, reminiscent of intracellular vesicles, does not disprove the 
initial hypothesis. 
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Figure 2: Reprentative images of an H2K myoblast fixed and immunostained with 
MANDAG2 (A) and 1709 (B). Shown are single channel fluorescence images 
(A,B) and (C) false colour merged images with MANDAG2 in red, 1709 in green 
and DAPI in blue. The two stains, whilst showing some overlap, generally show 
separate staining patterns. To the right are contrast-enhanced versions of the boxes 
in (C), which permit easier visualization in the difference of the two stains.  
C 
A B 
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3.2.2 Development of Biotinylation Assay: Optimization of 
Biotinylation Buffer 
To further probe the link between Y890 phosphorylation and internalization, a 
routine, biotinylation assay for endocytosis was employed (Smythe et al., 1992). 
The biotinylation assay for internalization requires the covalent modification of 
extracellular lysines of plasma membrane proteins with biotin attached by a 
disulfide linker (sulfo-NHS-ss-biotin). Following incubation at a temperature 
permissive for endocytosis, modified proteins that have been internalized are 
protected from washes in reducing agents, such as glutathione. Hence, internalized 
proteins retain the biotin modification, whereas proteins that remain at the plasma 
membrane lose this modification. Following lysis, proteins can be separated into 
internalized and membranous fractions based on streptavidin chromatography. As 
this assay had been used with various cell lines, but not H2K myoblasts, conditions 
suitable for this study were first elucidated. Fortunately, one paper had been 
published employing this assay to study β -dystroglycan and thus, this was used as 
a starting point for the development of the assay with H2K myoblasts (Sgambato et 
al., 2006). 
 
As a first step, the concentration of sulfo-NHS-ss-biotin that gave saturating 
labelling of β-dystroglycan was determined. Given the range of concentrations 
used to study various proteins, concentrations of 0.05-0.5mg/ml were initially 
tested. As the aim was to determine maximal surface labelling, the steps involving 
incubation at 33°C and washing with reducing agents were omitted from the 
biotinylation protocol (see Chapter 2, Section 2.3.5). From densitometric analysis 
of western blots probed for β-dystroglycan, it is clear that saturation of the system 
is reached at 0.3mg/ml sulfo-NHS-ss-biotin (Figure 4). To account for potential 
sources of error between experiments, such as variation in cell density or 
variations in the purity of sulfo-NHS-ss-biotin between batches, a concentration of 
0.5mg/ml sulfo-NHS-ss-biotin was used in the biotinylation buffer for all 
subsequent experiments. 
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Figure 3: An outline of the biotinylation assay for endocytosis. In this simplified 
outline there are two membrane proteins, one of which undergoes endocytosis 
(green), and one which does not (red). Both membrane proteins are covalently 
bound to a disulphide linker (brown) bound to biotin (blue). After allowing 
membrane proteins to internalize at a temperature permissive for endocytosis, an 
excess of reducing agent (yellow triangles), which is membrane impermeable, is 
added and the disulphide links are broken. The excess reducing agent and free 
biotin molecules are then washed away, leaving the only the internalized proteins 
labelled. 
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Figure 4: Estimating the concentration of sulfo-NHS-ss-Biotin at which saturating 
labelling of beta-dystroglycan occurs. H2K myoblasts were treated with various 
concentrations of sulfo-NHS-ss-Biotin for 30 minutes. After quenching, cells were 
lysed and the lysates were mixed with streptavidin-Sepharose. Following 
streptavidin chromatography, the pelleted proteins were resolved on SDS-PAGE 
gels, prior to western blotting with MANDAG2. The blots were scanned and 
analyzed by densitometry. A representative blot scan (A) and a curve of the data 
(B) are depicted. All treatments were performed in triplicate, error bars represent 
S.E.M. 
 
0.50 0.25 0.17 0.10 0.05 
Β-Dystroglycan 
(MANDAG2) 
Concentration of sulfo-NHS-ss-biotin (mg/ml) 
B 
A 
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3.2.3 Development of Biotinylation Assay: Optimization of 
Stripping Washes 
The second problem that needed to be addressed was what conditions, if any, 
would give suitable reduction of the disulfide linkers, and thus, stripping of the 
biotin tag, to ensure proper discrimination between internalized and membranous 
β-dystroglycan. Reagents that are fit for this purpose need to have a high reducing 
potential, be membrane impermeable and have a low cytotoxicity. Initially, a 
solution of 50mM reduced glutathione (pH 7.75) was used for this purpose, 
however it became clear from preliminary results that this was not sufficient. Table 
1 details a progressive iterative search, through several reducing agents, wash 
times and frequencies to find an ideal solution for this purpose. To establish if a 
particular set of washes were adequate, the biotinylation protocol was performed, 
except any incubation at 33°C was omitted. The rationale for this choice was that a 
“complete” reduction would remove all biotin tags on the cell surface after a 
saturating labelling step, or, in practical terms, any pellet immunoreactivity on 
western blots probed for β-dystroglycan (MANDAG2). Hence, a percentage 
stripping efficiency could be estimated from the immunoreactivity of the 
supernatant fraction divided by the total (supernatant plus pellet fraction)  
immunoreactivity, as determined by densitometry, for each wash condition. In this 
manner, the relative effectiveness of each wash trial could be compared.  
 
Treatment Estimated Stripping 
Efficiency (%) 
PBS, 3x20 minute washes (Control) 2 
50mM Glutathione in PBS (pH 7.75), 2x20 minute 
washes 
50mM Glutathione in PBS (pH 7.75), 3x20 minute 
washes 
50mM Glutathione in 75mM NaCl, 75mM NaOH, 1% 
(w/v) BSA, 3x20 minute washes 
50mM Glutathione in 150mM NaCl, 1mM CaCl2, 
1mM MgCl2, 3x20 minute washes 
50 
55 
 
51 
 
69 
15mM TCEP in 50mM HEPES (pH7.5), 150mM NaCl, 
1mM CaCl2, 1mM MgCl2, 2x30 minute washes 
50mM TCEP in 50mM HEPES (pH7.5), 150mM NaCl, 
1mM CaCl2, 1mM MgCl2, 2x30 minute washes 
100mM TCEP in 50mM HEPES (pH7.5), 150mM 
NaCl, 1mM CaCl2, 1mM MgCl2, 2x30 minute washes 
150mM TCEP in 50mM HEPES (pH7.5), 150mM 
NaCl, 1mM CaCl2, 1mM MgCl2, 2x30 minute washes 
200mM TCEP in 50mM HEPES (pH7.5), 150mM 
NaCl, 1mM CaCl2, 1mM MgCl2, 2x30 minute washes 
250mM TCEP in 50mM HEPES (pH7.5), 150mM 
NaCl, 1mM CaCl2, 1mM MgCl2, 2x30 minute washes 
 
10 
 
50 
 
50 
 
52 
 
62 
 
61 
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300mM TCEP in 50mM HEPES (pH7.5), 150mM 
NaCl, 1mM CaCl2, 1mM MgCl2, 2x30 minute washes 
 
68 
50mM MesNa in 50mM Tris-HCl (pH8.6), 100mM 
NaCl, 1mM EDTA, 0.2% (w/v) BSA, 2x30 minute 
washes 
100mM MesNa in 50mM Tris-HCl (pH8.6), 100mM 
NaCl, 1mM EDTA, 0.2% (w/v) BSA, 2x30 minute 
washes 
150mM MesNa in 50mM Tris-HCl (pH8.6), 100mM 
NaCl, 1mM EDTA, 0.2% (w/v) BSA, 2x30 minute 
washes 
200mM MesNa in 50mM Tris-HCl (pH8.6), 100mM 
NaCl, 1mM EDTA, 0.2% (w/v) BSA, 2x30 minute 
washes 
250mM MesNa in 50mM Tris-HCl (pH8.6), 100mM 
NaCl, 1mM EDTA, 0.2% (w/v) BSA, 2x30 minute 
washes 
300mM MesNa in 50mM Tris-HCl (pH8.6), 100mM 
NaCl, 1mM EDTA, 0.2% (w/v) BSA, 2x30 minute 
washes 
 
90 
 
86 
 
93 
 
99 
 
100 
 
100 
50mM MesNa in 50mM Tris-HCl (pH8.6), 100mM 
NaCl, 1mM EDTA, 0.2% (w/v) BSA, 3x20 minute 
washes 
100mM MesNa in 50mM Tris-HCl (pH8.6), 100mM 
NaCl, 1mM EDTA, 0.2% (w/v) BSA, 3x20 minute 
washes 
150mM MesNa in 50mM Tris-HCl (pH8.6), 100mM 
NaCl, 1mM EDTA, 0.2% (w/v) BSA, 3x20 minute 
washes 
 
93 
 
99 
 
100 
 
 
Table  1: A summary of all the stripping conditions tested and their estimated 
efficiencies for the biotinylation assay. H2K myoblasts were washed on ice with  
chilled biotinylation buffer (0.5mg/ml sulfo-NHS-ss-biotin in PBS) and then 
immediately treated with the various stripping conditions. H2K myoblasts were 
kept on ice throughout the stripping washes and subsequent lysis to prevent 
internalization. The lysates were then mixed with streptavidin-Sepharose. 
Following streptavidin chromatography, the pellet and supernatant proteins were 
resolved on SDS-PAGE gels, prior to Western blotting with MANDAG2. The blots 
were scanned and analyzed by densitometry. “Estimated Stripping Efficiency” is 
defined as the supernatant immunoreactivity, divided by the total (supernatant  and 
pellet) immunoreactivity and is expressed as a percentage.  
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Changes to the number of washes with, and the composition of, the reduced 
glutathione solution exhibited some improvements in stripping efficiency; however 
these improvements were still far below the required level. Adopting the method of 
Rojek et al. (2008), tris(2-carboxyethyl)phosphine (TCEP) was tested next as a 
potential stripping agent. The concentration taken from the literature, 15mM, gave 
the lowest stripping efficiency of all reagents tested (apart from PBS), so a series 
of higher concentrations up to 300mM were tested. Whilst this approach generated 
a considerable improvement, the maximal level  of stripping (68% with 300mM, 
Table 1) was comparable to that observed with reduced glutathione (69%, Table 1), 
and therefore an alternative reducing agent was trialled. An initial trial with 
100mM 2-mercaptoethane sulfonate (MesNa), which used the buffer conditions 
and wash frequencies of Carter et al., (1993) , gave a high stripping efficiency 
(86%, Table 1). A range of concentrations up to 300mM were subsequently tested, 
and concentrations of 200mM and above gave complete stripping (99% and above, 
Table 1).  
A subtle difficulty with the use of MesNa, and reducing agents in general, is that 
concentrated solutions can exert a cytotoxic effect, due to the additional reduction 
of the extracellular domains of adhesion proteins and consequent loss of adherent 
cells from the dish surface (Liz Smythe, personal communication). This problem 
was also observed with H2K myoblasts, which are an adherent cell line, and at 
higher concentrations of MesNa losses of up to 90% of cells were observed (data 
not shown). To ameliorate this experimental difficulty, a final series of triplicate 
washes with lower concentrations of MesNa were examined, with the reasoning 
that an additional wash would increase the stripping efficiencies without causing 
loss of H2K myoblasts. From the higher stripping efficiencie s observed (Table 1 
and Figure 5) and reduced or absent loss of cells (data not shown), it seems that 
this was the case. This series also served as a verification of the high efficiencies 
obtained with the original series of MesNa concentrations. As a result, triplicate 20 
minute washes with 100mM MesNa were used for  all subsequent biotinylation 
experiments. As an additional precaution, all subsequent experiments were also 
performed in parallel with a stripping control using the same experimental 
procedure to estimate stripping efficiency. On the occasion that the str ipping 
control failed, the data set was discarded and not used for the analysis presented in 
this thesis. 
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Figure 5: Testing combinations of MesNa concentration and wash  conditions for 
optimum stripping. H2K myoblasts were biotinylated and stripped as indicated. 
Following lysis and streptavidin chromatography the supernatant (S/N) and pellet 
samples were resolved on SDS-PAGE gels and western blotted with MANDAG2 
(β-dystroglycan).  The presence of immunoreactivity in the pellet lanes indicates 
incomplete or sub-optimal stripping. As shown here, the stripping efficiency with 
lower concentrations of MesNa can be improved by increasing the frequency of 
washes. It is also interesting to note that, to the eye, 3x20 minute washes with 
50mM MesNa is sufficient to remove all pellet immunoreactivity. However, as 
shown in Table 1, densitometric analysis reveals that there is residual reactivity.  
 
3.2.4 Development of Biotinylation Assay: A Loading Control 
for Pellet Fractions 
The final problem that required resolution was the need for a loading control for 
the pellet fractions upon western blotting. Normally, ubiquitous proteins such as 
tubulin or actin are used, and this was the case for the supernatant fractions. 
However, owing to the nature of the biotinylation experiment, these proteins would 
not make suitable loading controls. Other membrane proteins, which would be 
biotinylated and internalized in the course of the experiment, would make poor 
loading controls as these would be subject to endocytic regulation and hence, the 
levels of these proteins would vary between incubations. Natively biotinylated 
intracellular proteins were initially proposed as ideal loading controls, however 
western blotting of pellet fractions with extravidin-HRP produced no discernible 
bands (data not shown). Presumably this is because these proteins are either absent 
in H2K myoblasts or are present at levels below the detection limit of western 
blotting. 
  50mm MesNa         100mM MesNa     150mM MesNa 
   S/N        Pellet          S/N         Pellet         S/N       Pellet 
2 x 30 minute 
washes 
3 x 20 minute 
washes 
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As an alternative a biotinylated lectin, concanavalin A, was used to probe Western 
blots of pellet fractions. Concanavalin A binds to several sugar moieties present in 
glycoproteins (Lei et al., 2009). Assuming that H2K myoblasts contain such a 
protein, it would be possible to use this as a loading control specific for the pellet 
fractions. Figure 6 contains images of both a concanavalin A blot and Coomassie 
stained gel showing several low molecular weight bands which are specific for the 
pellet fraction and invariant between various incubation times. These bands were 
consistently resolved at around 15kDa and are therefore unlikely to reflect 
spurious reactivity at the gel front. Whilst the exact nature of these proteins is 
unknown, the identity of these proteins was considered to be beyond the scope of 
investigation. As concanavalin A blotting gave a robust, repeatable and pellet -
specific response it was used as a loading control for later experiments. It is also 
interesting to note that a slower migrating band appeared to be specific for the 
supernatant samples. Hence, the presence of this band in pellet fractions could be 
used as a marker for supernatant contamination and thus, provided an additional 
control for the purity of all pellet samples analyzed.  
 
 
  
 
 
 
 
 
 
 
Figure 6: (A) Coomassie stained gel and (B) Concanavalin A blot of the 
supernatant (S/N) and pellet (P) lanes of a biotinylation experiment. Only two 
concanavalin A reactive bands (marked by arrowheads) appear to be specific to the 
P (pellet) lanes.  The strong bands (or “doublet”) seen at the bottom of the 
coomassie stained gel are also detected upon Western blotting. As these bands 
appear to be specific for the pellet lane and did not vary over the course of 
incubation times used in these experiments, they were used as pulldown and 
loading controls for later work. 
 
B A 
Fraction: S/N P    S/N  P  S/N    P   S/N   P  S/N    P Fraction: S/N   P    S/N    P    S/N     P    
Time:           0 min    5 min      10 min    20 min  30 min    Time:      0 min        10 min     30 min  
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3.2.5 The pY890 Form of β-Dystroglycan is Selectively 
Internalized in H2K Myoblasts 
Having developed the biotinylation assay for internalization to the desired level, it 
was now possible to test if the change in cellular distribution observed with 
immunofluorescence microscopy was supported by the internalization of pY890-
modified β-dystroglycan from the plasma membrane. The internalization assay was 
performed as described in materials in methods (Section 2.3.5) and replicate 
samples for 10, 20 and 30 minutes of internalization at 33°C were collected. 
Representative Western blots corresponding to this time course are shown in 
Figure 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: A time course of β-dystroglycan internalization in H2K myoblasts at 
33°C. H2K myoblasts were treated for the biotinylation assay (as described in  
Chapter 2, Section 2.3.5), prior to lysis and streptavidin chromatography. 
Supernatant and pellet samples were resolved on SDS-PAGE gels prior to western 
blotting with the antibodies indicated. Y890-phosphorylated β-dystroglycan is 
specifically internalized and appears to peak at the 20 minute time point. Blotting 
for the transferrin receptor serves as a control for the experimental technique.  
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The most striking finding from these data is that the pY890-modified form of β-
dystroglycan can be detected in the internalized fractions, whereas the 
unphosphorylated form is not. Whilst this does not strictly suggest a causative link, 
it certainly shows that the phosphorylation of this residue is linked to the process 
of β-dystroglycan internalization. Furthermore, as no unphosphorylated β-
dystroglycan is detected in the internalized fractions, one can conclude that this 
pY890-modification persists for the duration of the time course, and that the native 
form of the protein is not left unmodified if it is internalize d. It is possible to draw 
this conclusion as the two antibodies used to discriminate the two forms of β-
dystroglycan both bind to the same 15-amino acid region (Figure 1). It was also 
interesting to see the presence of a doublet, which migrated more slowly than full-
length β-dystroglycan, specifically on blots of the pY890-modified and 
internalized form of β-dystroglycan. The potential identity of these bands will be 
discussed later. 
In addition to the loading controls, blotting for the transferrin receptor  (anti-CD71, 
Cell Signalling) gave a control for the experimental system. The transferrin 
receptor is a classic marker of endocytic studies and is known to undergo 
constitutive cycling between the plasma membrane and internal compartments 
(Ghosh et al., 1994). By comparing the ratio of internal to membranous 
immunostaining, it would appear that peak internalization of this receptor occurred 
within 10 minutes and that subsequent recycling back to the plasma membrane 
occurred after this time point. Whilst there is significant variation in the temporal 
dynamics of transferrin receptor internalization and recycling between different 
cell and tissue systems, this observation is in keeping with findings in the 
literature (Hopkins et al., 1983 ; Klausner et al., 1983) and with 
immunofluorescence studies on H2K myoblasts (see Chapter 5).  
By comparing the ratio of internal and membranous pY890-modified β-
dystroglycan in these blots, one can also conclude that the peak β -dystroglycan 
internalization occurs at around 20 minutes at 33°C. At the later, 30 minute time 
point this ratio has reduced. This could be due to recycling of β -dystroglycan back 
to the plasma membrane, loss of the pY890 modification or degradation of the 
protein. Unfortunately, this time course was difficult to replicate in entirety due to 
technical limitations: namely the loss of cells from dishes during the stripping 
washes, the amount of material required and the time taken to perform the 
experiment and subsequent analysis. Owing to these difficulti es, the peak of 
internalization at twenty minutes was used to test the hypothesis instead.  
As shown in Figure 8, the findings of the initial time course experiments could be 
robustly verified: the internalized β-dystroglycan was phosphorylated on Y890, 
whereas the unmodified form was found exclusively at the membrane. Repeating 
the assay without internalization, or  with 0 minutes of incubation at 33°C, shows 
that the biotin tag is not protected by a non-endocytic mechanism or anomaly of 
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the experimental system . Presumably these pools of β-dystroglycan exist in 
separate membrane domains or quickly separate upon internalization, as there is no 
internalized,  unmodified β-dystroglycan present after 20 minutes. However, the 
possibility that unmodified β-dystroglycan is internalized, if only due to bulk 
effects, cannot be excluded: the levels of this form may be below the  detection 
limits of the system. Nonetheless, the fact that pY890-modified β-dystroglycan is 
selectively internalized from the plasma membrane is conclusively demonstrated 
by these data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Replicates of the 0 (A) and 20 (B) minute time points of the biotinylation 
assay. H2K myoblasts were assayed as described (see Chapter 2, Section 2.3.5), 
prior to lysis and streptavidin chromatography. Post -chromatography samples were 
resolved on SDS-PAGE gels prior to western blotting for the proteins indicated. 
Whilst the specific internalization of Y890-phosphorylated β-dystroglycan is clear, 
the presence of slowly migrating bands, which is suggestive of further post -
translational modification, is less consistent yet still apparent.  
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3.2.6 Hyperphosphorylation is not Solely Responsible for the 
Modification of Internalized β-Dystroglycan 
The slow-migrating doublet present on the 1709 blots of the internal fractions, 
which can also be seen in the earlier t ime course experiments (Figure 7), is also 
seen in these data, although the intensity of immunoreactivity is variable. This 
doublet corresponds to a protein approximately 10kDa larger than the full -length 
(43 kDa) form of β-dystroglycan, which runs at 43kDa. Interestingly, these bands 
are only observed after 10 or 20 minutes of incubation (Figures 7 and 8) and are 
not observed at the 0 minute time point, which collectively suggests that they are 
the product of further modification of β-dystroglycan, after internalization has 
occurred. The cytoplasmic domain of β -dystroglycan contains multiple tyrosine 
residues that could be potential sites for phosphorylation. Thus, it can be 
hypothesized that the slower bands may be the result of hyperphosphorylation of β -
dystroglycan on residues other than Y890.  
Whilst this hypothesis has some credence in the literature (Moraz et al., 2012 and 
see below), it is unlikely to be the case in this experimental system. Orthovanadate 
treatment of cells is a means of causing hyperphosphorylation of proteins, 
including β-dystroglycan, due to the inhibition of tyrosine phosphatases present in 
the cell (James et al., 2000). Figure 9 shows the effects of a 30 minute treatment of 
H2K myoblasts in serum free media with or without 1mM orthovanadate The shifts 
in the electrophoretic mobility of both the unphosphorylated and pY890 -modified 
forms of β-dystroglycan, when visualized by western blotting, strongly suggest 
that other sites in the cytoplasmic domain are phosphorylated in H2K myoblas ts. 
One should note that the MANDAG2 blot is detecting the phosphorylation of these 
other sites, and not the Y890 residue, as phosphorylation at the Y890 would 
abrogate binding of the antibody (Figure 1). However, the fact remains that 
hyperphosphorylation does not cause the same magnitude of shift in 
electrophoretic mobility that is observed on western blots of the internalized 
fractions of β-dystroglycan (Figures 7 and 8). One can then conclude  that some 
other form of post-translational modification is responsible for these species and is 
potentially linked to the internalization of β -dystroglycan, although the presence of 
a doublet suggests that this modification may also be partnered with additional 
phosphorylations.  
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Figure 9: H2K myoblasts were treated with 1mM orthovanadate for 1 hour prior to 
lysis. Samples were resolved on SDS-PAGE gels and western blotted with either 
1709 or MANDAG2. Whilst orthovanadate treatment caused a shift in the 
electrophoretic mobility of β-dystroglycan detected with both antibodies, which 
suggests that other tyrosine residues within the cytoplasmic domain are 
phosphorylated, this shift was not as large as observed in the biotinylation 
experiments (Figures 7 and 8). 
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3.3.1 Discussion 
β-dystroglycan is traditionally thought of as part of the DGC, a static, costameric 
adhesion structure in muscle fibres (Yoshida et al., 1990 ; Ervasti et al., 1991a ; 
Rybakova et al., 2000). Despite the strong association of β -dystroglycan with 
dystrophin in the DGC (Anderson et al., 1996), and related proteins in other cell 
types, the maxim that a membranous localization of this protein is solely 
dependent on interactions with these proteins can be called into question 
(Matsumara et al., 1992 ; Deconinck et al., 1997 a ; Durbeej et al., 1999 ;  Loh et 
al., 2000 ; Dowling et al., 2002). When β -dystroglycan is phosphorylated on Y890, 
both the interaction with dystrophin and utrophin is blocked (James et al., 2000 ; 
Illsey et al., 2001) and the localization is altered (Sotgia et al., 2003 a). It was 
therefore hypothesized that Y890 phosphorylation would drive internalization of β -
dystroglycan from the plasma membrane in H2K myoblasts.  
Whilst MANDAG2 is a relatively robust and well -characterized antibody, a 
description of 1709 is required. 1709 is a polyclonal antiserum obtainined by 
immunization of a rabbit with the β-dystroglycan C-terminal phosphopeptide 
KNMTPYRSPPpYVPP. It is routinely used and was previously characterized 
without further affinity purification (Illsey et al., 2001; Miller et al., 2012). A 
number of lines of evidence support the notion that the antiserum specifically 
recognizes the Y890-phosphorylated form of β-dystroglycan. Firstly, peptide 
epitope mapping indicates that, when used at the appropriate dilutions, the highest 
affinity antibodies within the antiserum recognize the phosphor - but not the 
dephospho-form of the peptide used (Figure 1 and Miller et al., 2012). Secondly, 
1709-reactive bands are observed on western blots of muscle tissue lysates from 
wildtype and Dag1+/Y890F mice, but these bands are not observed in lysates from 
Dag1Y890f/Y890F mice. To be clear, the mutation of the pivotal tyrosine residue 
in the sequence, against which the 1709 antisera is raised, abolishes any binding to 
β-dystroglycan, and hence any detection on a western blot. In a similar vein, 
immunostaining of cross-sections of fixed muscle tissue from wildtype and 
Dag1+/Y890F mice results in an observable signal, whereas staining of 
Dag1Y890F/Y890F tissue cross-sections does not. Limited epitope mapping data 
suggest that both the N- and C-terminal elements surrounding the phosphorylated 
residue are required for epitope recognition, and bioinformatic analysis of relevant 
databases indicates a paucity of proteins that are likely to cross react with this 
antiserum when used at a high dilution. However, to detect such cross -reactive 
species one would have to use a significantly lower dilution of primary antibody 
and, as detailed in Chapter 2 (section 2.6.2), 1709 is used at a comparable dilution 
to the dilutions used in previously published work (Illsey et al., 2001; Miller et al., 
2012). Taken together, these data strongly support the notion that the cross-
reacting material identified by immunoblotting and by immunofluorescence in this 
thesis using this antibody represents phosphorylated forms of β -dystroglycan. 
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There remains the possibility, in the absence of affinity purification against the 
immunogen, that other antibodies present in the antisera may generate signals that 
are distinct from β-dystroglycan. A detailed characterisation of such species by 
mass spectrometry was beyond the scope of this thesis, but could be undertaken i n 
the future. 
 
3.3.2 Y890 Phosphorylation Changes the Cellular Localization 
of β-Dystroglycan 
By using antibodies specific for either the pY890-modified or native form of β-
dystroglycan, it is possible to visualize a change in the distribution of this prot ein 
in H2K myoblasts, in response to this modification, with immunofluorescence 
microscopy (Figure 2). It should be stressed that not all the β -dystroglycan 
molecules were segregated as spots of co-localization were apparent, however this 
may be attributable to the poor resolving power of epifluorescence microscopy 
within the Z-plane. Furthermore, the degree of co-localization is low enough to 
suggest that the two different phospho-forms of β-dystroglycan examined are 
distinctly separated, at least within the cell as a whole.  This idea is not without 
precedent, as β-dystroglycan has previously been demonstrated to be present in 
many different adhesive and signalling structures  (Thompson et al., 2008 ; 
Thompson et al., 2010). 
Within the cell, or muscle fibre, β-dystroglycan contributes to other forms of 
adhesion and so, one might expect particular modifications to be associated with 
changes in cellular localization. Components of the DGC are found within focal 
adhesions with integrin, and these are phosphorylated in response to adhesion 
(Yoshida et al., 1998 ; Kramarcy et al., 2000). β1 -integrin shares adhesive 
components with β-dystroglycan present in focal adhesions (Yang et al., 1995 a ; 
Oak et al., 2003 ; Cerecedo et al., 2008) and engagement of ECM ligands causes a 
change in the phosphorylation state of dystroglycan (Spence et al., 2004). The co -
dependence of the dystroglycan- and integrin-mediated systems of adhesion is 
exemplified by studies of mouse muscles depleted for components of either, or 
both (Rooney et al., 2006). α7-integrin expression is up-regulated when β-
dystroglycan is absent (Cote et al., 2002 ; Allikian et al., 2004) and transgenic 
overexpression (Burkin et al., 2001) or retroviral -mediated delivery (Heller et al., 
2013) ameliorates symptoms of muscular dystrophy in the mdx mouse model. 
Although these findings can be called into question on the basis that levels of β1 -
integrin are of equal, if not greater, importance than α7 -integrin (Brown et al., 
2004 ; Liu et al., 2012), the co-operative nature of these systems is readily 
apparent, with a similar co-dependency in other tissues and experimental systems 
(Nodari et al., 2008). 
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β-dystroglycan is also found in other types of cellular adhesion, besides focal  and 
fibrillar adhesions. These structures include: membrane ruffles (Spence et al., 
2004), filopodia (Batchelor et al., 2007), podosomes (Thompson et al., 2008) and 
the cleavage furrow (Higginson et al., 2008). These structures occur at specific 
sites, adapted to their particular functions and are also highly dynamic (Cox et al., 
2011). It then follows that different forms of β -dystroglycan, which are involved in 
all these different adhesive processes, would exhibit some degree of separation. 
Hence, the fact that the 1709 (pY890) and MANDAG2 (unphosphorylated) stains 
of H2K myoblasts show such a marked difference is not an unexpected finding. 
Indeed, a valid criticism of the H2K myoblast system is that components of many 
adhesive structures may not be expressed at a high enough level to enable this (Sen 
et al., 2011). Therefore, the expectation of such separation would seem unfounded. 
Fortunately a previous study, which uses perturbations in the levels of β -
dystroglycan to modulate cell spreading and adhesion in H2K myoblasts, discounts 
this possibility (Thompson et al., 2010). 
 
3.3.3 Developing the Biotinylation Assay for Internalization in 
H2K Myoblasts 
The need for dynamic changes in localization in the kinds of structures mentioned 
above, partnered with other observations suggesting an intracellular localization of 
the protein (Sotgia et al., 2003a), strongly suggest a requirement for the 
internalization of β-dystroglycan. Furthermore, the microscopy data, whilst not 
conclusive, did not rule out the possibility that pY890-modified β-dystroglycan 
puncta were intracellular, owing to the separate localization from unmodified, 
presumably membranous β-dystroglycan (Figure 2). Hence, a method for 
biochemically distinguishing between internalized and membranous protein s was 
required, so that the importance of Y890 phosphorylation in this regard could be 
addressed.  To this end the biotinylation assay was developed for use in the H2K 
myoblast system.  
The method of selectively biotinylating surface proteins and following  their 
internalization is a well developed technique in the field of endocytosis (see 
section 15.4.3 in “Current Protocols in Cell Biology”, 2 nd Ed.), and there are 
examples of its use in the literature concerning adhesion proteins (Le et al., 1999) 
and even β-dystroglycan (Sgambato et al., 2006). Whilst establishing saturating 
labelling in the experimental system was relatively simple (Figure 4), it quickly 
became apparent from preliminary experiments that achieving a suitable level of 
stripping of biotin tag from surface β-dystroglycan, which had not been 
internalized over the course of the experiment, was difficult. This problem was 
compounded by the fact that stronger stripping conditions, often with higher 
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concentrations of stripping agents, caused a detachment of cells from the 
substratum and their consequent loss (data not shown). Presumably this is due to 
the reduction of disulphide linkages in other membrane proteins that contribute to 
adhesion. Thus, a balance was struck between reduction efficiency and cell loss. 
Beyond reduced glutathione, TCEP (tris(2-carboxyethyl)phosphine) and MesNa 
(sodium mercaptoethane sulphonate), which both have been previously used in the 
literature, were trialled (Rojek et al., 2008 ; Smythe et al., 1992). With various 
adjustments, a final washing step was reached that gave practically complete 
stripping (99%, see Table 1 and Figure 5). However, although reduced, cell loss 
from the dish surface was a consistent technical problem that confounded 
replication and requires further optimization. 
 
3.3.4 The pY890 Form of β-dystroglycan is Internalized From 
the Plasma Membrane 
Despite these technical difficulties, it was possible to perform a time course of 
internalization, with further replication of the 20 minute time  point (Figures 7 and 
8). The most striking feature of these experiments is that the unphosphorylated 
form of β-dystroglycan is not internalized. Given that the pY890 form is present at 
the membrane (data not shown), this means that it is somehow selectively 
internalized and that this post-translational modification is not lost during any 
subsequent trafficking. It should be noted that it is still possible for the 
unphosphorylated form of β-dystroglycan to be internalized, or for this specific 
modification to be lost, however the detection of this is below the sensitivity of the 
experimental system. This is a distinct possibility, given that only a small 
proportion of the total β-dystroglycan within H2K myoblasts is absent from the 
membrane and therefore, despite enrichment with streptavidin chromatography, 
internalized biotinylated species are difficult to detect.  
The time course and subsequent assays are also verified by the internalization and 
recycling of the transferrin receptor, which served as a control for the experimental 
system (Figure 7). Unfortunately, there are no data in the literature regarding the 
kinetics of transferrin receptor recycling in H2K myoblasts. However, it is possible 
to infer that typical internalization and subsequent recycling is occurring from the 
peak internalization time, as defined by the time at which the ratio of internal 
protein levels are at their highest, relative to membrane protein levels. This peak 
internalization time for the transferrin receptor occurs at the earliest timepoi nt of 
10 minutes, which is in agreement with findings in other experimental systems 
(Hopkins et al., 1983 ; Klausner et al., 1983 ; Ghosh et al., 1994). The loss of 
pellet immunoreactivity at subsequent timepoints is largely due to recycling back 
to the plasma membrane where the biotin tag is cleaved and again, this is in 
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agreement with estimates of recycling times under 30 minutes for the transferrin 
receptor (Liz Smythe, personal communication). In a similar way, the pY890 -
modified β-dystroglycan also exhibits a peak of internalization at the 20 minute 
timepoint. Unlike the recycling of the transferrin receptor, which is a well 
documented process, it is not possible to say whether the decline of internalized β -
dystroglycan is due to recycling to the plasma membrane or subsequent 
degredation. Both ideas have precedence in the literature and the case for each is 
discussed below.  
The internalization of β-dystroglycan has been proposed to be part of a degradation 
mechanism (Sotgia et al., 2001) and the blockade of proteasomal degradation in 
mdx mice and DMD patient explants causes the restoration of β-dystroglycan to the 
sarcolemmal membrane (Bonnucelli et al., 2003 ; Assereto et al., 2005 ; Bonnucelli 
et al., 2007), suggesting that the two processes are linked. However, estimates for 
the lifetime of β-dystroglycan in mammary epithelial cells suggest a half-life of 
approximately 12 hours (Sgambato et al., 2006).  Thus it would seem that the 
kinetics of degradation and internalization are not the same.  This does not mean 
that the two processes are not linked: the loss of β -dystroglycan from the plasma 
membrane may be a pre-requisite for degradation, although only a minority of the 
internalized protein may be eventually degraded, with the majority being recycled 
back to the plasma membrane. Indeed, the studies involving proteasomal inhibition 
examine the effects of treatment over large timescales (24 hours – 8 days, 
Bonnucelli et al., 2003 ; Assereto et al., 2005 ; Bonnucelli et al., 2007), therefore 
the restoration of β-dystroglycan to the membrane may be the result of a slow, 
long-term process. Taking this into account, it seems logical to propose that the 
diminution in internal β-dystroglycan at later time points in these data is primarily 
due to recycling. This proposal is in better agreement with the involvement of β -
dystroglycan in dynamic adhesion structures, mentioned earlier, although whether 
this is exactly the case will ultimately require further testing. 
The internalization of full-length pY890-modified β-dystroglycan is also 
accompanied by the internalization of other forms of this protein, which share this 
modification, as determined by the presence of additional bands on western blots 
of the internalized fractions (Figures 7 and 8). These bands have a slower 
electrophoretic mobility, suggesting that these represent species of β -dystroglycan 
with additional modifications, beyond the phosphorylation of Y890. The presence 
of other species of β-dystroglycan, with a slower electrophoretic mobility, has 
been previously described in the literature (James et al., 2000 ; Fernandez et al., 
2010 ; Lara-Chacon et al., 2010) and is a subject of continuing investigation in the 
Winder lab. The cytoplasmic domain of β -dystroglycan contains other tyrosine 
residues, which have also been implicated in the internalization of the protein 
(Moraz et al., 2012). Furthermore, Moraz et al. propose that phosphorylation of 
Y890 is not linked to nor required for internalization. Hence, whilst the importance 
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of Y890 phosphorylation may be disputed, the potential involvement of other 
phosphorylations could not be ignored in this system.  
To test if a shift in the electrophoretic mobility of full -length dystroglycan, 
identical to that observed in the internalization assay, could be produced by hyper-
phosphorylation H2K myoblasts were treated with orthovanadate. Treatments of 
this kind involving β-dystroglycan have been previously used in the literature 
(James et al., 2000), as well as in the similar C2 myoblast system (Nawrotzki e t 
al., 1998). Treatment of H2K myoblasts with orthovanadate does produce a shift in 
the electrophoretic mobility of β-dystroglycan on MANDAG2 and 1709 blots 
(Figure 9). However, this shift is only a few kDa and is not of the same magnitude 
(approximately 10kDa) as is observed for internalized β-dystroglycan (Figures 7 
and 8). This, along with the absence of any bands detected with MANDAG2, 
which one would expect to see if other sites of phosphorylation were responsible 
for internalization, suggest that the additional bands detected on blots for Y890-
phosphorylated β-dystroglycan are due to another, subsequent form of post-
translational modification. Nonetheless, it should be noted that these bands are a 
closely migrating doublet, suggesting that they may rep resent another form of 
modification with and without additional phosphorylations. Furthermore, the data 
presented in this chapter do not exclude the possibility that internalized β -
dystroglycan is phosphorylated on residues other than Y890; they suggest in stead 
that phosphorylation of Y890 is exclusively linked to internalization.  
An alternative method to test this hypothesis would have involved the use of Y890 
mutants, such as the phosphomimetic Y890E or phospho-null Y890F on a 
dystroglycan null, or knocked down background. Such H2K myoblasts were 
available, however preliminary experiments with Y890 mutants (expressed as GFP 
fusion proteins) were inconclusive (data not shown). Whilst there were alterations 
in the kinetics of internalization, the Y890F-GFP mutant was able to internalize in 
a manner that was not significantly different to the Y890E -GFP mutant or the 
unmodified counterpart (Y890-GFP). This effect is potentially attributable to c -
terminal tagging with GFP, which may sterically exclude regulatory factors 
associated with internalization, or otherwise promote internalization in the absence 
of phosphorylation. Hence, GFP-tagged constructs are not suitable for 
internalization assays involving β -dystroglycan. Due to time constraints this 
approach was not pursued further, however future tests of this hypothesis could 
involve mutagenesis of Y890 to examine the contribution of phosphorylation to 
internalization. 
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3.3.5 Y890 Phosphorylation and β-Dystroglycan Internalization 
in Other Systems 
The implications of the data presented in this chapter extend to the realm of 
cellular biology in vivo. Whilst the hypothesis that Y890 phosphorylation leads to 
internalization in a more native state, such as a muscle fibre, has not been directly 
addressed, there is evidence to support the argument that the same mechanisms 
exist in muscle fibres as well as in H2K myoblasts. Data from mice harbouring 
both the mdx and β-dystroglycan Y890F mutations suggest that this residue is 
critical for internalization (Miller et al., 2012). On the mdx background, the loss of 
dystrophin would normally result in a loss of other DGC components, including β -
dystroglycan (Ohlendieck et al., 1991a), however with the Y890F mutation several 
components of the DGC, including β-dystroglycan, are retained at the sarcolemmal 
membrane (Miller et al., 2012). Assuming that the Y890F mutation does not alter 
the expression levels of any proteins, beyond that typical of the mdx disease state, 
one can conclude that the phosphorylation of Y890 has an important mechanistic 
effect: namely the internalization, and subsequent degradation, of β-dystroglycan. 
The data presented in this chapter is certainly in agreement with the former if not 
both ideas. 
Beyond this, in current estimates of protein stoichiometries in healthy human 
muscle, it is suggested that there are ten molecules of β -dystroglycan  for every 
dystrophin molecule (Jim Ervasti, personal communication). Given that β -
dystroglycan binds to dystrophin with a 1:1 stoichiometry (Ervasti et  al., 1993), 
that leaves nine ‘free’ β-dystroglycan molecules for every DGC. Some of the other 
β-dystroglycan molecules will be involved in other structures with alternative 
scaffolding proteins, such as utrophin at the neuromuscular junctions (Khurana et 
al., 1991 ; Gramolini et al., 1997), or be part of other, adhesion and signalling 
complexes such as focal adhesions (Thompson et al., 2010), but, within a muscle 
fibre, it is not impossible to imagine a pool of free β -dystroglycan. Importantly, β-
dystroglycan that is not bound by or scaffolding any other proteins would b e a 
substrate for phosphorylation on Y890. This would subject ‘free’ β -dystroglycan to 
internalization and recycling to other parts of the fibre where needed, so that the 
dynamic, changing needs of the muscle fibre were met. Again, the data presented 
in this chapter is compatible with this hypothesis.  
Finally, the argument for phosphorylation as a regulator of the internalization of β -
dystroglycan can be furthered by a consideration of the conditions that promote a 
loss of β-dystroglycan from the plasma membrane: namely the altered signalling 
state of dystrophic muscle. The levels and activity of Akt kinase are significantly 
altered in mdx muscle (Peters et al., 2006), and normalizing these levels has 
potential as a therapy for muscular dystrophy due to the restoration of DGC 
components, including β-dystroglycan, to the sarcolemmal membrane (Peters et al., 
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2009). In addition, the levels of signalling around the paxillin -FAK-MAPK nexus 
are also altered in mdx muscle (Sen et al., 2011). These changes may be an effect, 
rather than a cause, of the loss of the DGC from the sarcolemmal membrane in 
dystrophic pathology (Marshall et al., 2012a ; Marshall et al., 2012b). However, in 
all cases the phosphorylation state of a dystrophic fibre is not the same as a healthy 
counterpart. The effects of this are apparent beyond the typical hallmarks of 
dystrophy and exhibit peculiar phenotypes, such as the fragmentation of the golgi 
apparatus, which can be attributed to the altered activity of c -Src (Percival et al., 
2007 ; Weller et al., 2010). Whilst there is currently no conclusive evidence for 
direct targeting of β-dystroglycan by c-Src, that it is a downstream target of c-Src 
dependent phosphorylation is evident (Sotgia et al., 2001 ; Thompson et al., 2008 ; 
Daniel Leocadio Victoria, personal communication). Hence, when one considers 
the altered phosphorylation state of dystrophic fibres, at least within the mdx 
model, it is possible to speculate how the phosphorylation of β -dystroglycan may 
contribute to the dramatic loss of this protein, along with the DGC, from the 
sarcolemmal membrane. On this account, the kinase(s) responsible for Y890 
phosphorylation and the mechanisms and stimuli governing this process are of 
interest and importance for future research. 
 
3.3.6 Summary 
The data presented in this chapter can be summarized as follows:  
1. The phosphorylation of Y890 of β-dystroglycan is linked to a change in the 
cellular localization of this protein. 
2. In the context of Y890, the phosphorylated form of β -dystroglycan is 
internalized, whereas the unphosphorylated form is retained at the plasma 
membrane. 
3. Following internalization, β-dystroglycan is modified by further post -
translational modification. This modification may include the 
phosphorylation of other tyrosine residues, but only when partnered with 
another form of unidentified modification. 
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4.1.1 Introduction 
From the data presented in the previous chapte r, it seems that β-dystroglycan 
internalization is linked to to phosphorylation of Y890 (Chapter 3, Figures 5 and 
6). However, this phosphorylation is partnered with additional post -translational 
modifications, which can not be solely attributed to the phosphorylation of other 
tyrosine side chains within the cytoplasmic domain (Chapter 3, Figure 7). The 
current understanding of the diversity and varying functions of post -translational 
modifications, beyond phosphorylation, is limited, however modifications 
including ubiquitylation (Goldstein et al., 1975), neddylation (Kumar et al., 1993) 
and sumoylation (Matunis et al. 1996 ; Mannen et al., 1996) are all subjects of 
intense investigation. It was hypothesized that one of these forms of modification 
is responsible for the higher bands observed on western blots of internalized, 
pY890-modified β-dystroglycan.  
 
4.1.2 Identifying a Candidate for the Post-Translational 
Modification of β-Dystroglycan 
In general, it is possible to propose candidates for a particular  modification based 
on criteria elucidated from the known substrates and responses involving that 
modification. Owing to the infancy of the current understanding of alternative 
post-translational modifications, the list of “known substrates and responses” is 
limited, however general rules, or dogmas, have emerged that can be used to 
inform and direct scientific enquiry. For example, modifications associated with 
the immune response and lymphoid cells (ISG15, FAT10 and MNSFβ), 
autophagosomes (ATG8), megakaryoctye and erythroid differentiation (Ufm1), 
tRNA thiolation and oxidant exposure (URM1) and splicing in yeast (Hub1) are 
poor candidates for the modification of an adhesion protein in a skeletal muscle 
cell line (van der Veen et al., 2012). Neddylation , another form of modification, is 
usually restricted to components of E3 ubiquitin ligases, such as the cullin protein 
family and the IAPs (inhibitor of apoptosis proteins), where it enhances the 
activity of these ligases and promotes ubiquitylation (Rabut et  al., 2008). As there 
is no evidence supporting the presence of β -dystroglycan in such a complex, this 
post-translational modification may also be dismissed as a candidate.  
An interesting candidate for the modification of internalized β -dystroglycan is 
sumoylation. Sumoylation is usually associated with translocation to, or retention 
within, the nuclear compartment (Lin et al., 2003 ; Matunis et al., 1996 ; 
Yurchenko et al., 2006) or specific sub-compartments of the nucleus, as is 
suggested for the VHL (Von-Hippel Lindau) and PTP1B (protein tyrosine 
phosphatise 1B) proteins (Cai et al., 2009 ; Yip et al., 2012). There is a strong 
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body of evidence for the presence and function of full -length and truncated β-
dystroglycan within the nucleus (Fuentes-Mara et al., 2006 ; Oppizzi et al., 2008 ; 
Lara-Chacon et al., 2010 ; Martinez et al., 2013 ; Mitchell et al., 2013), but given 
the apparent cytoplasmic location and rapid modification of pY890 -modified β-
dystroglycan (see Chapter 3, Figure 1 and Chapter 5), as well  as the proposed 
nuclear localization of the sumoylating E1 and E2 ligases (Matunis et al., 1996 ; 
Rodriguez et al., 2001 ; Truong et al., 2012), it seems unlikely that this 
modification is responsible for the changes observed here (Chapter 3, Figure5).  
Yet there is still precedent for the cytoplasmic sumoylation of β -dystroglycan. 
Recent studies have identified several membrane proteins within the central 
nervous system that present an intracellular, cytoplasmic localization in response 
to sumoylation (reviewed in Silveirinha et al., 2013). Furthermore, the sumoylating 
enzymes, despite having a predominantly nuclear localization, also show 
peripheral, dendritic localization in cultured neurons (Martin et al., 2007 ; 
Wilkinson et al., 2012). In particular, the GluK2 subunit of the kainate receptor is 
sumoylated in the cytoplasm (Martin et al., 2007). This sumoylation event occurs 
downstream of phosphorylation of S868 by protein kinase C (Konopacki et al., 
2011 ; Wilkinson et al., 2012). Importantly, inhibition of the phosphorylation or 
sumoylation of GluK2 decreases the internalization of the kainate receptor in 
response to kainate treatment (Martin et al., 2007). Here, one can draw a parallel 
with β-dystroglycan, which is phosphorylated and further modified u pon 
internalization.  
However, one can not necessarily draw a parallel between the systems of neuronal 
signalling and myoblast adhesion. The sumoylation and internalization of the 
kainate receptor may represent a very specific response, as sumoylation has no 
effect on kainate receptor endocytosis in response to NMDA treatment (Martin et 
al., 2007 ; Wilkinson et al., 2012). Indeed, sumoylation has been postulated to be 
part of both protective and degenerative mechanisms in neurons, as well as a part 
of long-term potentiation (Jaafari et al., 2012 ; Silveirinha et al., 2013). 
Furthermore, changes in the activity, and not the localization, of sumoylated 
proteins have been reported in the literature (Dou et al., 2010 ; Dou et al., 2011) , 
and it may be that the sumoylation of the GluK2 subunit is a means of modulating 
MLK3-JNK3 signalling (Zhu et al., 2012). Examples also exist in the literature of 
membrane proteins that are protected from sumoylation upon phosphorylation, 
such as the progesterone receptor (Knutson et al., 2012). Nonetheless, one cannot 
discount the possibility of the sumoylation of Y890-phosphorylated β-dystroglycan 
on account of a cytoplasmic or membranous localization.  
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Alternatively, ubiquitylation may be the cause of the slower migrating bands 
observed in the internalized fractions of β -dystroglycan. The ubiquitylation of 
proteins is normally associated with degradation in an ATP-dependent manner (via 
the 26S proteasome) (Wilkinson et al., 1981). To quote Stefan Jentsch: “...the 
ubiquitin/proteasome system also detects and eliminates abnormal proteins that 
would otherwise be part of a larger complex, but fail to find their partners” 
(Jentsch et al., 1995). Given that pY890-modified β-dystroglycan is unable to bind 
its normal anchoring proteins, dystrophin and utrophin (James et al., 2000 ; Illsey 
et al., 2001) and is lost from the sarcolemmal membrane, where other components 
of the DGC are typically found (Ohlendieck et al., 1991 a ; Ohlendieck et al., 1993 ; 
Sotgia et al., 2003a), it would seem logical to think of internalized β -dystroglycan 
as an “abnormal protein that would otherwise be part of a larger complex” and 
hence, a likely target for ubiquitylation. In support of this, inhibi tion of the 
proteasome, with either  MG-132, velcade or mln273, in mdx mice or patient 
explants leads to a restoration of β-dystroglycan to the sarcolemmal, suggesting an 
involvement of ubiquitin in the loss of this protein from the membrane (Bonnucelli 
et al., 2003 ; Assereto et al., 2005 ; Bonnucelli et al., 2007). However, this 
argument has opposition from the fields of both DMD and proteasome research. 
Whilst significantly enhanced protein degradation is reported in the muscle fibres 
of mdx mice (Kämper et al., 1992), this has been attributed to the increased 
activity of calcium-dependent proteases and altered calcium homeostasis (Spencer 
et al., 1995 ; Collet et al., 1999 ; Badalamente et al., 2000). In models of cardiac 
hypertrophy and ischemic injury, which are both associated with the DMD disease 
state, there is evidence to suggest a link between β -dystroglycan levels and 
protease activity (Armstrong et al., 2003 ; Daicho et al., 2009). Furthermore, with 
the loss of components of the DGC, in this case  in the muscle fibres of mice that 
lack α- or β-SG, there is an enhanced proteolysis and loss of β -dystroglycan from 
the sarcolemma, which can be reversed by treatment with calpain inhibitors 
(Duclos et al., 1998 ; Araishi et al., 1999). In a similar vein,  the enhanced levels of 
matrix metalloproteinase (MMP) activities in the mdx disease state have been 
linked to an enhanced proteolysis of β -dystroglycan (Michaluk et al., 2007 ; 
Daicho et al., 2009). Although the exact MMP(s) responsible for the cleavage o f β-
dystroglycan is currently unresolved (Delfin et al., 2011), the general inhibition of 
MMPs by treatment with suramin can cause a restoration of β -dystroglycan to the 
sarcolemma in the mdx mouse (Taniquiti et al., 2012). Together, these form an 
argument against β-dystroglycan being degraded by the proteasome, or at least, 
make this possibility less likely.  
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A valid criticism of these studies is that they may reflect general changes in 
dystrophic pathology, and that the effects of calpain or MMP inhibition on β-
dystroglycan represent an indirect mechanism, rather than direct cleavage.  In 
support of this, the levels of the muscle-specific calpain CANP3 are altered in 
LGMD2A patients, but with no change in β -dystroglycan levels (Spencer et al., 
1997).  However, an argument made in this manner is equally applicable to the 
effects of proteasome inhibition mentioned earlier, making a resolution between 
the mechanisms that mediate the loss of β -dystroglycan from the sarcolemma 
difficult. Furthermore, the treatment of mdx mice with MG-132 also causes an 
increase in muscle calpain activity, suggesting that these mechanisms are both 
potentially responsible for the loss of β-dystroglycan from the sarcolemma 
(Bonnucelli et al., 2003). Thus, when one takes into  account the full evidence 
surrounding the degradation of β-dystroglycan, any conclusions drawn in support 
of the ubiquitylation of β-dystroglycan are indirect at best.  
Returning to the field of ubiquitin research, there is also a further issue with 
drawing inferences between proteasomal inhibition and the loss of β -dystroglycan 
from the membrane. A central dogma of proteasomal degradation is that 
polyubiquitylation, with 4 or more ubiquitin proteins covalently linked in a chain, 
is a prerequisite (Thrower et al., 2000). Although this dogma is challenged by the 
suggestion that monoubiquitylation is sufficient for the proteasomal degradation of 
substrates with 150 residues or less (Shabek et al.,2012), this would not be the case 
for full-length β-dystroglycan, which is approximately 240 residues in length. The 
observed shift in the electrophoretic mobility of internalized β -dystroglycan on 
western blots equates to approximately 10kDa (Chapter 3, Figures 5 and 6), 
therefore one would expect that mono or possib ly diubiquitylation is occurring, but 
certainly not the tetraubiquitylation that is required for proteasomal processing. 
Thus, by ascertaining the criteria for ubiquitylation from the process of targeting 
for degradation, it seems unlikely that β -dystroglycan is modified in this manner. 
However, degradation is not the only process associated with the ubiquitylation of 
a substrate. 
 
4.1.3 Monoubiquitylation and the Internalization of β-
Dystroglycan 
In the literature, there is a growing body of evidence suggesting that 
monoubiquitylation on particular or multiple lysine side chains can cause the 
trafficking of a substrate, as opposed to proteasomal degradation (Nichols et al., 
2001). Monoubiquitylation of the PDGF, EGF, FGF and interferon-α receptors 
drives internalization of these proteins and, in a manner to analogous to β -
dystroglycan, this internalization is coupled to tyrosine phosphorylation (Karlson 
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et al., 2006 ; Kumar et al., 2007 ; Hayes et al., 2011). The importance of 
monoubiquitylation in trafficking can be questioned, as neddylation is suggested to 
also play a role in the internalization of the EGF receptor (Oved et al., 2006). 
However, this particular study may be criticised on the basis that neddylation is 
driven by Nedd8 overexpression, which can lead to the identification of false 
substrates owing to non-specific neddylation by ubiquitin E3 ligases (Rabut et al., 
2008).  
Monoubiquitylation is also proposed to cause the cytoplasmic reten tion, or the 
nuclear export, of substrate proteins, often in an antagonistic manner to 
sumoylation (Cai et al., 2010 ; Wang et al., 2012). The monoubiquitylation of p53 
by MDM2 leads to the nuclear export of the protein, whereas proteasomal 
degradation is initiated by polyubiquitylation (Li et al., 2003). Similarly, the VHL 
and CTP:phosphocholine cytidylyltransferase (CTT) proteins are retained in the 
cytoplasm by monoubiquitylation, and in the case of CTT this is thought to be due 
to masking of the nuclear localization sequence (NLS) by ubiquitin (Chen et al., 
2009 ; Cai et al., 2010). An important exception to these studies is that 
monoubiquitylation can drive the nuclear import of the PTEN tumour suppressor 
(Trotman et al., 2007). Nonetheless, the prevail ing consensus is that 
monoubiquitylation is linked to protein trafficking within the cytoplasm and, in 
this regard, ubiquitylation is therefore an ideal candidate for the additional post -
translational modification of internalized β-dystroglycan. 
 
4.1.4 Hypothesis: Y890 Phosphorylation is Required for the 
Ubiquitylation of β-Dystroglycan in H2K Myoblasts 
To this end, it was initially hypothesized that β -dystroglycan could also be 
ubiquitylated and that it was this that was responsible for the shift in 
electrophoretic mobility observed on western blots of internalized β -dystroglycan. 
Given the rapid emergence of this modification during internalization (Chapter 3, 
Figure 5), the predominantly cytoplasmic distribution of the presumably 
internalized puncta observed with epifluorescence microscopy (Chapter 3, Figure 
2and Chapter 5), as well as previous work in the literature suggesting a link 
between β-dystroglycan internalization and proteasomal degradation, 
ubiquitylation was an ideal candidate modification. Owing to the lack of any 
additional bands observed on western blots for the unphosphorylated form of β -
dystroglycan, it was also hypothesized that ubiquitylation would be exclusively 
linked to Y890 phosphorylation. 
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4.2.1 Enrichment of Cellular Ubiquitin by Affinity Tagging 
Assuming that the ubiquitylation of β -dystroglycan is a constitutive process, like 
internalization, this hypothesis could be tested by enrichment of proteins 
conjugated with ubiquitin and probing with modification specific ant ibodies 
against β-dystroglycan. Owing to the availability of antibodies in the Winder lab, 
initial experiments utilized the transient transfection of H2K myoblasts to express 
exogenous, HA-tagged ubiquitin, so that immunoprecipitation with anti -HA could 
be used to enrich for ubiquitylated proteins. This approach is widely used 
(Yurchenko et al., 2006 ; Rabut et al., 2008 ; Cai et al., 2010) and is thought to 
cause minor perturbations to the cell ubiquitylation and degradation systems (Love 
et al., 2013). However, poor expression of this plasmid and unexpectedly high 
levels of cell death following transfection prevented the use of this approach to test 
the initial hypothesis in H2K myoblasts. 
 
4.2.2 Enrichment of Cellular Ubiquitin with the MultiDsk 
Protein 
The MultiDsk system was used as an alternative method to enrich ubiquitylated 
proteins from H2K myoblast lysates. The MultiDsk protein is an artificial 
recombinant protein containing five Dsk ubiquitin binding domains , which are 
linked by flexible spacers, with N-terminal GST and C-terminal 6xHis fusion tags 
(Figure 1).  
 
 
 
 
 
Figure 1: A schematic representation of the GST-MultiDsk fusion protein. 
Included are the sequence of a single Dsk domain (upper case) and the sequence of 
a spacer (lower case). Reproduced with permission from Marcus Wilson. 
 
The MultiDsk protein is designed to bind all mono-ubiquitylated and poly-
ubiquitylated proteins and does so with a high level of avidity and specificity 
(Wilson et al., 2012). In this manner it is similar to other , previously published 
recombinant proteins designed for a similar purpose, such as the GST -Dsk2 and 
 81 
TUBE-1 proteins (Hjerpe et al., 2009). As little information is available in the 
literature concerning the expression of this protein, induction and purifi cation data 
are presented in Figure 2. When induced in E.coli BL21 (DE3), the GST-MultiDsk 
protein is expressed in inclusion bodies, hence an atypical purification protocol is 
used (Wilson et al., 2012). Details of this protocol are in Chapter 2 (Section 2.2.3). 
Although contaminant cleavage products and dimers were observed, high yields of 
relatively pure GST-MultiDsk protein were reproducibly obtained (Figure 2, C and 
D). By retaining the purified GST-MultiDsk protein on glutathione-Sepharose, the 
beads could be used for the subsequent pulldown and enrichment of ubiquitylated 
proteins from H2K myoblast lysates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Coomassie stained gels (A and C) and anti -GST immunoblots (B and D) 
of MultiDsk induction and purification. The MultiDsk (arrowheads) protein is 
rapidly induced to sufficiently high levels within 3 hours at 37°C (A and B) and 
migrates as a band at approximately 60kDa. Purification of the MultiDsk protein 
yields a large amount of full-length protein with some smaller cleavage products 
(D) and larger bands that migrate at approximately 130kDa (C).  
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Next, the ability of the GST-MultiDsk protein to specifically enrich ubiquitylated 
proteins from H2K myoblast lysates was tested. To examine the effect of 
background binding or non-specific pulldown of proteins, unconjugated 
glutathione-Sepharose was used as a control for these experiments and all 
subsequent enrichments. The presence of the MultiDsk protein enabled the 
enrichment of ubiquitylated proteins from H2K myoblast lysates, with no non -
specific pulldown of ubiquitylated or anti -GST immunoreactive proteins mediated 
by the unbound glutathione-Sepharose (Figure 3). For a full or complete 
enrichment of ubiquitylated proteins, one would expect to see a smear of 
immunoreactivity in the pellet lane of the MultiDsk pulldown  upon blotting with 
an anti-ubiquitin antibody. However, this is not observed in the data presented 
here. That there is enrichment is evident: a comparison of the two treatments 
reveals a reciprocal shift of immunoreactivity from the supernatant to the pellet 
lanes in the presence of MultiDsk protein that is not observed for glutathione-
Sepharose alone. Therefore, the lack of a regular smear may be due to the anti -
ubiquitin antibodies used rather than incomplete enrichment, with other, lower 
bands being below the detection limit of the system. In support of this, the same 
banding pattern is observed in the supernatant lanes of the anti -ubiquitin western 
blots shown in Figure 5, indicating this is a reproducible result of the anti-
ubiquitin antibody used. Furthermore, successful anti-ubiquitin antibodies are 
notoriously hard to generate, and this is why alternative methods for the detection 
of ubiquitin, such as tagging with HA, are commonly used in the literature (Love 
et al., 2013). Nonetheless, despite the inherent limitations of detection, one can 
conclude that the GST-MultiDsk fusion protein elicits a specific enrichment of 
ubiquitylated proteins from H2K myoblast lysates, as is reported for yeast extracts 
(Wilson et al., 2012). 
 
4.2.3 Y890 Phosphorylation is Linked to the Ubiquitylation of 
β-Dystroglycan 
Having established the use of the GST-MultiDsk fusion protein as a method for 
enriching ubiquitylated proteins, it was now possible to test the hypothesis that the 
pY890 form of β-dystroglycan is ubiquitylated. H2K myoblasts were incubated 
with Sepharose-bound MultiDsk or glutathione-Sepharose alone and the 
supernatant and pellet fractions were immunoblotted with MANDAG2 and 1709. 
As shown in Figure 4, western blotting for the pY890-modified form of β-
dystroglycan reveals the presence of a large band with the same electrophoretic 
mobility as the doublet observed in the previous internalization assays ( Chapter 3, 
Figures 5 and 6). As this band is only present in the pellet fraction of the GST -
MultiDsk fusion protein pulldown, one can conclude that it is a ubiquitylated form 
of β-dystroglycan that has been enriched. The absence of such a band, or indeed 
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any bands, in the pellet fraction of the control pulldown strengthens  the notion that 
this is a specific pulldown of a ubiquitylated species of  β-dystroglycan. 
Furthermore, the lack of observable bands in the pellet fractions upon detection of 
the unmodified form of β-dystroglycan suggests with MANDAG2 that 
ubiquitylation is exclusively coupled to  the phosphorylation of Y890 (Figure 4). 
This is expected, given that forms of β -dystroglycan with electrophoretic 
mobilities slower than that of the full -length protein were only observed on 
western blots for the pY890-modified form of the protein previously (Chapter 3, 
Figures 5 and 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Control experiments  for the MultiDsk pulldown and ubiquitin 
enrichment of H2K myoblast lysates. Glutathione-Sepharose alone does not enrich 
ubiquitin nor any other GST-containing proteins. By comparison, pulldown with 
the MultiDsk protein bound to glutathione-Sepharose causes a significant 
enrichment of ubiquitylated proteins. The bands with a slower and faster 
electrophoretic mobility than the GST-MultiDsk fusion protein (approximately 
60kDa) probably represent dimers and cleavage products respectively.  
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Figure 4: Glutathione-Sepharose and GST-MultiDsk pulldowns of H2K myoblasts. 
Supernatant and pellet samples were separated by SDS-PAGE and western blotted 
for pY890-modified β-dystroglycan (1709, B) or the unphosphorylated counterpart 
(MANDAG2, A). 
The hypothesis that Y890 phosphorylation and the ubiquitylation of β-dystroglycan 
are coupled was further tested by means of reciprocal immunoprecipitation and 
detection. In this instance, the pY890-modified form of β-dystroglycan was 
immunoprecipitated from H2K myoblast lysates and detected with anti -ubiquitin 
immunoblotting (Figure 5). Immunoprecipitation in the absence of 1709 antibody 
and western blotting with 1709 were used as controls for the pulldown. The 
presence of a band in Figure 5, specifically enriched by 1709 pulldown, with the 
same electrophoretic mobility as that in the reciprocal blot (Figure 4) is detected 
upon western blotting for ubiquitin. The presence of this band is difficult to 
discern in the 1709 control blot due to spurious IgG heavy chain reactivity. 
However, that enrichment has occurred is clear when one compares the absence of 
immunoreactive bands in the control pellet lane  of both the 1709 and anti-ubiquitin 
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blots. As it was possible that the enriched band detected on the anti -ubiquitin blot 
was an artefact of secondary antibody detection (possibly due to limited cross -
reactivity for rabbit IgG heavy chain), an additional control blot was performed 
using only the same anti-mouse IgG. The lack of immunoreactivity on this blot 
(Figure 5, C) strongly suggests that the band observed on the anti-ubiquitin 
immunoblot is not an experimental artefact and does represent ubiquitylated β-
dystroglycan. Thus, the hypothesis that Y890 phosphorylation and ubiquitylation 
are linked is not disproved by this experiment and together the reciprocal 
pulldowns provide strong evidence that this is indeed case.  
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Figure 5: Immunoprecipitation of pY890-modified β-dystroglycan from H2K 
myoblasts. Western blots of lysates immunoprecipitated with 1709 and with 
protein A beads alone (See Chapter 2, Section 2.2.3) and probed with anti-
ubiquitin (A), 1709 (B) or anti-Mouse IgG (C). Arrowheads represent forms of 
pY890-modified β-dystroglycan, whereas the arrow represents immunoreactivity 
due to rabbit IgG chains. 
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4.2.4 Identification of the Ligase Responsible for the 
Ubiquitylation of β-Dystroglycan 
Having established that β-dystroglycan could be ubiquitylated, it was of interest to 
identify the ligase responsible next. Fortunately, two likely candidates for this role 
were available: the E3 ubiquitin ligases Nedd4 and Nedd4L. Nedd4 and Nedd4L 
are members of a family of HECT domain ubiquitin ligases that includes the yeast 
essential protein Rsp5 (Yang et al., 2010). Nedd4 and Nedd4L are closely related, 
owing to a gene duplication event, and possess a similar overall domain 
organization (Figure 6). WW domains 1 and 3  of Nedd4 and domains 3 and 4 of 
Nedd4L have been previously shown to bind the cytoplasmic domain of β -
dystroglycan in vitro and there is a strong conservation of key residues both 
between domains and between species (Pirozzi et al., 1997 ; Yang et al., 20 10). A 
previous yeast two-hybrid screen in the Winder lab also identified Nedd4L as a 
potential binding partner of the cytoplasmic tail of β -dystroglycan (Jane Illsey, 
PhD Thesis, 2001). Data from phage library screens had also identified the 
consensus targets of these WW domains and, with the exception of the first WW 
domain of Nedd4, these all preferentially bind canonical WW domain target 
motifs: specifically, LPxY and PPxY (Gary Bader, personal communication). 
Figure 7 shows the predicted target motifs of each WW domain, as well as the 
degree of degeneracy, and phylogenetic relation of these WW domains to each 
other. The cytoplasmic domain of β-dystroglycan contains several of these motifs,  
and any or several of these may be bound by one or multiple WW domains of these 
proteins (Ibraghimov-Beskrovnaya et al., 1992 ; Chen et al., 1995 ; Kay et al., 
2000 ; Illsey et al., 2002).  
 
 
 
Figure 6: The general domain organization of Nedd4 and Nedd4L: C2 domain 
(yellow), WW domains (green), HECT domain (red). Figure not drawn to scale. 
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As multiple binding sequences could be identified within β -dystroglycan, it was 
necessary to use a method that allowed the visualization of specific binding 
sequences. To this end, CelluSpots
TM
 peptide arrays representing the entire 
cytoplasmic domain of β-dystroglycan in 15-residue sections with a single residue 
step between spots were purchased from Intavis. pUC18 vectors expressing the 
separate WW domains as recombinant fusion proteins with GST and 6xHis tags 
were provided as a generous gift (Haiming Huang, Siddhu Lab). Following 
bacterial expression and purification, elution fractions containing the largest 
amounts of protein, as judged by Coomassie staining and spectrophotometry, were 
pooled and used for subsequent binding experiments with peptide arrays. Figure 8 
contains two elution profiles of the second WW domain of Nedd4L. These images 
are representative of all WW domains purified in this study in that a high 
(approximately 50% of total protein) level of cleavage is apparent, with equally 
dense bands migrating at the masses corresponding to the uncleaved fusion protein 
(approximately 35kDa) and the GST fusion tag alone (approximately 30kDa). 
Despite several attempts to rectify the problem, this phenomenon was 
uncontrollable, and most likely represents an inherent instability of these particular 
fusion proteins. For further information on the purification of these fusion 
proteins, please consult Section 2.2.2. 
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Figure 7: A phylogenetic tree of the WW domains of Nedd4 and Nedd4L with the 
target sequences, as determined by phage display screening depicted. The tree is 
not drawn to scale and all data is generously provided by Gary Bader (personal 
communication). 
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Figure 8: Representative elution profiles of a GST-WW domain fusion protein: (A) 
A Coomassie stained gel of the elution fractions and (B) An anti -GST immunoblot 
of elution fractions 1, 5 and 7. On both the gel and the blot the presence of two 
bands with electrophoretic mobilities corresponding to approximately 35 and 
30kDa is apparent. These bands correspond to the full -length fusion protein 
(arrowheads), and the GST tag alone (arrows).  The spurious bands with 
electrophoretic mobilities of approximately 60 and 70kDa are presumed to be 
dimers, whereas the fastest migrating band is presumably a cleavage product.  
                               Elution Fractions 
   1           2           3            4           5          6            7         
80 
 
58 
 
46 
 
30 
23 
 
17 
7 
                               Elution Fractions 
         1                                 5                                  7         
80 
 
58 
 
46 
 
 
30 
23 
 
17 
7 
A 
B 
 91 
After purification, the recombinant WW domain proteins were loaded onto peptide 
arrays at a concentration of 20µg/ml. Owing to the large amount of cleavage, and 
as a control, purified GST protein alone was also loaded onto an array at the same 
concentration. Following the incubation with recombinant protein, the arrays were 
washed and immunoblotted with anti-GST. Figure 9 contains images of the arrays 
after exposure with ECL solution, with the detected binding sequences displayed 
underneath. Unfortunately, as is evident from comparison with the GST control, 
there was a large amount of GST-dependent binding for all experiments. Why this 
is the case is uncertain as previous experiments of a similar nature have failed to 
detect any binding of GST to the cytoplasmic domain of β -dystroglycan 
(Rentschler et al., 1999). Nonetheless, any binding to the motif EGKGSR was 
excluded from further analysis, owing to the clear binding to this motif mediated 
by GST alone (Figure 9). In spite of this technical difficulty, WW domains 1 and 2 
of Nedd4L also exhibited separate binding to another motif within the cytoplasmic 
domain, LEDQATFIKKGVPI (Figure 9). Although this motif is not a typical WW 
domain target (Kay et al., 2000 ; Illsey et al., 2002), and is not in agreement with 
the target motif predicted by phage display screening (Figure 7), the absence of 
any binding to this motif by GST protein suggests that this motif is specifically 
bound by these WW domains in vitro.  
One should also note that WW domains 1 and 2 of NEdd4 also exhibit some 
weaker, less consistent binding to this motif (Figure 9). This is unsurprising, given 
the close phylogenetic relationship of these domains (Figure 7). However, this 
binding was deemed too weak or inconsistent to merit further investigation. 
Whether this is due to the nature of the experimental system, transient binding by 
the WW domains, or a combination of both factors remains unresolved.  
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Nedd 4 WW domain #1: EGKGSR       Nedd4L WW domain #1: 
LEDQATFIKKGVPI, EGKGSR  
 
 
                    
Nedd 4 WW domain #2: PMEGKGSR      Nedd4L WW domain #2: 
LEDQATFIKKGVPI, EGKGSR 
 
 
 
Nedd4 WW domain #3: EGKGSR        Nedd4L WW domain #3: EGKGSR 
 
 
 
Nedd4 WW domain #4: EGKGSR        Nedd4L WW domain #4: EGKGSR 
 
 
 
   GST: EGKGSR 
 
Figure 9: Peptide array images with the corresponding consensus binding 
sequences underneath. Peptide arrays were loaded with 20µg/ml of fusion protein 
and immunoblotted with anti-GST. Each box on the arrays represents a repeat unit, 
thus all binding sequences are the results of triplicate experiments. 
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To substantiate these findings, it was necessary to examine if this interaction was 
also true in the context of H2K myoblasts. Owing to the limited availability of 
Nedd4L antibodies, an antibody with cross-reactivity to Nedd4 was used. 
Unfortunately, this antibody was also raised in the same species as 1709, the 
antibody used to detect the pY890-modified form of β-dystroglycan, so the 
hypothesis of an interaction with the pY890-modified form could not be tested 
easily. Since the proposed binding site for Nedd4L was outside of the c -terminal 
residues of β-dystroglycan, it was assumed that binding of the ligase may not be 
strictly dependent on phosphorylation. Furthermore, whilst the data so far had 
suggested a link between Y890 phosphorylation and ubiquitylation, there was 
nothing to suggest that phosphorylation was causative of Nedd4L binding or 
subsequent ubiquitylation. Thus, immunoprecipitation of β -dystroglycan from H2K 
myoblasts with MANDAG2 was performed, with the view that an interaction with 
Nedd4L could still be tested in this manner. Despite a significant pulldown and 
enrichment of β-dystroglycan, no Nedd4L protein was detected in the pellet 
fraction upon western blotting with anti -Nedd4/4L (Figure 10). From the high 
levels of immunoreactivity in the supernatant fractions one can conclude that 
Nedd4 and Nedd4L are expressed in H2K myoblasts, but the data from this 
experiment suggest that the interaction of Nedd4/4L with the unmodified form of 
β-dsytroglycan is not significant in vivo. 
 
 
 
 
 
 
 
 
Figure 10: Immunoprecipitation of unmodified (non-pY890) β-dystroglycan  from 
H2K myoblasts. Lysates were immunoprecipitated with or without MANDAG2 and 
the supernatant and pellet fractions were separated on SDS-PAGE gels and western 
blotted with MANDAG2 or Anti-Nedd4/Nedd4L. 
 
 
                            -Ab                                                   +Ab 
           S/N                    Pellet                      S/N                      Pellet 
Anti-Nedd4/Nedd4L 
MANDAG2 
(Anti-β-dystroglycan) 
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The apparent binding of the WW domains to the cytoplasmic domain of β -
dystroglycan in vitro could represent an artifact of the experimental system used: 
the presentation of this domain as 15 residue peptides, out of the context of 
flanking residues found in the full amino acid sequence, may permit binding that is 
not usually possible due to steric or energetic barriers. Similarly, the apparent 
absence of an interaction in vivo could be attributed to a dependence on Y890 
phosphorylation for recruitment and binding of the Nedd4L protein. To address the 
former argument , and to further test the hypothesis that Nedd4L binds to β -
dystroglycan, an alternative in vitro approach was used. The cytoplasmic domain 
of β-dystroglycan was expressed as a recombinant protein in E. coli BL21(DE3) 
and purified for use in a far western blot with the GST-WW domain fusion proteins 
of Nedd4L. As shown in Figure 11, the cytoplasmic domain of β -dystroglycan 
could be expressed and purified as a relatively pure protein, with minor 
contaminants and degradation. However, after resolution on SDS-PAGE gels and 
far western blotting, this protein was not bound by any of the WW domains of 
Nedd4L including domains 1 and 2, which had both been previously shown to bind 
to a specific motif on the peptide arrays (Figure 9). Instead, presumably through 
non-specific or spurious interactions, the GST-WW domain fusion proteins bound 
to residual, contaminant proteins present in the purified, cytoplasmic β -
dystroglycan samples. Hence, given the lack of any interaction with the 
LEDQATFIKKGVPI motif in the context of the entire cytoplasmic domain, these 
data collectively suggest tha t Nedd4L does not bind β-dystroglycan, and may not 
be the ligase responsible for its ubiquitylation. 
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Figure 11: Purification of the cytoplasmic domain of β -dystroglycan and far 
western blots with the WW domains of Nedd4L. (A) A coomassie stain of the 
purified cytoplasmic domain of β-dystroglycan. Some contaminating proteins are 
clearly present, but the cytoplasmic domain has a relatively higher yield. (B) 
Western blot of the cytoplasmic domain of β -dystroglycan with MANDAG2. A 
large band with the expected electrophoretic mobility is observed, confirming the 
observations of (A), as well as several bands with a faster electrophoretic mobility. 
These faster, immunoreactive bands are presumably cleavage products. (C) Far 
western blots of the cytoplasmic domain of β -dystroglycan with the GST-fusion, 
WW domains 1-4 of Nedd4L and anti-GST. Despite high levels of non-specific 
binding (arrowheads), no immunoreactivity at the expected position of the 
cytoplasmic domain of β-dystroglycan (arrow) is observed. 
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4.3.1 Discussion: Establishing the Use of the MultiDsk Protein 
Initial attempts to transfect H2K myoblasts with a plasmid containing the HA-
ubiquitin fusion gene, with the aim of using affinity purification to enrich the 
cellular pool of ubiquitylated proteins, were unsuccessful. The expression of HA-
tagged ubiquitin, as well as HA-tagged forms of other post-translational 
modifications, is a procedure that is routinely used in the literature (Yurchenko et 
al., 2006 ; Rabut et al., 2008 ; Cai et al., 2010 ; Love et al., 2013), and exactly why 
this approach failed with H2K myoblasts is uncertain. Electroporation of H2K 
myoblasts with the HA-ubiquitin construct resulted in abnormally high levels of 
cell death (data not shown), which are normally attributable to excess salt or a 
volume of DNA in the electroporation mixture larger than 10% (v/v) (Neon
TM
 
Transfection System User Manual, Invitrogen). However, attempts to desalt or 
reduce the volume of DNA used were unsuccessful as evidenced by persistent cell 
death or low transfection efficiency (data not shown). The Neon
TM
 transfection 
system is successfully used elsewhere in this thesis, so why it does not give 
adequate transfection of H2K myoblasts with HA-ubiquitin remains uncertain. 
Fortunately, another method of ubiquitin enrichment became available: the 
MultiDsk system. 
The recombinant MultiDsk protein relies on the activity of the c-terminal ubiquitin 
binding (UBA) domain of the S. cerevisiae protein Dsk2, which binds both 
ubiquitin and polyubiquitin chains with a relatively high affinity (Raasi et al., 
2005). The MultiDsk protein consists of five Dsk2 UBA domains in tandem, 
separated by 8-amino acid flexible linkers (Wilson et al., 2012). In a manner 
similar to another recombinant protein comprised of 4 UBA domains in tandem, 
the commercial TUBE protein (Hjerpe et al., 2009), the Multi Dsk protein both 
binds ubiquitylated proteins and protects these proteins from deubiquitylation and 
proteasomal degradation, presumably through steric hindrance of the enzymes 
responsible (Wilson et al., 2012). Furthermore, the MultiDsk protein does not 
exhibit any non-specific interactions with non-ubiquitylated proteins, which is a 
common technical problem for GST-UBA fusion proteins (Kang et al., 2007 ; 
Wilson et al., 2012). Fortunately, both the tertiary structure and key residues of the 
ubiquitin protein are well conserved between species and even kingdoms, making 
the purification of ubiquitylated proteins from a murine cell line with an S. 
cerevisiae protein domain possible (Goldstein et al., 1975 ; Vijay-Kumar et al., 
1987). 
Due to the presence of an N-terminal GST tag, both the purification of the 
MultiDsk protein from E.coli BL21(DE3), and the pull down of ubiquitylated 
proteins from H2K myoblast lysates, were possible (Figures 2 and 3). Importantly, 
control pull downs with glutathione-Sepharose did not result in any enrichment of 
ubiquitylated proteins (Figure 3) or the forms of β -dystroglycan studied in this 
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thesis (Figure 4). Whilst little information concerning the MultiDsk protein was 
available in the literature at the time of these experiments, the data presented here, 
along with successful preliminary results from other labs, confirms its use in the 
specific enrichment of ubiquitylated proteins. Although not tested in these 
experimental conditions, pull downs with the GST-MultiDsk fusion protein are not 
thought to result in the enrichment of sumoylated or neddylated proteins (Marcus 
Wilson, personal communication). Together, these data suggest that the GST -
MultiDsk fusion protein can be used to specifically enrich the pool of 
ubiquitylated proteins present in H2K myoblasts. 
 
4.3.2 The Link Between Y890 Phosphorylation, Ubiquitylation 
and Internalization 
Having established a method to enrich ubiquitylated proteins from H2K myoblasts, 
it was then possible to test the hypothesis that phosphorylation of Y890 was linked 
to ubiquitylation. Western blots of GST-MultiDsk and GSH control pull downs of 
H2K myoblast lysates with antibodies against the pY890-modified and unmodified 
forms of β-dystroglycan reveal a striking difference; Y890 phosphorylation is 
linked to the presence of a slowly migrating, presumably ubiquitylated, band with 
a mass of approximately 55kDa (Figure 4). That this band represents a 
ubiquitylated form of pY890-modified β-dystroglycan is confirmed by the 
detection of the same, or very similar, protein species in a reciprocal pull down 
experiment (Figure 5). Furthermore, the inability to detect this band with 
MANDAG2, akin to the western blots of unmodified β -dystroglycan presented in 
chapter 3 (Figures 5 and 6), suggest that the ubiquitylation event is linked to Y890 
phosphorylation. The inability to detect β -dystroglycan with an antibody against 
the unphosphorylated form of the protein after MultiDsk enrichment does not 
necessarily preclude the idea that it can be ubiquitylated, as this f orm of the 
protein may be below the detection limits of the system. However, the data 
presented here certainly suggest a strong link between the events of Y890 
phosphorylation and ubiquitylation. 
These findings lend themselves to the natural question: is ubiquitylation 
responsible for the higher bands observed on western blots of internalized, pY890 -
modified β-dystroglycan? Unfortunately, experiments designed to directly address 
this question were inconclusive and could not be fully developed due to time 
constraints. However, it is possible to speculate that this is indeed the case. To 
begin, both the slowly migrating bands described in the internalization assay and 
the ubiquitylated bands reported in this chapter all migrate at the same position, 
which equates to approximately 55kDa. Whilst the bands observed previously 
clearly migrated as a doublet (Chapter 3, Figures 5 and 6), the bands observed in 
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Figures 4 and 5 do not appear to do so. However, in both western blots, there is the 
presence of faint, additional immunoreactivity, suggesting that these bands may in 
fact be unresolved doublets. This may reflect variation in the SDS-PAGE gel 
system used between experiments and so, one can not exclude the idea that these 
bands are equivalent species of β-dystroglycan. Additionally, as mentioned in the 
introduction to this chapter, monoubiquitylation is linked to the internalization of 
several surface membrane proteins (Karlson et al., 2006 ; Kumar et al., 2007 ; 
Hayes et al., 2011). Given that full -length, pY890-modified β-dystroglycan 
migrates at an approximate mass of 43kDa on SDS-PAGE gels, one would 
conclude that the electrophoretic mobility shift observed in these data is due to 
modification with a single ubiquitin. Hence, given the potential involvement of 
monoubiquitylation with the internalization of β -dystroglycan, one could speculate 
that the approximately 55kDa band observed in these experiments is related to 
those observed in the internalized fractions earlier (Chapter 3, Figures 5 and 6). 
Although a conclusive answer to this question will ultimately require further 
experiments, these data certainly form a strong basis for future enquiry.  
 
4.3.3 The Proposed Interaction of β-Dystroglycan and 
Nedd4/Nedd4L  
Having established that β-dystroglycan is ubiquitylated, it was of interest to 
determine the E3-ubiquitin ligase responsible. Fortunately, several lines of 
evidence made the HECT domain ligases Nedd4 and Nedd4L promising 
candidates. Both proteins are expressed in murine skeletal muscle and satellite 
cells, and are both thought to be involved in both the formation of the pre -synaptic 
membrane of neuromuscular junctions and the response to skeletal muscle atrophy 
(Yang et al., 2010 ; Nagpal et al.,  2012). Using a dual-specificity antibody, the 
presence of either one, or both, of these proteins in H2K myoblasts was also 
verified by western blot (Figure 8). Both these ligases are predicted to bind to their 
substrates by one or several of the four, closely related WW domains that each 
protein possesses. These domains are typically thought to bind PPXY and LPSY 
motifs present in membrane proteins, although this idea has been questioned 
recently (Lin et al., 2008 ; Yang et al., 2010 ; Hayes et al., 201 1). Nonetheless, the 
cytoplasmic domain of β-dystroglycan is a candidate target as it contains two 
PPxY motifs, as well as several closely related sequences, all of which could be 
the binding target of a WW domain. In support of this, several WW domains of  
these proteins have been demonstrated to bind polyproline regions of the 
cytoplasmic domain of β-dystroglycan in vitro (Pirozzi et al., 1997) and phage 
display screening data indicates an interaction of these WW domains with PPXY or 
LPXY motifs (Gary Bader, personal communication). Hence, an interaction 
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between the WW domains of Nedd4 and Nedd4L with β -dystroglycan was 
examined in closer detail. 
Unfortunately, the binding data from peptide arrays representing the cytoplasmic 
domain of β-dystroglycan chiefly reveals the presence of a binding site for GST, 
which was used as a fusion protein for the purified WW domains used in this study 
(Figure 9). The binding motif for GST, EGKGSR, and any binding of GST to the 
cytoplasmic domain of β-dystroglycan have not been reported in previous studies 
using similar experimental approaches (Suzuki et al., 1994 ; Chung et al., 1999 ; 
Rentschler et al., 1999 ; Russo et al., 2000). Given that the proteins used to probe 
the arrays in these experiments were free from unexpected contaminants (Figure 
8), one can conclude that the apparent binding of GST represents an in vitro 
artefact, which is possibly the result of loading at too high a concentration. Indeed, 
a loading concentration of 20µg/ml was used due to the high (approxim ately 50%) 
levels of untagged WW domain protein present in the purified fractions. Future 
experiments of a similar nature may benefit from establishing concentrations of 
GST which do not give such prominent non-specific binding. 
In spite of these technical difficulties, potential binding sites for the first and 
second WW domains of Nedd4L were detected using the peptide array approach 
(Figure 9). The binding site contains the consensus sequence LEDQATFIKKGVPI 
and is located between residues 783-796 of the Dag1 sequence (Ibraghimov-
Beskrovnaya et al., 1992). Whilst this binding motif is very different from the 
motif predicted by phage display (Gary Bader, personal communication), as well 
as those typically reported in the literature (Yang et al., 2010), the p resence of 
unusual, or non-canonical binding motifs for Nedd4L, which do not conform to the 
PPXY or LPSY consensuses, have been reported (Hayes et al., 2011). Thus, the 
motif identified could represent a novel binding site for these WW domains. 
Conversely, binding to this motif could represent an in vitro artifact, similar to that 
observed for GST (Figure 9), which highlights the importance of recognizing 
caveats associated with this experimental approach and the need for subsequent 
alternative experiments. 
As the binding data generated by the peptide arrays could be biased by the 
presentation of the cytoplasmic domain as 15-residue peptides, which are out of 
the correct context of any surrounding sequence, alternative approaches to test the 
interaction between Nedd4L and β-dystroglycan were employed. Testing an 
interaction within the context of H2K myoblasts by co-immunoprecipitation is a 
favourable technique, as it permits examination within the context of the full 
sequence and any additional co-factors that may be involved in the putative 
interaction. Despite the successful immunoprecipitation of β -dystroglycan with 
MANDAG2, Nedd4L does not co-immunoprecipitate, suggesting that no direct or 
indirect interaction exists between these proteins (Figure 10). Ideally, one would 
test co-immunoprecipitation of Nedd4L with both the pY890-modified and 
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unphosphorylated forms of β-dystroglycan. However, due to limitations described 
in the results section, only an interaction with the unphosphorylated form could be 
tested. Arguably, testing the dependence of Nedd4L binding on Y890 
phosphorylation might not be necessary, as the proposed binding site  identified 
from the peptide array data is separated from Y890 by at least 100 residues that are 
predicted to be unstructured, due to a high proline content.  Nonetheless, 
phosphorylation of Y890 may generate a binding site for additional scaffolding 
factors, which then recruit Nedd4L and permit binding to the motif identified in 
this study. Hence, especially in light of the proposed link between Y890 
phosphorylation and ubiquitylation (Figures 4 and 5), the data generated by this 
approach does not fully resolve the question of whether Nedd4L binds β-
dystroglycan, but suggest that this is not true for the unphosphorylated form of the 
protein. 
Whilst testing the hypothesis that Nedd4L and β -dystroglycan interact in H2K 
myoblasts by co-immunoprecipitation was limited by antibody usage, it was 
possible to further verify the peptide array data with an additional in vitro 
experiment. A pinpoint vector containing the cytoplasmic domain of β -
dystroglycan was expressed in BL21 (DE3) E.coli and purified by streptavidin 
chromatography. Due to the inherent instability of the cytoplasmic domain of β -
dystroglycan when expressed in bacteria (Steve Winder, personal communication), 
it was only possible to obtain sufficiently high yields of protein together with the 
presence of several, unidentified contaminants (Figure 11, A). However, the 
purification of the cytoplasmic domain allowed the testing of the potential WW 
domain interactions by far-western blotting, in a manner similar to the approach 
used for the peptide arrays. This approach allows testing of the interaction with the 
predicted binding motif, LEDQATFIKKGVPI, but within the context of a more 
complete sequence. Despite successful detection of the purified cytoplasmic 
domain with MANDAG2 (Figure 11, B), which suggests  that the cytoplasmic 
domain is amenable to protein binding after electroblotting, no specific binding is 
observed for any of the WW domains of Nedd4L. Thus, it is possible to conclude 
that neither Nedd4 nor Nedd4L directly binds to β -dystroglycan with a high level 
of specificity or affinity in vitro, which in turn makes it less likely that these are 
ligases responsible for the ubiquitylation of β -dystroglycan. 
Nonetheless, it is not possible to dismiss an interaction between β -dystroglycan 
and either of these proteins, despite the data presented here strongly suggesting 
that no such interaction exists. As stated earlier, the phosphorylation of Y890, 
potentially along with the additional phosphorylations reported by Moraz et al., 
(2012) in response to internalization, may create a binding platform for a factor 
which recruits Nedd4 or Nedd4L. In support of this, a family of proteins termed 
arrestin related transporters (ARTs) have been identified in S. cerevisiae, which 
function as adaptor proteins for E3 ubiquitin ligases that modify plasma membrane 
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proteins (Lin et al., 2008). It is of particular interest that in Lin et al. (2008), 
ART1 binds to plasma membrane proteins and then recruits the WW domain 
containing E3 ubiquitin ligase Rsp5, which is the yeast homologue of Nedd4, via a 
PPXY motif. Hence, similar substrate adaptors could play a role in the 
ubiquitylation of β-dystroglycan by Nedd4 or Nedd4L. So, whilst a direct 
interaction between the WW domains of the Nedd4 and Nedd4L proteins and β-
dystroglycan is unlikely, the possibility of an indirect interaction involving one or 
several adaptor proteins is worthy of future investigation.  
 
4.3.4 Summary 
The data presented in this chapter can be summarized as follows:  
1. The pY890-modified and not the unphosphorylated form of β-dystroglycan 
is monoubiquitylated. 
2. Monoubiquitylation of pY890-modified β-dystroglycan can explain the 
presence of additional protein species observed upon internalization of this 
protein. 
3. The WW domains of the E3 ubiquitin ligases Nedd4 and Nedd4L do not 
directly interact with the unmodified cytoplasmic domain of β -dystroglycan, 
but may interact in the presence of post -translational modifications or 
adaptor proteins. 
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Chapter 5: 
Phosphorylation of Y890 and 
the Endocytosis of β-
Dystroglycan 
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5.1.1 Introduction 
Having established that phosphorylation of Y890 is linked to the internalization 
(Chapter 3) and ubiquitylation (Chapter 4) of β -dystroglycan, it was of interest to 
examine where exactly in the cell this form of the protein traffics to.  An 
understanding of which pathway(s) and endosomal compartments are involved in 
this process would give insights into how, as well as why, the internalization and 
ubiquitylation of pY890-modified β-dystroglycan occurs. Furthermore, an 
understanding of the endocytic routes and mechanisms associated with this process 
would enhance the current understanding of the pathology of DMD (and other 
dystrophic diseases), as well as increase the potential for therapeutic applications 
of this research. Hence, the work presented here focussed on understanding the 
internalization and endocytosis of pY890-modified β-dystroglycan. 
 
5.1.2 The Co-localization of pY890-modified β-Dystroglycan 
with the Clathrin-mediated Endocytic Pathway 
Returning to one of the key references for this thesis, Sotgia et al. (2003 a) describe 
the internal localization of pY890-modified β-dystroglycan, which is in agreement 
with the results presented in this thesis (see Chapter 3). pY890-modified β-
dystroglycan is present in an internal membranous compartment (Sotgia et al., 
2003a), and the authors note a co-localization with compartments containing the 
transferrin receptor and early endosomal antigen 1 (EEA1), suggesting the 
presence of β-dystroglycan in early and recycling endosomes. From the co -
localization of pY890-modified β-dystroglycan with these compartments, one 
could conclude that β-dystroglycan internalizes and recycles via the clathrin -
mediated endocytic pathway described for the transferrin receptor, with sequential 
migration from clathrin- and rab5-positive vesicles, to rab5- and EEA1-positive 
tubulovesicular compartments, and finally to rab-11 positive vesicles (Harding et 
al., 1983 ; Mu et al., 1995 ; Trischler et al., 1999).  
However, this conclusion is challenged by the existence of alternative pathways, 
which mediate the delivery of alternative cargoes to the same compartments used 
by the transferrin receptor. For example, BODIPY-LacCer (boron-dipyrromethene-
lactosylceramide), a marker of lipid rafts (Marks et al., 2005), internalizes in a 
clathrin- and rab5-independent manner, but co-localizes with transferrin receptors 
in the early endosomal compartment (Sharma et al., 2003). Conversel y, neuropilin 
1  (NRP1) internalizes in a clathrin-dependent manner, but within ten minutes is 
transferred to an alternative, GM1-positive (monosialotetrahexosylganglioside) 
compartment due to the action of Transient Axonal Glycoprotein 1 (TAG1) (Dang 
et al., 2012). Hence, the co-localization with a particular set of compartments 
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during the endocytic process does not necessarily describe the mechanism of 
internalization of pY890-modified β-dystroglycan. 
A further, criticism of the Sotgia et al. (2003 a) paper is that the overexpression of 
exogenous, alkaline phosphatase-tagged β-dystroglycan is used for the co-
localization experiments described above. The levels of specific proteins and 
endocytic components can influence the mechanism by which a protein 
internalizes. For example, β1-integrin normally internalizes via a mechanism 
dependent on lipid-rafts and caveolin-1, which is activated downstream of c-Src 
activation (Sharma et al., 2005 ; Shi et al., 2008 ; Shi et al., 2010). However, 
clustering of β1-integrin, which is caused by the perturbation of protein levels, 
antibody cross-linking, changes in local cholesterol levels, or a combination of 
these factors, can also cause internalization (Sharma et al., 2005). Indeed, the 
internalization of the β subunit of the cholera toxin protein  (ChTxB), a marker of 
the pathway used by β1-integrins, is dependent on an ability to cross-link multiple 
GM1 gangliosides (Singh et al., 2003). Hence, it is no surprise that modulating the 
levels of proteins may cause experimental artefacts that do not represent typical 
endocytosis and recycling. Therefore, in the context of overexpression, the 
endocytosis of β-dystroglycan described in Sotgia et al. (2003a) could be altered 
and not represent the normal trafficking of the protein.  
Unfortunately, beyond the findings of Sotgia et al., (2003 a), there is little 
information in the literature regarding the endocytosis of β-dystroglycan and as 
such, any endocytic mechanism may be involved in the internalization and 
trafficking of the protein. This work uses the H2Kb-tsA58 myoblast cell line as an 
experimental model, but H2K myoblasts have not been used previously for 
endocytic studies. Thus, it is unknown which endocytic pathways are active in this 
model and one can not suggest a likely pathway, or at least eliminate a non -
existent pathway, on this basis. However, one can form tentative suggestions based 
on the findings of previous studies. For example, the presence of a caveolar-
dependent endocytic apparatus is suggested by the predominantly sub-sarcolemmal 
localization and association of either caveolin-1 or caveolin-3 with known 
components of the endocytic pathway in mammalian myoblasts and skeletal muscle 
(Parton et al., 1994 ; Song et al., 1996 ; Parton et al., 1997).  
Whilst the caveolins are thought to have structural roles within skeletal muscle, 
such as the biogenesis of t-tubules (Parton et al., 1997),  there are plenty of 
examples of these proteins mediating typical caveolar -dependent endocytosis, 
suggesting that this pathway is present in H2K myoblasts (Parton et al., 2007 ; 
Hernández-Deviez et al., 2008 ; Cai et al., 2009; Hertzog et al., 2012). Although 
other endocytic pathways have not been studied in H2K myoblasts, the presence of 
early, late, recycling and lysosomal endosomes has been verified (Kaisto et al. 
1999). Furthermore, endocytic proteins such as the transferrin receptor (Kaisto et 
al., 1999) and the flotillins (Volonte et al., 1999) are present in mature skeletal 
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muscle fibres suggesting that these pathways are also active, as one would expect 
from their ubiquitous nature (Pearse et al., 1976). Hence, whilst the clathrin -
mediated endocytosis of pY890-modified β-dystroglycan in cell lines and muscle 
tissue is a possibility, whether it is the case for the internalization described in this 
thesis is uncertain. 
 
5.1.3 Alterations to the Membrane within the Dystrophic State  
Additional clues concerning the internalization of β -dystroglycan may instead be 
deduced from studies of the changes to muscle fibres that accompany the 
mdx/DMD disease state, as well as dystrophic pathologies in general.  Ex vivo, 
mdx muscle fibres show an increased susceptibility to stretch-induced sarcolemmal 
breakage and mdx myotubes have a reduced stiffness, relative to their wildtype 
counterparts (Petrof et al., 1993 ; Pasternak et al., 1995). These changes are 
partnered by alterations to the cholesterol content of the fibre, which may 
represent a compensatory mechanism in DMD pathology. Indeed, electron 
micrographs of digitonin-labelled muscle fibres from DMD patients show an 
increase in sarcolemmal cholesterol levels with age (Fischbeck et al., 1983) , and 
cholesterol depletion reduces the fatigue resistance of ex vivo muscle fibres in 
response to eccentric contraction, a feature typical of DMD and mdx pathology 
(Dellorusso et al., 2002 ; Sonnemann et al., 2009 ; Vega -Moreno et al., 2012). 
These changes, by themselves, may not be part of a cellular readjustment of 
endocytosis, but the notion that they would have no impact on endocytosis can be 
challenged. 
Caveosomes are endocytic pit structures present at the surface membrane, which 
are decorated by caveolins and require cholesterol for correct formation and 
function (Chang et al., 1992 ; Rothberg et al., 1992 ; Rodal et al., 1999). When 
visualized by freeze-fracture electron microscopy, these structures are 
distinguishable from clathrin coated pits, owing to the distinct lattice formation 
that coats the latter structures (Larkin et al., 1986). Electron microscopic analysis 
of dystrophic chicken and DMD patient muscle fibres reveals an increase in both 
the number and size of caveosomes at the sarcolemma, as well as a loss of the 
normal I-band localization of these structures (Costello et al., 1979 ; Bonilla et al., 
1981 ; Repetto et al., 1999). A possible explanation for this is an increase in the 
cholesterol content of the sarcolemma. Hence, changes to the cholesterol content 
of dystrophic sarcolemma may have an impact on caveolar -mediated endocytosis, 
with the formation of aberrant and mislocalized caveosomes as described above .  
Given that endocytosis is altered or impaired in dystrophic pathology, one w ould 
expect to see causative links to the expression of endocytic proteins. In support of 
this hypothesis, caveolin-3 expression is increased in the fibres of DMD patients, 
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and caveolin-3 knockout mice exhibit a dystrophic phenotype (Repetto et al., 1999 
; Gazerro et al., 2010). Furthermore, other forms of endocytosis, which are 
dependent on cholesterol levels, but not clathrin or caveolae, may also be effected 
by the changes in the dystrophic sarcolemma (Shogomori et al., 2001 ; Kokuba et 
al., 2003 ; Glebov et al., 2006). Hence, in DMD pathology, where the loss of 
sarcolemmal proteins is associated with alterations to components of the endocytic 
machinery, one can suggest that these altered pathways may play a role in the 
internalization of β-dystroglycan. 
The chief difficulty with this suggestion, at present, is the inability to discriminate 
between what is truly cause and effect in the aetiology of DMD and dystrophic 
pathologies in general. To take one of the arguments presented in Data Chapter 1 
as an example: the changes in phosphorylation signalling that accompany 
dystrophic pathology could promote the internalization of β -dystroglycan, or could 
be a result of the loss of this protein, which scaffolds several kinases 
(Chockalingham et al., 2002 ; Oak et al., 2003 ; Spence et al., 2004 ; Sen et al., 
2011). Similarly, changes to the sarcolemmal cholesterol content could promote 
the endocytosis of β-dystroglycan, or could be a mechanical response to the loss of 
the protein instead, such as the up-regulation of integrin expression (Cote et al., 
2002 ; Allikian et al., 2004 ; Rooney et al., 2006 ; Sen et al., 2011 ; Liu et al., 
2012). A pre-requisite for these altered pathways having a causative impact is the 
presence of β-dystroglycan in lipid rafts, as it is these, whether in caveolae 
clathrin-coated pits, or other vesicles, that are critically dependent on the 
cholesterol content of the plasma membrane.  
In support of this there are reports of β -dystroglycan in cold, Triton-X-100 
insoluble membrane fractions (Vega-Moreno et al., 2012), which is a common 
method of lipid raft purification (Shogomori et al., 2001 ; Sotgia et al., 2003b), 
however similar experiments in both the Winder and other labs have produced a 
negative result (Steve Winder, personal communication). Furthermore, viruses that 
use α-dystroglycan as a surface receptor  internalize in a cholesterol -dependent 
manner, but the presence of either α- or β-dystroglycan in lipid rafts has not been 
detected in cell lines that can be infected by these viruses (Kunz et al., 2003 ; Shah 
et al., 2006 ; Pasqual et al., 2011). Therefore, the argument for altered 
sarcolemmal cholesterol levels driving the internalization of β -dystroglycan in 
DMD pathology, or for endocytosis of this protein using lipid-rafts, is not without 
strong criticism.  
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5.1.4 The Interaction with Caveolin-3 and Dystrophic 
Pathology 
Nonetheless, the contribution of endocytosis to the pathology of muscular 
dystrophies, including DMD, should not be overlooked. Mutations in caveolin-3 
are associated with limb-girdle muscular dystrophy 1C, as well as several similar 
diseases affecting skeletal muscle (Gazerro et al., 2010) and can cause the 
mislocalization of several proteins, including components of the DGC (Herrmann 
et al., 2000 ; Sotgia et al., 2003b ; Sotgia et al., 2003c). In particular, the dysferlin-
dependent repair response is critically dependent on the trafficking mediated by 
caveolin-3 (Hernandez-Davies et al., 2007 ; Cai et al., 2009). In addition to having 
a role in endocytosis, Caveolin-3 multimers provide a sub-sarcolemmal scaffold 
for several proteins (Song et al., 1996 ; Hezel et al., 2010 ; Whiteley et al., 2012). 
Importantly, the levels of caveolin-3 mRNA and protein are increased in the mdx 
mouse disease state (Vaghy et al., 1998), which, when partnered the altered 
phosphorylation state of dystrophic muscle tissue, could influence the 
internalization of this protein, as is the case for functionally equivalent c aveolin-1 
in other tissues (Parton et al., 1994 ; Aoki et al., 1999 ; Pelkmans et al., 2002). 
Indeed, the internalization of β1-integrin by caveolin-1 is dependent on 
phosphorylation of both proteins, downstream of c -Src activation (Sharma et al., 
2005 ; Shi et al., 2008), and several of the kinases associated with β -dystroglycan 
regulate caveolar-mediated endocytosis (Pelkmans et al., 2005). Furthermore, the 
loss of integrin adhesion has been proposed to act as a trigger for caveolar -
dependent uptake of this protein (Hertzog et al., 2012). Hence, whether it is due to 
a global, genetic changes or a local phenomenon within the muscle fibre, the loss 
of adhesion in the absence of dystrophin binding could stimulate a similar 
caveolar-dependent internalization of β-dystroglycan. 
Unfortunately, this hypothesis has several key problems, which make the caveolar -
dependent endocytosis of β-dystroglycan a less distinct possibility, despite the 
potential parallel with β1-integrin internalization. The hypothesis requires  an 
interaction between β-dystroglycan and caveolin-3 multimers and, whilst co-
sedimentation of the two proteins is observed in myoblasts (Song et al., 1996)  and 
an interaction with the c-terminus of β-dystroglycan has been reported (Illsey et 
al., 2002), these interactions are deemed to be indirect or transient owing to the 
inability to co-purify caveolin-3 with the DGC (Crosbie et al., 1998). In a similar 
vein, caveolin-3 may only have a scaffolding role in the localization of β -
dystroglycan, as is the case for caveolin-3 and components of neuromuscular 
junctions (Hezel et al., 2010), and caveolin-3 and the ryanodine receptor (Whiteley 
et al., 2012). Interestingly, caveolin-3 has been reported to bind both a Y890-
phosphorylated and an unphosphorylated moti f present at the c-terminus of β-
dystroglycan in vitro (Illsey et al., 2002). However, the overexpression of 
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caveolin-1 or -3 in cell lines blocks the phosphorylation of β-dystroglycan on 
Y890, suggesting that caveolin-3 scaffolds would block the internalization of this 
protein, rather than facilitate entry into the cell  (Sotgia et al., 2003a). Thus, one 
can not infer how β-dystroglycan might be internalized from the compartments it is 
localized to, an understanding of analogous adhesion systems, a knowledge of the 
pathways present in H2K myoblasts, or the changes to endocytic components 
within the dystrophic state: for all potential hypotheses there is either insufficient 
evidence, or worse, conflicting data. 
 
5.1.5 Hypothesis: pY890-modified β-Dystroglycan Internalizes 
from the Plasma Membrane in a Clathrin-dependent Manner in 
H2K Myoblasts 
Using the results described in Sotgia et al. (2003 a) as a starting point for enquiry, it 
was initially hypothesized that pY890-modified β-dystroglycan internalized from 
the plasma membrane of H2K myoblasts in a clathrin-dependent manner. Whilst 
there was little data to support this hypothesis, there were also few findings that 
negated this possibility, unlike other potential endocytic mechanisms. To test this 
hypothesis 3 different general techniques could be employed: RNAi screening of 
endocytic proteins and associated signaling kinases, as performed in Pelkmans et 
al. (2005); treatment or transfection of H2K myoblasts with endocytic inhibitors, 
similar to that used in Pasqual et al. (2011); or co-localization of the pY890-
modified form of β-dystroglycan with endocytic markers, as visualized by 
immunofluorescence microscopy. All 3 approaches would have caveats, however 
given the previous use of the technique to visualize the clear punctate staining of 
pY890-modified β-dystroglycan, as well as the ability to directly extend the key 
findings of Sotgia et al. (2003a), immunofluorescence microscopy of H2K 
myoblasts was used.  
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5.2.1 Controls For Immunofluorescence Experiments 
Prior to all immunofluorescence microscopy described in this chapter, secondary 
control experiments were performed. As shown in Figure 1, all secondary 
antibodies used in this study exhibited a low level of non-specific binding to H2K 
myoblasts, resulting in low levels of fluorescent signal. Background fluorescence 
of this kind is routinely observed in experiments of this nature. Fortunately, the 
levels of these non-specific backgrounds were low compared to the signals 
generated upon primary antibody or fluorescent dye incubation. Hence, for each set 
of experiments, the contrast and exposure settings of the microscope were adjusted 
to exclude this background fluorescence. For each data set, the modified contrast 
and exposure settings were maintained throughout the acquisition of data.  
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Figure 1: Controls for the secondary antibodies used extensively in this study. 
Antibodies used are: (A) FITC anti-mouse IgG, (B) FITC anti-rabbit IgG, (C) 
Texas Red anti-mouse IgG, and (D) Texas Red anti-rabbit IgG. In all cases, faint, 
background reactivity is observed throughout the cell  that is highest in the 
perinuclear regions. Contrast and exposure settings were adjusted on the 
microscope to discount this immunoreactivity for all images presented.  
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5.2.2 Establishing the Use of Transferrin-568 in H2K 
Myoblasts 
The initial hypothesis that β-dystroglycan internalizes and traffics via a clathrin-
mediated pathway was tested in H2K myoblasts. To replicate the experiments of 
Sotgia et al. (2003a) as closely as possible, transferrin-568 (Molecular Probes) was 
used to label the transferrin receptors present in H2K myoblasts, which are known 
to internalize in a clathrin-dependent manner (Harding et al., 1983). Labelling was 
performed in a pulse-chase manner: H2K myoblasts were incubated with 10µg/ml 
transferrin-568 in growth medium for one minute at 37°C, prior to switching to 
growth media without transferrin-568 and subsequent incubation at 37°C. In this 
way, the overall endocytosis of the transferrin receptor (internalization, recycling 
or degradation) could be visualized by formalin fixation after various incubation 
times. As the endocytosis of the transferrin receptor is well characterized in other 
cell lines, but not in H2K myoblasts, an initial characterization of the endocytic 
pathway was performed. 
Figure 2 presents a series of representative images of the transferrin-568 
fluorescence observed in H2K myoblasts after various pulse -chase incubation 
times. With time, there were progressive changes in the visual phenotype of 
transferrin-568 stain observed, indicative of progression through compartments of 
the endocytic pathway described for the transferrin receptor in other cell systems. 
As no co-staining was used for these experiments, exact definitions of the 
endocytic compartments harbouring these fluorescent puncta could not be 
elucidated. However, general changes in the visual phenotype exhibited by 
transferrin-568 staining of H2K myoblasts could be defined. These definitions 
were: “cytosolic”,  a diffuse punctuate stain between the nucleus and periphery of 
the cell with little or no perinuclear accumulation (1, 2 and 3 minute  time points, 
Figure 2) ; “perinuclear”, an accumulation of punctuate staining around the 
nucleus of the cell (10 minute time point, Figure 2); and “mixed” an intermediate 
of “cytosolic” and “perinuclear” staining with predominant staining both around 
the nucleus and throughout the cell (5, 15, 20 and 30 minute time points, Figure 2). 
Importantly, relatively few puncta were observed in control experiments, where 
transferrin-568 had been allowed to bind to surface receptors before acidic 
stripping without any internalization, indicating that the majority of fluorescent 
puncta observed at the various time points were internal (0 minute time point, 
Figure 2). Hence, these definitions could be used to describe the transferrin -568 
staining observed in the experimental system. 
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Figure 2: (A) Representative images of a time course of transferrin-568 
internalization and recycling in H2K myoblasts. H2K myoblasts were incubated 
with a saturating concentration of transferrin-568 for 1 minute at 37°C prior to 
washing with growth media and subsequent incubation at 37°C. Following 
incubation, H2K myoblasts were stripped of surface bound transferrin -568 at 4°C 
and processed for immunofluorescence microscopy. Displayed are red channel 
(transferrin-568) and false colour merged (transferrin-568 and DAPI) images of the 
time points indicated. 
(B) Stripping control for these experiments. H2K myoblasts were incubated with 
transferrin-568 for 1 hour at 4°C, prior to stripping and processing as described in 
part (A). 
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Although the images shown in Figure 2 are representative of the main visual 
phenotype observed at each time point, a distribution of phenotypes were in fact 
observed at all time points. This is to be expected, owing to the heterogeneous 
nature of endocytosis between individual  cells. Hence, an equal number of H2K 
myoblasts were imaged and scored for visual phenotype at each incubation time 
point, in order to better estimate the progression of transferrin receptor endocytosis 
in this experimental system. Figure 3 contains a graphical representation of these 
data, with the percentage of cells exhibiting each of the defined visual phenotypes 
for each time point. The data shows several overall changes in the predominant 
visual phenotype of H2K myoblasts pulse-chased with transferrin-568, which can 
be equated to what is known about this receptor in other experimental systems.  
 
Figure 3: Changes in the visual phenotype of transferrin -568 staining during 
internalization and subsequent recycling in H2K myoblasts. 30 images were scored 
per time point for one of the 3 visual phenotypes. The percentage of cells 
exhibiting each visual phenotype was then plotted against the pulse-chase 
incubation time. 
 
Initially, transferrin-568 puncta are “cytosolic”, suggesting a localization to sub-
membranous or early endosomes within the endocytic system. Clathrin -mediated 
endocytosis begins with dynamin-dependent scission from the plasma membrane 
and delivery of endocytic vesicles to the early endosomal compartment (Mu et al., 
1995 ; Trischler et al., 1999). Hence, the “cytosolic” phenotype probably 
represents localization of labelled transferrin receptors within these compartments. 
In other experimental systems the transferrin receptor then follows various 
Cells 
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pathways, which function to either recycle or degrade the protein, via recycling or 
late endosomal compartments. Whilst direct recycling could not be discerned, as 
this would contribute to the “cytosolic” visual phenotype, trafficking to the late 
endosomal compartment could be visualized as this compartment is known to be 
perinuclear (Piper et al., 2001). It is interesting to note that at the 10 mi nute time 
point, both the “mixed” and “perinuclear” visual phenotypes replace “cytosolic” as 
the dominant staining pattern, suggesting that delivery of pulse-chased transferrin 
receptors to the late endosomal compartment  has occurred. Whilst the majority of 
stained H2K myoblasts exhibited a “perinuclear” visual phenotype at the 10 minute 
time point, this shifted to a “mixed” phenotype at subsequent time  points, with loss 
of “cytosolic” and “perinuclear” staining. This could represent either trafficking 
via the recycling or degradation compartments, or even subsequent internalization 
of exocytosed transferrin-568. It is important to note that saturation of the system, 
presumably with recycling of transferrin receptor to the plasma membrane, occurs 
between 15-30 minutes (Figure 2 and 3), which is in agreement with both estimates 
from other systems (Harding et al., 1983 ; Hopkins et al., 1983 ; Klausner et al., 
1983) and the biochemical data presented earlier (Figure 5, Data Chapter 1). Thus, 
one can conclude that transferrin receptor endocytosis, as visualized by transferrin -
568 pulse-chase staining, is not significantly different from other experimental 
systems. 
 
 
 
5.2.3 β-Dystroglycan Does Not Traffic with the Transferrin 
Receptor 
Having established that transferrin-568 pulse-chase staining could be used in H2K 
myoblasts, co-localization of pY890-modified β-dystroglycan with the 
compartments marked by this stain was tested by co-staining with 1709 (Figure 4). 
Co-localization was examined at the 3, 10, 15 and 30 minute time points, which 
correspond to the time points used by Sotgia et al., (2003 a), as well as the earlier 
stages of clathrin-dependent endocytosis (Figure 3 and Trischler et al., 1999). At 
all time points examined little co-localization was observed between the 
transferrin-568 and 1709 stains (Figure 15, A-D). This data strongly suggests that 
pY890-modified β-dystroglycan does not share a common endocytic compartment 
with the transferrin receptor during internalization or subsequent trafficking. To 
further verify this conclusion, the co-localization between internalized β-
dystroglycan and a known compartment of transferrin receptor endocytosis was 
tested. 
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Figure 4: Representative images of 1709 (pY890-modified β-dystroglycan) and 
transferrin-568 co-staining of H2K myoblasts following a one minute transferrin -
568 pulse and incubation at 37°C in growth media for the time points indicated. 
Following stripping of surface transferrin, H2K myoblasts were then processed for 
immunofluorescence as described in Materials and Methods. Shown are green 
channel (1709) fluorescence, red channel (Tfn-568) fluorescence and false colour 
merge (1709, Tfn-568, DAPI) images. 
10 Min 
3 Min 
15 Min 
30 Min 
1709 Transferrin-568 Merge 
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The early endosomal compartment, as defined by the presence of the Rab5 effector 
Early Endosomal Antigen 1 (EEA1), is a destination of the transferrin receptor 
during endocytosis (Mu et al ., 1995 ; Rubino et al., 2000). Western blots of H2K 
myoblast lysates identified that EEA1 is expressed in this cell line (data not 
shown). Furthermore, staining H2K myoblasts with anti -EEA1 revealed a punctate 
staining throughout the cell, typical of the staining pattern observed in other 
experimental systems (Figures 5 and 6 and Stenmark et al., 1996). Co -
immunostaining of H2K myoblasts for pY890-modified β-dystroglycan and EEA1 
showed little co-localization between these proteins (Figure 5 and Figure 15,  E), 
suggesting that internalized β-dystroglycan does not traffic via this compartment. 
Furthermore, the absence of co-localization between pY890-modified β-
dystroglycan and the EEA1-positive early endosomal compartment, a known 
destination of internalized transferrin receptors, verifies the lack of co-localization 
observed between the pY890-modified β-dystroglycan and transferrin-568 stains 
(Figure 4). 
These data suggest that the initial hypothesis is incorrect, and are in disagreement 
with the findings of Sotgia et al., (2003a). Although this could be due to the 
improved resolution of the epifluorescence microscopy used in this study, it could 
also be due to abnormal transferrin receptor endocytosis or EEA1 staining in H2K 
myoblasts. To test if the latter was the case, H2K myoblasts were pulse-chased 
with transferrin-568 and co-stained with anti-EEA1 after a 3 minute incubation at 
37°C. Assuming that the cytosolic fluorescent puncta predominantly observed 
during the early time points of transferrin-568 internalization represent 
internalizing vesicles or early endosomal compartments (Ghosh et al., 1994), then 
a co-localization between the transferrin-568 and EEA1 stains should be apparent 
at this time point. For this experiment a confocal fluorescence microsc ope was 
used to visualize stained H2K myoblasts, so that false co -localization due to 
spatial overlap in the z-plane could be excluded. Figure 6 contains a series of 
confocal slice images showing transferrin-568 and EEA1 staining at various 
positions within the z-plane. Whilst not all transferrin-568 puncta are EEA1-
positive, the majority of EEA1-positive puncta are also positive for transferrin-
568. This finding is in agreement with what one would expect to see if transferrin 
endocytosis were occurring as described in other experimental systems (Mu et al., 
1995). When quantitatively analyzed, the two stains show a moderate level of co-
localization, however a comparison of the individual average Manders coefficients 
(0.95 for EEA1 with transferrin-568, 0.6 for transferrin with EEA1) affirms the co-
localization by eye, as well as explaining the relatively low overall co-localization 
(Figure 15, F,G,H). Together, these findings suggest  that the lack of co-
localization of these markers with pY890-modified β-dystroglycan is due to 
trafficking via different pathways, rather than any abnormal staining of these 
compartments in H2K myoblasts. 
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Figure 5: A representative image of 1709 (pY890-modified β-dystroglycan) and 
EEA1 co-immunostaining of H2K myoblasts. Shown are green channel (1709) 
fluorescence, red channel (EEA1) fluorescence and false colour merge (1709, 
EEA1, DAPI) images. 
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1709 EEA1 
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Figure 6: A representative series of Z-stack confocal immunofluorescence 
microscopy images of EEA1 (green) and transferrin-568 (red) co-staining of H2K 
myoblasts. Following a one minute transferrin-568 pulse and incubation at 37°C in 
growth media for a further two minutes, H2K myoblasts were  transferred to 4°C, 
stripped and processed for immunofluorescence microscopy as described in 
Materials and Methods. 
 
EEA1 Transferrin-568 Merge 
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Although these data suggest that pY890-modified β-dystroglycan does not traffic 
via the pathways used by the transferrin, as internalized β-dystroglycan does not 
share a common compartment with the transferrin receptor or EEA1, they do not 
properly test if internalization occurs in a clathrin -dependent manner. It is 
conceivable that, following clathrin-dependent internalization, pY890-modified β-
dystroglycan traffics via alternative endocytic compartments. If this is the case in 
H2K myoblasts then there should be some overlap between immunostains of 
pY890-modified β-dystroglycan and the clathrin heavy chain (CHC), an essential 
component of the clathrin lattice which coats internalized pits (Larkin et al., 1986). 
However, as shown in Figures 7 and 15 (I), these two immunostains show little or 
no overlap. In the face of these data it seemed unlikely that β -dystroglycan 
internalizes in either a clathrin-dependent manner, or traffics via any of the typical 
compartments downstream of clathrin-dependent internalization, so the initial 
hypothesis was revised. 
 
5.2.4 Establishing the Use of 594-ChTxB in H2K Myoblasts 
A plausible alternative is that β-dystroglycan internalizes using lipid rafts, 
potentially in association with caveolin-3. As discussed in the introduction, the 
argument for raft- or caveolar-dependent endocytosis of β-dystroglycan is not 
without justified criticism; however internalization via a pathway that does not 
utilize clathrin would explain the observed lack of co -localization of pY890-
modified β-dystroglycan with the transferrin receptor, EEA1 and CHC stains. 
Thus, it was hypothesized that β-dystroglycan is endocytosed via a clathrin-
independent mechanism. Beyond caveolar-mediated endocytosis, markers for these 
alternative pathways are not as robust or as well characterized as those of the 
“classical” clathrin-dependent pathway. However, one well-reported marker is the 
B subunit of the toxin from V. cholerae. Cholera toxin B subunit (ChTxB) 
selectively binds to GM1 gangliosides, which are present in lipid rafts in the 
plasma membrane, and has, by itself, little or no cytotoxicity (Nichols et al., 200 1 ; 
Puri et al., 2001). For the experiments presented herein the fluorescently tagged 
Alexa Fluor 594-ChTxB (Invitrogen) was used. 
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Figure 7: A representative image of 1709 (pY890-modified β-dystroglycan) and 
clathrin heavy chain co-immunostaining of H2K myoblasts. Shown are green 
channel fluorescence (1709), red channel (clathrin heavy chain) and false colour 
merge (1709, clathrin heavy chain and DAPI) images.  
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Initially, labelling conditions which gave adequate staining and stripping were 
determined. Figure 8 contains images depicting the typical stages of 594 -ChTxB 
staining of H2K myoblasts. Incubation of myoblasts with growth media containing 
1µg/ml 594-ChTxB for 30 minutes at 4°C produced a diffuse, patchy stain (Figure 
8, A). Presumably, this is due to binding to GM1 gangliosides within the plasma 
membrane, with enriched membrane microdomains appearing as patches of more 
intense staining, although it is important to note that these patches do not app ear as 
intense as the internalized puncta observed following incubation at 37°C (Figure 8, 
C). To ensure any membranous staining was excluded following internalization at 
37°C, various stripping buffers and conditions were trialled (data not shown). The 
most optimal of these stripping conditions did not fully remove all membranous 
staining, however the remaining levels of 594-ChTxB staining were low enough to 
be disregarded from analysis as background (Figure 8,B).  Thus, the use of 
stripping washes after incubation at 37°C permitted visualization of the 
internalized puncta, due to the large difference in staining intensity between 
residual membranous stain and internalized vesicles (Figure 8, C).  
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Figure 8: Representative images of H2K myoblasts stained with 594-ChTxB. 
Shown are red channel (594-ChTxB) and false colour (594-ChTxB and DAPI) 
merged images. (A) Surface labelling of H2K myoblasts at 4°C without subsequent 
internalization at 37°C gives a membranous, patchy stain. (B) As (A), but with a 
series of stripping washes at 4°C. The washes remove the majority of stain, but a 
residual stain is left. (C) Staining of H2K myoblasts with 594 -ChTxB as described 
in Materials and Methods. In this instance, a ten minute incubation at 37°C was 
used.  
A 
B 
C 
594-ChTxB Merge 
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5.2.5 β-Dystroglycan Does Not Traffic with Lipid Rafts 
Containing GM1 
Having established conditions which gave suitable 594-ChTxB staining of H2K 
myoblasts, it was possible to visualize the vesicular compartments involved in 
endocytic pathways that utilise lipid rafts. As before with transferrin -568 staining, 
H2K myoblasts were labelled in a pulse chase manner: myoblasts were incubated 
with 1µg/ml 594-ChTxB at 4°C prior to switching to growth media without ChTxB 
and subsequent incubation at 37°C. With formalin fixation and co-immunostaining 
for pY890-modified β-dystroglycan after various 594-ChTxB incubation times, the 
extent of co-localization between these markers could be determined. At all of the 
time points examined (1, 3, 6, 10, 15, and 20 minutes), little or no co-localization 
was observed (Figures 9 and 15, J-O). This suggests that β-dystroglycan does not 
internalize via a pathway that involves lipid rafts that contain GM1.  
Unlike the well-characterized transferrin receptor endocytic system, it was not 
possible to characterize the changes in staining observed with varying chase times 
following a 594-ChTxB pulse. Whilst there was an analogous transition of 
punctuate staining from peripheral to perinuclear compartment s with time (Figure 
9), exactly what these compartments are is harder to define. Furthermore, owing to 
the involvement of lipid rafts in multiple endocytic pathways, verification of the 
staining observed with 594-ChTxB in H2K myoblasts by co-localization with 
known markers was not possible. However, an important question to address, 
especially in light of the revised hypothesis, was whether this staining was a 
consequence of internalization in a clathrin-independent manner. To address this 
question, H2K myoblasts were pulsed with 594-ChTxB and chased for short times 
(30 and 60 seconds) in order to visualize the degree of co -localization with CHC, a 
bona fide marker of clathrin-dependent internalization. As shown in figures 10 and 
15 (P,Q), 594-ChTxB staining does not co-localize with CHC immunostaining at 
these early time points, suggesting that labelling with 594-ChTxB does not 
visualize vesicles that internalize in a clathrin-dependent manner. Furthermore, the 
lack of co-localization between the pY890-modified β-dystroglycan and 594-
ChTxB stains over the time points examined suggests that β -dystroglycan does not 
internalize or traffic via a pathway that involves lipid rafts.  
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Figure 9: Representative images of H2K myoblasts pulse -chased with 594-ChTxB 
for the incubation times shown and then co-immunostained with 1709. Shown are 
green channel (1709), red channel (594-ChTxB) and false colour merged (1709, 
594-ChTxB, DAPI) images. Figure continued on next page. 
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Figure 9: Continued from previous page. 
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Figure 10: Representative images of H2K myoblasts pulse -chased with 594-ChTxB 
for the incubation times shown and then co-immunostained with anti-CHC. Shown 
are green channel (anti-CHC), red channel (594-ChTxB) and false colour merged 
(Anti-CHC, 594-ChTxB, DAPI) images.  
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5.2.6 Internalized β-Dystroglycan Does Not Traffic to the 
Lysosome 
Being unable to establish a route of internalization for β -dystroglycan, the work 
focussed instead on the endocytic fate of β -dystroglycan. As described in Data 
Chapter 2, pY890-modified β-dystroglycan is also monoubiquitinated. Although 
the exact function of this monoubiquitination was not determined, it could be 
potentially involved in endolysosomal degradation, as is the case for the EGF 
receptor (Oved et al., 2006). Furthermore, the degradation of membrane proteins 
via endocytic delivery to the lysosomal compartment is a well documented and 
common process (Nichols et al., 2001). It was therefore of interest to see if a 
similar process occurs in H2K myoblasts and so, it was hypothesized that some of 
the internal β-dystroglycan staining observed was due to  localization of this 
protein to the lysosomal compartment. Lysotracker
TM
 Red DND-99 (Molecular 
Probes), hereafter referred to as “Lysotracker” was used to stain H2K myoblast 
lysosomes. In the literature involving the use of this dye, positive control 
experiments involving inhibition or neutralization of the lysosomal compartment 
are performed (Gotink et al., 2011). Neutralization of the lysosomal compartment 
by ammonium chloride treatment is a well -established protocol (Selgen et al., 1976 
; Ohkuma et al., 1978) and was adapted to establish correct staining of H2K 
myoblasts with Lysotracker. Pre-treatment of H2K myoblasts with growth media 
containing 50mM NH4Cl for 2 hours abolishes the punctuate staining normally 
observed with lysotracker (Figure 11). In addition to a significant reduction in the 
number of puncta observed in H2K myoblasts stained with Lysotracker after 
NH4Cl treatment, there is an increase in non-specific background staining and 
swollen vesicles are apparent (Figure 11). The swelling (or inhibition) of 
lysosomes in response to ammonium chloride neutralization is well -documented 
(Wibo et al., 1974 ; Selgen et al., 1976) and this observation, partnered with the 
loss of punctuate staining, suggests that Lysotracker can be used as a marker of th e 
endolysosomal compartment in H2K myoblasts.  
Having established the use of Lysotracker with H2K myoblasts, the co -localization 
of internalized β-dystroglycan with the lysosomal compartment was examined 
next. Co-staining with lysotracker and 1709 showed no co-localization overall 
(Figure 15, R), although some false co-localization, mainly due to excessive 
perinuclear signal in the green channel was apparent in several images (Figure 12).  
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Figure 11: (A) Representative images of Lysotracker DND-99 staining of H2K 
myoblasts with and without 50mM ammonium chloride pre -treatment. Shown are 
red channel (lysotracker) and false colour merge images. (B) A scatter plot 
representation of the data. N=25 per treatment, with a significant difference 
between the means (p<0.001, Students t -test). 
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Figure 12: A representative image of 1709 and lysotracker  staining of H2K 
myoblasts. H2K myoblasts were stained with Lysotracker as described in Materials 
and Methods, prior to processing for immunofluorescence microscopy and co -
immunostaining with 1709. Shown are green channel (1709), red channel 
(Lysotracker) and false colour merge (1709, Lysotracker and DAPI).  
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However, even when this is included in the analysis the mean Manders coefficient 
for co-localization is 0.382, and this is not significantly different from other, 
negative co-localizations (Figure 15). Therefore, these data suggest that 
internalized, pY890-modified β-dystroglycan does not traffic to the endolysosomal 
compartment. However, the possibility exists that only a small proportion of 
pY890-modified β-dystroglycan would reside in this compartment, making 
detection of any potential co-localization difficult due to the sensitivity of this 
particular system. Therefore, alternative means of visualizing the lysosomal 
compartment in H2K myoblasts were employed to further test the hypothesis.  
GFP-Sialin and Lamp1-mCherry are two markers of the lysosomal compartment, 
which have both been reported in the literature (Dozynkiewicz et al., 2012). 
Eukaryotic expression vectors containing either of these proteins were provided as 
generous gifts by Professor Jim Norman. H2K myoblasts were transfected with 
either one of the vectors expressing these proteins by electroporation. 24 hours 
after electroporation, H2K myoblasts were  processed for immunofluorescence 
microscopy and immunostained for pY890-modified β-dystroglycan. For both 
GFP-Sialin and Lamp1-mCherry there is no co-localization with pY890-modified 
β-dystroglycan (Figures 13 and 15, S-T). The lack of co-localization could be 
interpreted as a verification of the experiments with Lysotracker,  or could be due 
to improper localization of these two constructs. However, expression of both 
GFP-Sialin and Lamp1-mCherry in H2K myoblasts by electroporation results in 
almost complete co-localization (Figures 14 and 15, U), which makes the argument 
for improper localization of either tagged protein less likely. It is therefore more 
likely that a lack of co-localization with pY890-modified β-dystroglycan is due to 
these proteins residing in separate subcellular compartments. Hence, when the data 
from the Lysotracker, GFP-sialin and Lamp1-mCherry experiments are considered 
collectively, one can conclude that internalized β -dystroglycan does not traffic to 
the endolysosomal compartment or that the 1709-reactive epitope is lost early 
during the degradation process. 
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Figure 13: Representative images of H2K myoblasts transfected with either 
Lamp1-mCherry or GFP-sialin and co-immunostained with 1709. Shown are green 
channel (1709 or GFP-sialin), red channel (1709 or Lamp1-mcherry) and false 
colour merge images. 
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Figure 14: Representative images of H2K myoblasts transfected with Lamp1 -
mCherry and GFP-sialin. Shown are green channel (GFP-sialin), red channel 
(Lamp1-mcherry) and false colour merge images. 
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5.2.7 Quantification of Co-localization for All Experiments 
Finally, a post-hoc co-localization analysis was performed using JACoP, as 
described in Materials and Methods (Bolte et al., 2006). Where appropriate, the 
Manders (co-localization) coefficients obtained from this analysis have been 
referred to in the text. Visually, one can see that there is limited variation between 
the negative co-localization results (A-E and I-T), whereas the positive results (F-
H and U) are considerably higher. The non-zero value for negative co-localization 
can be attributed to the high perinuclear staining with 1709 and the relatively low 
resolution of epifluorescence microscopy used. The full implications of this are 
discussed later. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: The mean Manders coefficient for all experiments shown in this 
chapter. N=30 per treatment. Transferrin-568 and 1709: 3 minutes (A), 10 minutes 
(B), 15 minutes (C), 30 minutes (D). 1709 and EEA1 (E). Transferrin -568 and 
EEA1 (F, G, H). 1709 and CHC (I). 1709 and 594-ChTxB: 1 minute (J), 3 minutes 
(K), 6 minutes (L), 10 minutes (M), 15 minutes (N), 20 minutes (O). 594-ChTxB 
and CHC: 30 seconds (P), 60 seconds (Q). 1709 and Lysotracker (R). 1709 and 
GFP-Sialin (S). 1709 and Lamp1-mCherry (T). GFP-Sialin and Lamp1-mCherry 
(U). 
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5.3.1 Examining β-Dystroglycan Internalization With 
Epifluorescence Microscopy 
The internalization of β-dystroglycan is linked to Y890 phosphorylation (Chapter 
3). In order to understand the mechanism governing this process, the endocytic 
route that β-dystroglycan internalization utilises was investigated. As seen 
throughout this chapter, the intracellular form of β -dystroglycan is readily detected 
by immunofluorescence microscopy and H2K myoblasts are amenable to the 
staining of endosomal compartments. Despite examining a wide range of likely 
endocytic routes, the mechanism of internalization was not identified by these 
approaches and exactly how β-dystroglycan internalizes in response to Y890 
phosphorylation remains uncertain. However, it is now possible to rule out several 
pathways, which are present in H2K myoblasts and other cell lines, with a 
relatively high level of confidence. 
The use of immunofluorescence microscopy as an approach can be justified on the 
basis that it does not suffer the same technical difficulties or caveats as other, 
contemporary methods. Establishing a method of genetic screening was 
unfortunately beyond the scope of this work and was therefore not pursued. The 
treatment of cell lines with inhibitors is widely used in the literature to examine 
the dependence of certain pathways in the endocytosis of proteins (Huth et al., 
2006), and this approach could have been partnered with immunofluorescence 
microscopy or the internalization assay described previously. However, the utility 
of this approach has been recently called into question, owing to the lack of 
efficacy or specifity of inhibition: many, if not all inhibitors effect pathways other 
than those that they are supposed to selectively inhibit and therefore, the 
conclusions drawn from this approach are not always reliable  (Anderson et al., 
1996 ; Shogomori et al., 2001 ; Sharma et al., 2003 ; Vercauteren et al., 2010). For 
example, in Vercauteren et al., (2010), the inhibition of clathrin -independent 
endocytosis (as visualized by lactosylceramide uptake) by chlorpromazine, which 
is a supposedly specific inhibitor of clathrin-dependent uptake, is reported in 
several cell lines. 
However, a drawback of the data presented in this chapter is the high level of peri -
nuclear and nuclear staining with 1709. This problem arises primarily due to the 
use of epifluorescence microscopy, which cannot sufficiently resolve the 
fluorescent signals near the centre of the cell. The analysis of co -localization with 
JACoP was partially hampered by this, as fluorophores within this region did co-
localize leading to a baseline Manders coefficient of approximately 0.35 (Figure 
15). Whilst it was possible to distinguish positive co-localization (Figure 15, X,Y, 
and Z), one cannot deny that the sensitivity of analysis was affected by the method 
of microscopy used. Epifluorescence microscopy was chosen as a primary imaging 
method, as it was fast and readily available in the Winder lab . However, if 
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significant co-localization were observed, confocal fluorescence mic roscopy was 
used as a secondary imaging method, as was the case for the transferrin -568 and 
EEA1 co-stain (Figure 6). Due to the potentially limited extents of co -localization 
between sub-populations of pY890-modified β-dystroglycan and endocytic 
markers, future work may consider the use of confocal microscopy as a primary 
imaging method. This would improve the sensitivity of co-localization analysis 
and thus, provide a better means to test future hypotheses.  
 
5.3.2 β-Dystroglycan and Transferrin Receptor Endocytosis 
The endocytosis of the transferrin receptor is one of the most studied processes in 
the field of cellular biology and therefore, one can ascertain the reliability of the 
co-localization experiments presented here by a comparison with what is known in 
other experimental systems. The internalization of the transferrin receptor in H2K 
myoblasts is rapid and occurs within 60 seconds (Figure 2), which is in agreement 
with kinetics reported in the literature (Klausner et al., 1983 ; Ghosh et al., 1994 ). 
This internalization is clathrin-dependent and saturation of the system and 
subsequent release of transferrin occurs within 20-30 minutes (Harding et al., 
1983, Hopkins et al., 1983). Although recycling was not accessed, as 
internalization was the focus of this work, the transition of transferrin-568 
staining, from peripheral to perinuclear sub-cellular regions and eventually both, 
occurred within a time frame in H2K myoblasts (Figure 3). Presumably, the 
changes in stain represent changes from early to late and recycling endosomal 
compartments (Trischler et al., 1999 ; Piper et al., 2001), owing to the proposed 
localization of these compartments in muscle fibres (Kaisto et al., 1999). Whether 
this is the case was not addressed fully and future work may fu rther verify the 
endocytosis of the transferrin receptor in H2K myoblasts by examining co-
localization with rab 11 and the mannose-phosphate receptor (Dozynkiewicz et al., 
2012). However, one can conclude that the internalization and early endocytic 
processing of the transferrin receptor is typical of other systems owing to the high 
degree of co-localization with EEA1 after a 3 minute pulse-chase (Figure 6 ;  Mu 
et al., 1995). Hence, staining with transferrin-568 and for EEA1 were suitable 
approaches for testing if the internalization of β-dystroglycan is clathrin-
dependent. 
The lack of any co-localization between 1709 and transferrin-568 at any of the 
pulse-chase time points examined suggests that pY890-modified β-dystroglycan 
does not internalize in a clathrin-dependent manner, or traffic via the 
compartments that house the transferrin receptor (Figure 4). These conclusions are 
supported by the lack of any significant co-localization with clathrin heavy chain 
or EEA1 immunostaining (Figures 5 and 7).  These  findings are in direct 
opposition to those of Sotgia et al., (2003a) and may reflect variability between the 
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different cell lines used, artefacts of overexpression or the limited resolution of the 
light microscopy employed in the publication. The data presented here does not use 
transgenic expression of β-dystroglycan tagged with alkaline phosphatise, and is of 
a higher resolution, which together make the conclusions one draws seem more 
favourable. However, one cannot exclude variability between cell lines  and 
consequent alterations in endocytic mechanisms, as is the case for ChTxB 
endocytosis (Shogomori et al., 2001). Ultimately, an analysis of further cell lines 
will be required before any definite conclusions can be made, but from the data 
presented here it seems that pY890-modified β-dystroglycan uses an alternative 
internalization mechanism to that of the transferrin receptor in H2K myoblasts.  
 
5.3.3 β-Dystroglycan and Lipid Raft Endocytosis 
Having tested clathrin-dependent endocytosis, the focus of the work moved to 
clathrin-independent mechanisms. Several endocytic pathways use lipid rafts, as 
determined by a requirement for cholesterol and insensitivity to clathrin -dependent 
endocytic inhibition, and these include caveolar- and flotillin-dependent 
endocytosis (Anderson et al., 1996 ; Nichols et al., 2001 ; Pelkmans et al., 2002 ; 
Kokuba et al., 2003 ; Glebov et al., 2006). ChTxB selectively binds to GM1 
gangliosides that are present in lipid rafts and can be used to follow the 
endocytosis of proteins dependent on these  rafts (Puri et al., 2001; Shogomori et 
al., 2001). Although there is some dispute over how selective this marker is for 
clathrin-independent endocytosis, owing to the variability of the pathways used 
between cell lines and the potential incorporation of lipid rafts into clathrin-coated 
pits (Torgersen et al., 2001 ; Singh et al., 2003 ; Huth et al. 2006), these criticisms 
are equally applicable to alternative markers, such as the fluorescently-tagged 
lactosylceramides (Sharma et al., 2003 ; Marks et al., 2005). These issues could 
represent the passive accumulation of lipid rafts in clathrin-coated pits (Chang et 
al., 1992), or a minor requirement for cholesterol  in clathrin-mediated endocytosis 
(Rodal et al., 1999). Either way, this issue raises the requirement for verification 
of ChTxB staining in experimental systems and so , co-localization with clathrin-
positive vesicles was tested in H2K myoblasts. After 30 or 60 seconds of 
incubation at 37°C, internalized vesicles positive for 594-ChTxB do not co-
localize with clathrin-positive vesicles (Figure 10). This suggests that ChTxB can 
be used as a valid marker for clathrin-independent endocytosis in the H2K 
myoblast cell line, as internalization does not occur within clathrin-coated 
vesicles. 
 
 
 137 
Owing to the labelling of multiple pathways with 594-ChTxB, an examination of 
changes to the visual phenotype of staining was not performed. However, an 
examination of the data presented in Figure 9, as well as the other images 
presented in this chapter, shows a similar pattern to transferrin-568 staining: 
namely a progression from cytosolic to peri -nuclear accumulation. This suggests 
that clathrin-independent endocytosis functions in a typical manner in H2K 
myoblasts, although future work may attempt to verify this by examining the co -
localization with established markers, such as cavin-1 (Hertzog et al., 2012). When 
co-immunostained with 1709, the lipid raft -positive vesicles did not co-localize 
with the β-dystroglycan stain at any of the time points examined. This suggests 
that β-dystroglycan does not internalize or traffic via a pathway using lipid rafts. 
As discussed earlier, whilst there is evidence in the literature suggesting an 
association of β-dystroglycan with components of raft-mediated endocytosis or 
lipid rafts themselves (Song et al., 1996 ; Vega-Moreno et al., 2012), these 
associations are contentious (Crosbie et al., 1998 ; Shah et al., 2006). A possible 
resolution of this argument would be to investigate the presence of pY890-
modified β-dystroglycan in cold Triton-insoluble rafts. However, previous 
experiments from the Winder lab and other groups have indicated that β -
dystroglycan (either native or pY890-modified) is not present in such fractions 
(Steve Winder, personal communication). 
Collectively, both the 594-ChTxB and transferrin-568 experiments may also be 
criticized on the basis of temporal resolution. Although the pulse -chase and 
incubation conditions were used to examine a wide range of time points, there is 
the potential that co-localization between internal, pY890-modified β-dystroglycan 
occurs at time points not studied by this work. Furthermore, the endocytosis of a 
surface protein does not necessarily take a linear route and can switch between 
multiple compartments and pathways, as is the  case for neuropilin 1 (Dang et al., 
2012). Hence it is possible that internalized β -dystroglycan exhibits a transient 
association with the compartments stained by transferrin -568 and 594-ChTxB that 
is not detected with the time points used in this work. Although one can counter 
this argument with the fact that, over a large sample of imaged cells, there is a 
variation in the compartments stained with these pulse -chase markers and hence, 
one would expect to see some co-localization, this may have been below the 
sensitivity of the analysis used, or be simply indiscriminate to the eye.  
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5.3.4 β-Dystroglycan and the Lysosomal Compartment 
Being unable to establish a mechanism of internalization, the work instead 
focussed on the potential importance of monoubiquitylation of pY890-modified β-
dystroglycan (Data Chapter 2). Although this post -translational modification is 
traditionally associated with degradation (Jentsch et al., 1995), there is a growing 
body of evidence that it can direct lysosomal degradation,  as is the case for the 
EGFR (Oved et al., 2006). Given the proposed link between β -dystroglycan 
internalization and degradation as a mechanism for the sarcolemmal loss of the 
protein in the mdx and DMD pathologies, it was of interest to examine the co-
localization with the lysosomal compartment. Two methods of visualizing this 
compartment were available: Lysotracker
TM
-DND-99 staining and transfection 
with fluorescently-tagged lamp1 and sialin. Both of these methods to visualize 
lysosomes have been previously reported in the literature (Pelkmans et al., 2001 ; 
Gotink et al., 2011 ; Dozynkiewicz et al., 2012) , and both were demonstrated to 
give correct staining in H2K myoblasts, on account of the ability to inhibit staining 
with NH4Cl treatment (Figure 11 and Ohkuma et al., 1978), or the high degree of 
co-localization between the two fluorescently-tagged markers (Figure 14). Whilst 
Lysotracker binding is pH-dependent and hence, Lysotracker can stain endocytic 
compartments that are late endosomes, the f luorescently-tagged proteins served as 
positive controls for any co-localization observed.  
As shown in Figures 12 and 13, the immunostaining for pY890-modified β-
dystroglycan did not co-localize with lysosomal staining with either approach. The 
interpretation of these findings is complicated by the fact that the epitope detected 
by 1709 immunostaining may be degraded by the action of the resident proteases 
of the lysosomal compartment (Seglen et al., 1976). Hence, it is not possible to 
conclusively disprove the lysosomal degradation of β-dystroglycan with these data. 
However, lysosomal inhibition could inhibit the internalization of β -dystroglycan, 
which could be visualized with the internalization assay described in Data Chapter 
1. Unfortunately this experiment was not pursued due to time constraints and, 
therefore, it is only possible to form the limited conclusion that pY890 -modified β-
dystroglycan is not targeted to the lysosomal compartment.  
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5.3.5 The Endocytosis of β-dystroglycan in H2K Myoblasts 
Whilst the data presented here does not support any of the proposed hypotheses for 
the internalization of β-dystroglycan, it is possible to discern a more likely 
mechanism from this work. The internalization of β -dystroglycan is unlikely to be 
clathrin-dependent or involve lipid rafts that contain GM1, as chiefly determined 
by transferrin-568 and 594-ChTxB staining respectively. It could however, involve 
one of the less well characterized endocytic mechanisms that also exist (Huth et 
al., 2006). During the writing of this thesis,  preliminary data was reported 
suggesting that β-dystroglycan co-traffics with the low density lipoprotein (LDL) 
receptor (Qi Lu, personal communication). Binding to the LDL receptor enables 
the co-trafficking of the urokinase receptor (Czekay et al., 2001) and one can 
speculate that a similar direct or indirect interaction with the pY890 -modified form 
of β-dystroglycan also mediates internalization. A potential flaw of this hypothesis 
is that the LDL receptor, like the transferrin receptor, is classically thought of as a 
marker of the clathrin-mediated endocytic pathway (Garcia et al., 1996), which 
would be in conflict with the data presented here. However, there is a growing 
body of evidence to suggest that the LDL receptor  also utilizes a non-constitutive 
pathway that is clathrin-, caveolae- and dynamin-independent (Wu et al., 2005 ; 
Sorrentino et al., 2013 ; Scotti et al., 2013). Thus, on the basis of these findings 
and the data presented in this chapter, one can hypothesize that β-dystroglycan 
might co-traffic with the LDL receptor, and this hypothesis can form the basis of 
future work studying the mechanism of β -dystroglycan internalization in H2K 
myoblasts. 
 
5.3.6 Summary 
The data presented in this chapter can be summarized as follows: 
1. pY890-modified β-dystroglycan does not internalize in a clathrin-dependent 
manner, or utilize compartments containing the transferrin receptor during 
subsequent endocytosis. 
2. pY890-modified β-dystroglycan does not internalize with lipid rafts 
containing GM1, or utilize compartments containing this marker during 
subsequent endocytosis. 
3. It is unlikely that pY890-modified β-dystroglycan is targeted to lysosomal 
compartment for degradation. 
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6.1.1 A Model for the Internalization of β-Dystroglycan 
From the data presented in the preceding chapters, several conclusions may be 
drawn. In H2K myoblasts, β-dystroglycan is internalized in response to Y890 
phosphorylation. Without this particular post -translational modification, β-
dystroglycan remains at the plasma membrane. Furthermore, there is a clear 
distinction between the localization of forms of β -dystroglycan with and without 
this modification. The internalization of β -dystroglycan may be linked to other 
phosphorylation events, however these are not solely responsible for the additional 
species detected on western blots of the internalized protein. Whilst it was not 
possible to demonstrate that internalized β -dystroglycan is ubiquitylated, the data 
presented here suggests a link between the processes of Y890 phosphorylation and 
ubiquitylation. Given this link, and that both the ubiquitylated and internalized 
forms of β-dystroglycan have similar electrophoretic mobilities, one can assume 
that ubiquitylation is also linked to internalization. The lead ca ndidate ubiquitin 
E3-ligase for β-dystroglycan, Nedd4L, does not appear to directly bind β -
dystroglycan, despite previous in vitro and screening data suggesting otherwise. It 
remains unresolved whether this ubiquitylation drives endocytic trafficking, or 
permits subsequent polyubiquitylation and degradation. From kinetic, spatial and 
co-localization analysis, one can conclude that the endosomal systems involving 
the transferrin receptor and GM1-positive lipid rafts within H2K myoblasts are not 
atypical, and that labelling of the compartments containing these trafficking 
proteins, as well as the endolysosomal compartment, was possible.  However, 
despite examining a range of time points β -dystroglycan does not internalize or 
traffic with these markers, suggesting that an alternative mechanism of endocytosis 
is used. 
These data, when combined with more established findings, can be summarized 
diagrammatically as the model shown in Figure 1. From an examination of this 
overview, several key criticisms and questions arise , which will be discussed in the 
next section. 
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Figure 1: A model for the internalization of β -dystroglycan and questions that arise 
from this model. From the data presented in this thesis, one can conclude that 
Y890 phosphorylation causes internalization and subsequent ubiquitylation, but the 
mechanism for this process, as well as the involvement of other proteins is unclear.  
All artwork provided as a generous gift by Sarah Palmer.  
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6.1.2 Key Criticisms and Future Directions 
The chief and main criticism of these findings is that they are not supported by 
replicate experiments in other cell lines. Whilst the H2K myoblast system was 
chosen on a basis that it most closely mimics primary myoblasts in vivo (see 
Chapter 1, Section 1.3.1), and could be used to support findings from 
contemporary projects in the Winder lab, it is by no means an exhaustive method 
of investigation in itself. The H2K myoblast system can be criticized as an in vitro 
model, along with other myoblast cell lines, as several components of the DGC are 
not expressed (Sen et al., 2011). Whilst H2K myoblasts do express other 
components and even form the closely related UGC (Thompson et al., 2008), and 
an altered localization of Y890 phosphorylated β -dystroglycan is reported in 
skeletal muscle sections (Sotgia et al., 2003 a), the data presented in this thesis are 
only suggestive of mechanisms present within skeletal muscle. Potential in vitro 
discrepancies can be reduced by testing these hypotheses in either myoblast cell 
lines that express dystrophin, as used in Goyenvalle et al. (2009), or in myotubes: 
myoblasts that have fused and differentiated in vitro and hence, more closely 
resemble mature skeletal muscle tissue (Yaffe et al., 1965). Furthermore, assuming 
that the process of internalization is a key feature of dystrophic pathology, it 
would be beneficial to verify these findings in either mdx or DMD patient 
myoblasts (Morgan et al., 1994). Whilst the findings described here are supported 
by observations from the Y890F/mdx mouse (discussed later), a direct examination 
of this process in skeletal muscle has not been performed. Thus, pursuing these 
options, as well as utilizing other experimental systems that express β -
dystroglycan, would only serve to strengthen any conclusions drawn from the H2K 
myoblast data presented here. 
The data supporting a link between the internalization and ubiquitylation of β -
dystroglycan is suggestive, and is certainly not conclusive. As described in 
Chapter 4 (Section 4.3.2), an experiment was designed to test this hypothesis, 
however this gave no conclusive result. In addition, whether the proposed mono-
ubiquitylation was linked to subsequent poly-ubiquitylation and degradation was 
not ascertained. As previously described, there is a large body of evidence 
suggesting a link between β-dystroglycan internalization and degradation by the 
proteasome (Ohlendieck et al., 1991a ; Kämper et al., 1992 ; Ohlendieck et al., 
1993 ; Sotgia et al., 2001 ; Bonnuccelli et al., 2003 ; Assereto et al., 2005 ; 
Bonnuccelli et al., 2007). A key step in testing the hypothesis that β -dystroglycan 
internalization is linked to proteasomal degradation would involve the detection of 
poly-ubiquitylated forms of the pY890-modified protein. Owing to the transient 
and minimal presence of poly-ubiquitylated protein species within the cell, it is 
possible that further ubiquitylations of β -dystroglycan were below the sensitivity 
of detection. The experiments performed in this thesis did not involve proteasomal 
inhibition, but repeating these experiments in the presence of proteasomal 
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inhibitors, such as velcade or MG-132, may allow the detection of such species. 
Furthermore the veracity of ubiquitylation, as well as an involvement in 
degradation, could also be tested by lysine mutagenesis. Indeed, the site of 
ubiquitylation for β-dystroglycan is not described in this thesis, but data from mass 
spectrometry analyses have positively identified K806 as a site of ubiquitylation 
(Derek Blake, personal communication). In addition to his, K791 and K792 have 
also been identified as potential ubiquitylation sites through proteomic screening 
(Kim et al., 2011). Hence, future work could utilize proteasomal inhibition and 
mutagenesis of these sites to test the involvement of ubiquitylation in the 
internalization of β-dystroglycan further. 
Currently, the endocytic route or method of internalization for Y890-
phosphorylated β-dystroglycan is unknown, although this work permits the 
exclusion of several possible pathways. It is unlikely that clathrin -dependent 
internalization occurs, and the lack of co-localization with the transferrin receptor 
at later time points suggests that compartments of this pathway, such as EEA1-
positive early endosomes, do not house internalized β-dystroglycan (Mu et al., 
1995 ; Rubino et al., 2000). Similarly, the lack of co -localization with GM1-
positive rafts suggests that β-dystroglycan does not internalize via a caveolar - or 
flotillin-dependent mechanism and does not traffic via the caveosome or golgi 
compartments (Volonte et al., 1999 ; Nichols et al., 2001 ; Puri et al., 2001 ; 
Glebov et al., 2006 ; Huth et al., 2006 ; Hernandez-Deviez et al., 2007). Given the 
reported interaction of Y890-phosphorylated β-dystroglycan with caveolin-3 
(Illsey et al., 2002), or the reported co-localization with the transferrin receptor 
(Sotgia et al., 2003a), one might expect β-dystroglycan trafficking in H2K 
myoblasts to occur via the mechanisms mentioned above. However, the differences 
reported here may reflect variation between experimental systems: whilst 
expression of caveolin-3 in primary myoblasts has been demonstrated (Parton et 
al., 1997), other myoblast cell lines do not express this protein unti l after 
differentiation, although the functionally equivalent caveolin -1 is expressed during 
proliferation (Song et al. 1996). The expression of either caveolin -1 or caveolin-3 
in H2K myoblasts is not examined in this thesis. Hence, the establishment of 
whether either of these proteins is expressed, as well as components of other 
endocytic pathways, would be of benefit to future studies. Furthermore, 
demonstrating an interaction, by co-immunoprecipitation for example, between 
specific components of endocytic pathways and Y890-phosphorylated β-
dystroglycan may provide a better basis for subsequent microscopic investigation.  
In addition, there are still alternative compartments which could contain 
internalized β-dystroglycan that were not examined in this study. For example, the 
alternative early endosomal compartment defined by APPL1 (Zoncu et al., 2009), 
or later compartments defined by the mannose-6-phosphate receptor (Trischler et 
al., 1999 ; Piper et al., 2001), may house internalized β-dystroglycan. Similarly, 
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endocytic trafficking may occur by alternative raft -mediated pathways that do not 
contain GM1 and thus, are not visualized by 594-ChTxB staining (Nichols et al., 
2001 ; Puri et al., 2001). To address this, one could perform similar pulse -chase 
experiments with alternative markers of raft -mediated endocytosis, such as 
fluorophore-conjugated lactosylceramide (Singh et al., 2003 ; Marks et al., 2005), 
and test for co-localization with Y890-phosphorylated β-dystroglycan. 
Furthermore, the internalization and trafficking of β-dystroglycan may not be 
initiated by the protein alone, but occur together with other proteins , or as part of a 
larger process. As described earlier (Chapter 5, Section 5.3.5), co -trafficking with 
the LDL receptor via a clathrin-, caveolin- and dynamin-independent mechanism 
would fit with the data presented in this thesis, and is a possible avenue of future 
investigation (Qi Lu, personal communication). Finally, the internalization of β -
dystroglycan may be part of a larger, macropinocytic mechanism. In support of this 
β-dystroglycan has been detected in membrane ruffles, where it is proposed to 
functionally interact with dynamin and ERK (Spence et al., 2004 ; Zhan et al., 
2005). In these instances β-dystroglycan trafficking may not have a strict pathway 
dependence and this possibility is worth considering in future investigations of the 
mechanism of internalization. 
The model is also hampered by the lack of a definite kinase responsible for the 
phosphorylation of Y890. Many phosphorylation  pathways are altered in the 
dystrophic state (Batchelor et al., 2006 ; Peter et al., 2006 ; Sen et al., 2011), 
possibly as a consequence rather than a cause of the loss of sarcolemmal β -
dystroglycan, which is proposed to act as signaling scaffold (Oak et al., 2003 ; 
Spence et al., 2004 ; Batchelor et al., 2006 ; Thompson et al., 2008). Thus, it is not 
possible to elucidate a candidate kinase from an examination of the state in which 
β-dystroglycan is lost from the sarcolemma (Ohlendieck et al., 1991 a ; Ohlendieck 
et al., 1993). Alternative approaches identifying kinases linked to β -dystroglycan 
phosphorylation also fail to identify a single, likely candidate.  Whilst 
phosphorylation downstream of c-Src activation is evident from a number of 
studies and is suggestively associated with β-dystroglycan internalization (Sotgia 
et al., 2001 ; Sotgia et al., 2003 a ; Thompson et al., 2010), there is no evidence to 
suggest a single effector of the Src family kinases, or a downstream target thereof, 
as being responsible for Y890 phosphorylation.  The identification of the kinase 
responsible for β-dystroglycan internalization would not only serve to expand and 
verify the model presented here, but would provide a basis for future therapeutic 
intervention in dystrophic pathology and as such, is an important focus of future 
work. 
A question arising from this model is whether β -dystroglycan co-traffics with other 
proteins normally associated with complexes containing dystroglycan. As 
described earlier, β-dystroglycan is seldom observed in isolation; it is only through 
a myriad of associated and interacting proteins that this protein exerts a biological 
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function (see Chapter 1, Sections 1.1.3 and 1.1.4). Furthermore, these components 
are held together by various intermolecular contacts, and are lost together from the 
sarcolemma in various dystrophies (see Chapter 1, Sections 1.2.1 to 1.2.4). 
Admittedly, one can postulate that the regulation and internalization of each of 
these components is separate and that the loss of these components from the 
sarcolemma in dystrophic pathology may occur in a sequential nature. In support 
of this, the levels of α- and β-dystroglycan present at the surface membrane in 
cancer tissue and cell lines are not always correlative, which suggests post -
translational regulation of these two proteins by separate mechanisms. However, 
one cannot dismiss the possibility that components of the dystroglycan complexes 
are co-trafficking with β-dystroglycan, and this hypothesis should therefore be 
addressed.  
It is conceivable that complex components and transiently associated proteins, 
such as α-dystrobrevin-3, sarcospan, Grb2 and the syntrophins, could specify a 
membrane microdomain around internalized β -dystroglycan, with signaling 
functions separate to those suggested at the surface membrane. In the study of 
other surface receptors that undergo endocytic regulation, these internal 
microdomains are referred to as signalosomes and are an expanding field of cell 
biology. For example, the neurokinin 1 receptor initiates endosomal signaling from 
a microdomain defined by β-arrestin and substance P (Pelayo et al., 2011). From 
the work presented in this thesis it would be easy to extend the experiments and 
test this hypothesis, for example by co-immunoprecipitation or immunofluorescent 
co-localization of these complex components with 1709  staining. Furthermore, 
proteins that traffic with β-dystroglycan may control the endocytic route of this 
protein and an understanding of how these proteins function in this regard may 
provide new insights into the pathology of muscular dystrophies.  
In a similar vein, one also can not dismiss the importance of scaffolding proteins, 
which are specifically recruited to the Y890-phosphorylated form of β-
dystroglycan, in extending the current model. For example, the data presented in 
Chapter 4 did not demonstrate a direct interaction between β-dystroglycan and the 
candidate E3-ubiquitin ligase, Nedd4L. However, the data presented does not 
disprove the hypothesis that Y890-phosphorylated β-dystroglycan indirectly 
interacts with this ligase through an additional binding partner, as is proposed for 
other atypical β-dystroglycan complexes: the β-dystroglycan-Grb2-dynamin 
complex (Zhan et al., 2005), and the β-dystroglycan-ezrin-Cdc42 complex 
(Higginson et al., 2008). The phosphorylation of Y890 generates an SH2 (Src 
Homology 2) domain binding site (Russel et al. 1992) and indeed, the SH2 domain 
of c-Src has been demonstrated to bind this motif in vitro and in vivo (Sotgia et al., 
2001). Whilst it is possible to view Y890 phosphorylation as key in the mechanism 
of internalization of β-dystroglycan, owing to the lack of internalized, 
unphosphorylated protein, Y890 phosphorylation may just act as an initiator for 
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the process. In this model, “free” cytoplasmic tails of β-dystroglycan are tagged 
for internalization by Y890 phosphorylation, but it is only the subsequent 
recruitment of scaffolding proteins and kinases, potentially through SH2 
interactions, that initiates the endocytic process.  This idea is significant in the 
interpretation of the data presented in this thesis, as one can only draw a 
correlative link between the processes of Y890 phosphorylation and 
internalization; although all internalized β-dystroglycan is phosphorylated on 
Y890, phosphorylation of Y890 does not necessarily cause internalization. Hence, 
future work should also establish the importance of additional binding factors in 
the internalization of β-dystroglycan. 
 
6.1.3 β-Dystroglycan Internalization and Nuclear 
Translocation  
Although not addressed in this thesis until now, any model dealing with the 
internalization of β-dystroglycan has to take into account a recently identified 
phenomenon: the translocation of β-dystroglycan to the nucleus. Evidence for this 
process is still emerging, but from an examination of various systems a common 
mechanism can be suggested. β-dystroglycan has been observed in the nucleus of 
LnCaP (Mitchell et al., 2013), HeLa (Fuentes-Mara et al., 2006), Hepa-1, A549 
(Lara-Chacón et al., 2010) and C2C12 cells (Martinez-Vieyra et al., 2013). The 
exact function of β-dystroglycan in this sub-cellular context is unknown, however 
nuclear translocation has been proposed to be under cell cycle control (Grinu 
Mathew, PhD Thesis, Sheffield 2011). In support of this, the modulation of β -
dystroglycan levels alters cell cycle progression (Sgambato et al., 2004 ; Sgambato 
et al., 2006) and alters the stability of nuclear components, such as lamin B1, 
which has a role in the organization of the nuclear organelle (Martinez-Vieyra et 
al., 2013). Furthermore, the presence of β -dystroglycan within the nucleus alters 
the expression of several genes, as determined by microarray analysis (Grinu 
Mathew, PhD Thesis, 2011). Thus, although how β-dystroglycan functions within 
the nucleus is unknown, that some nuclear function is exerted by the presence of 
the protein in this organelle is almost certain.  
The translocation of β-dystroglycan to the nucleus is dependent on a nuclear 
localization sequence (NLS) between residues 776-782 (see Chapter 1, Figure 1) 
and is independent of α-dystroglycan (Oppizzi et al., 2008 ; Lara-Chacón et al., 
2010 ; Mitchell et al., 2013). Entry occurs via the nuclear pore complex and 
involves α- and β-importin (Lara-Chacón et al., 2010). It is conceivable that import 
into the nucleus occurs after tyrosine phosphorylation and internalization from the 
membrane and indeed, treatment with orthovanadate has been shown to increase 
the levels of β-dystroglycan within the nucleus (Lara-Chacón et al., 2010). 
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However, Y890F mutagenesis promotes nuclear accumulati on of β-dystroglycan 
(Lara-Chacón et al., 2010). This observation would appear to be in direct 
opposition to the hypothesis that internalization is dependent on phosphorylation 
of this residue, as nuclear localization must occur downstream of loss from the 
surface membrane. This finding, however, is not without several important caveats.  
Lara-Chacón et al. (2010) report that the Y890F mutant is expressed within an 
artificial construct containing the cytoplasmic domain of β -dystroglycan fused to a 
c-terminal GFP tag. One would assume that such a construct, which lacks the 
transmembrane and ecto domains of β-dystroglycan, would not be anchored to the 
surface membrane to begin with and hence, according to the model presented in 
this thesis, Y890 phosphorylation is not required for internalization. Furthermore, 
assuming that this construct is localized at the surface membrane by binding to 
other proteins, the presence of the c-terminal GFP tag could impair any 
dependence on Y890 phosphorylation for internalization. Indeed, biotinylation 
experiments performed with c-terminally GFP-tagged Y890E and Y890F 
constructs in H2K myoblasts support this idea, as the internalization of β-
dystroglycan appears to occur constitutively in the presence of this tag (Data not 
shown and Steve Winder, personal communication). However, there still remains a 
discrepancy in the data presented in Lara-Chacón et al. (2010): if orthovanadate 
treatment (and presumably Y890 phosphorylation) increases nuclear accumulation, 
why would Y890F mutagenesis also enhance this?  
With the data presented in this thesis it is possible to propose an answer to this 
question and, more importantly, arrive at a model which links the processes of 
internalization from the surface membrane and nuclear translocation. The nuclear 
translocation of β-dystroglycan appears to be a dynamic process (Oppizzi et al., 
2008), and, at steady-state conditions, a split distribution of cytoplasmic and 
nuclear protein is always observed (Lara-Chacón et al., 2010 ; Mitchell et al., 2013 
; Martinez-Vieyra et al., 2013 ; Grinu Mathew, personal communication). In 
contrast, Y890F mutagenesis appears to cause a single localization of β -
dystroglycan to the nucleus, with no protein in the cytoplasm (Lara-Chacón et al., 
2010). This localization would suggest that either a factor responsible for nuclear 
export, or a factor promoting cytoplasmic retention, is lost. The data presented in 
Data Chapter 2 suggests that the ubiquitylation of β-dystroglycan is exclusively 
linked to Y890 phosphorylation, thus one could hypothesize that a Y890F mutant 
would not be ubiquitylated. As discussed previously, the monoubiquitylation of β-
dystroglycan may control the nuclear localization of the protein, especially if this 
modification occurs within or near an NLS (Li et al., 2003 ; Yurchenko et al., 2006 
; Chen et al., 2009 ; Cai et al., 2010 ; Wang et al., 2012). This is possible as 
ubiquitylation has been proposed to occur at K806, which is near the NLS 
(residues 776-782) (Derek Blake, personal communication).  
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The modified model would then occur as follows: β-dystroglycan is internalized 
from the surface membrane following Y890 phosphorylation and is subsequently 
sorted for nuclear transport, degradation or subsequent trafficking by 
ubiquitylation. It is interesting to note that the reports of endogenous β -
dystroglycan in the nucleus mostly involve the use of antibodies raised against the 
unphosphorylated, Y890 epitope, suggesting that Y890 phosphorylation is 
dispensable for nuclear localization. In this instance, one can then predict that the 
kinase responsible for Y890 phosphorylation and the initiation of this process is 
localized exclusively to the cytoplasm; this prediction serves a s a means to identify 
candidate kinases for Y890 phosphorylation, and is an important test of the model 
described. However, the model is not without an important caveat, which should be 
considered.  
As mentioned earlier, orthovanadate treatment increases the levels of nuclear β-
dystroglycan in HeLa cells, which would suggest that ubiquitylation is not 
important for cytoplasmic retention (Lara-Chacón et al., 2010). However, the 
increase in levels of nuclear protein does not occur with a concomitant reductio n in 
the levels of cytoplasmic protein (Lara-Chacón et al., 2010). In this instance one 
can then suggest that the global level of internalized β -dystroglycan is increased by 
orthovanadate treatment, but the extent of ubiquitylation is unaltered and the 
excess internalized protein is localized to the nuclear compartment, appearing as 
an increase in nuclear accumulation in the steady state. This suggestion relies on 
the assumption that global levels of ubiquitin and the activity of the E3 -ubiquitin 
ligase that targets β-dystroglycan are unaltered by orthovanadate treatment, but 
this assumption can be tested by future investigation using this model.  
Nonetheless, an examination of the related field of nuclear β -dystroglycan prompts 
an extension of the model presented in this thesis, as well as instigating the basis 
of future investigation. In light of the predictions outlined above, it is equally 
possible that the mechanisms governing nuclear trafficking are entirely separate 
from the findings presented here. Indeed, whilst the establishment of nuclear β -
dystroglycan in C2C12 myoblasts (Lara-Chacón et al., 2010 ; Martinez-Vieyra et 
al., 2013) suggests that this process also occurs in H2K myoblasts, there is no 
conclusive data to confirm this. The high levels of perinuclear β-dystroglycan 
immunoreactivity observed with epifluorescence microscopy ( see Chapter 5) may 
be linked to nuclear import in the H2K myoblast system, but this could equally 
represent localization in a late endosomal compartment, as discussed prev iously. 
Furthermore, the in vivo relevance of this process is, as of yet, unresolved.  
 
 
 
 150 
6.2.1 The in vivo Relevance of Y890 Phosphorylation  
As mentioned earlier, the findings presented in this thesis are not directly 
supported by equivalent experiment performed in vivo, or even in an ex vivo 
system, such as isolated muscle fibres, yet several inferences can be drawn from 
the associated study of the β-dystroglycan Y890F knock-in mouse (Miller et al., 
2012). The Y890F knock-in mouse displays no overt phenotype and, excepting the 
absence of any Y890-phosphorylated β-dystroglycan, is indistinguishable from 
control littermates. Homozygous Y890F mice were crossed with mdx mice to 
obtain Dag1
Y890F/Y890F
:mdx mice. As Y890 phosphorylation causes the loss of β -
dystroglycan from the surface membrane, and DMD pathology is characterized by 
the loss of β-dystroglycan from the sarcolemma (Ohlendieck et al., 1993), a 
phospho-null form of β-dystroglycan should be retained at the sarcolemma and, 
through the formation of alternative adhesion complexes, such as the UGC, be able 
to ameliorate dystrophic pathology. Findings from Dag1
Y890F/Y890F
:mdx mice 
suggest that this is the case as parameters of muscle of histopathology are reduced, 
relative to mdx mice, and components of the DGC, including α-sarcoglycan and 
sarcospan, are restored to the sarcolemma (Miller et al., 2012). Furthermore, 
physiological parameters, specifically the force drop in response to eccentric 
contractions, are improved in Dag1
Y890F/Y890F
:mdx mice and the increased levels of 
sarcolemmal plectin 1f, an alternative cytoskeletal protein that binds β -
dystroglycan (Rezniczek et al., 2007), suggest that the formation of alternative 
adhesion complexes is critical in this process.  
From these data one can infer that the internalization in response to Y890 
phosphorylation described in H2K myoblasts is also a process present in vivo in 
skeletal muscle fibres and is an important step in the pathology of DMD. The key 
nature of this process is evidenced by the fact that all developing therapies for 
muscular dystrophy to date, which cause a restoration of β -dystroglycan to the 
sarcolemma, involve the blockade of Y890 phosphorylation. Whilst the route of 
administration or mechanism of action varies, these therapies commonly involve 
the expression of a protein containing a domain which binds to and prevents the 
phosphorylation of Y890. These therapies include: transgenic expression of 
utrophin or dystrophin (Cox et al., 1993 ; Phelps et al., 1995 ; Rafael et al., 1998), 
adenoviral delivery of truncated utrophin or dystrophin genes (Gilbert et al., 1998 ; 
Wang et al., 2000 ; Wakefield et al., 2000), induction of utrophin overexpression 
by trophic factors (Krag et al., 2004), small molecules (Tinsley et al., 2011) or 
artificial transcription factors (Onori et al., 2013), and skipping or directed 
splicing of mutated exons (Goyenvalle et al., 2004 ; Aartsma -Rus et al., 2004a).  
Before, this was presumed to be due to a scaffolding effect: that bindin g localized 
β-dystroglycan to the surface membrane but, in light of the data presented in this 
thesis, one can now propose that the blockade of Y890 phosphorylation drives 
membranous localization. Furthermore, the deletion of the very c-terminus of 
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dystrophin, the region after the β-dystroglycan binding region, produces no 
obvious histological or physiological defects in mice (Rafael et al., 1994).  
Conversely, small lesions in the β-dystroglycan binding domain almost always 
cause DMD (Aartsma-Rus et al., 2006). Thus, together these data suggest that 
prevention of Y890 phosphorylation, in these examples by steric protection within 
a binding domain, is critical in DMD pathology and support the in vivo relevance 
of Y890 phosphorylation in this process. 
However, one cannot only stress the importance of the Y890 phosphorylation of β -
dystroglycan in dystrophic pathology. Transgenic overexpression of dystrophin 
isoforms that include the β-dystroglycan binding region, which omit the N-
terminal actin binding domain, on the mdx background worsen dystrophic 
pathology (Cox et al., 1994 ; Judge et al., 2006). Similarly, genetic lesions within 
the actin binding domain of dystrophin present as DMD in patients (Beggs et al., 
1991 ; Corrado et al., 1996 ; Aartsma-Rus et al., 2006), indicating the importance 
of not only Y890 phosphorylation and β -dystroglycan loss, but the mechanical link 
mediated by dystroglycan complexes within muscle fibres. In addition to this, one 
only has to examine the wide range of developing therapies that do not involve a 
restoration of β-dystroglycan to the sarcolemma to understand the importance of 
other mechanisms in dystrophic pathology.  
For example, alterations in the calcium handling of dystrophic muscle fibres has 
been demonstrated, and these are proposed to result in enhance proteolysis 
(Kämper et al., 1992 ; Spencer et al., 1995; Dowling et al., 2003), and the 
inhibition of calcium-dependent proteases, blockade of calcium channels, or 
transgenic expression of proteins involved in calcium regulation have been 
demonstrated to ameliorate dystrophic pathology (Kämper et al., 1992 ; 
Badalamente et al., 2000 ; Goonaserka et al., 2011). In addition, in dystrophic 
pathology one must also consider the importance of: altered iNOS and nNOS 
activity and signaling (Louboutin et al., 2001 ; Wehling et al., 2001 ; Ito et al., 
2013b ; Ramachandran et al., 2013), tissue fibrosis (Ito et al., 2013 a), changes to 
the stem cell niche and impaired regeneration (Mendell et al., 1995 ; Nguyen et al., 
2002 ; Griffin et al., 2009 ; Beffy et al., 2010; Boldrin et al., 2012 ; Lin et al., 
2013), growth factor signaling and muscle differentiation (Maltzahn et al., 2012 ; 
Mikami et al., 2012), Akt signaling and the hypertrophic response (Peter et al., 
2006 ; Peter et al., 2009 ; Marshall et al., 2012a), NF-κB activation and the 
inflammatory response (Louboutin et al., 2001 ; Bonnuccelli et al., 2007), the 
stabilization of the DGC by components of the ECM (Amenta et al., 2011), 
sphingosine-1-phosphate signaling (Pantoja et al., 2013), integrin regulation and 
signaling (Burkin et al., 2001 ; Liu et al., 2011 ; Sen et al., 2011) and matrix 
metalloproteinase cleavage of β-dystroglycan (Matsumara et al., 2005 ; Michaluk 
et al., 2007 ; Delfin et al., 2011 ; Taniquiti et al., 2012).  
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Arguably, this long list of additional mechanisms within dystrophic pathology is a 
consequence of the loss of β-dystroglycan and the DGC from the sarcolemma. 
Microlesions in the sarcolemma, due to impaired sarcolemmal integrity in the 
absence of the DGC, are proposed to be responsible for altered calcium 
homeostasis and NOS signaling, which lead to necrosis and the hypertrophic 
response (Collet et al., 1999 ; Batchelor et al., 2006 ; Tinsley et al., 2011 ; Ito et 
al., 2013b). These responses could then lead to the impaired regeneration, 
exhaustion of the stem cell niche and fibrosis observed in dystrophic muscle tissue 
(Coulton et al., 1988 ; Mendell et al., 1995). Furthermore, one would expect to see 
large changes in cellular signaling in the absence of β -dystroglycan, which acts as 
a scaffold for various signaling proteins, and indeed this is the case (Oak et al., 
2003 ; Spence et al., 2004 ; Peter et al., 2006 ; Thompson et al., 2008 ; Sen et al., 
2011). However, if the loss of β-dystroglycan from the sarcolemma were of such 
importance, why does the blockade of Y890 phosphorylation not fully prevent all 
dystrophic pathology? In the case of gene or molecular therapy trials one might 
cite the age at which a therapy is administered and an inability to prevent 
pathological changes that have occurred during development (McDonald et al., 
2010 ; Cirak et al., 2011; Goemans et al., 2011 ; Malerba et al., 2011). Yet, to 
return to the Y890F knock-in mouse data, if this is true why does the blockade of 
Y890 phosphorylation from the embryonic stages of development not fully cure the 
relatively mild mdx pathology (Miller et al., 2012)? 
 
6.2.2 Towards a Cure for Duchenne Muscular Dystrophy  
The answer to this question is found upon re -examination of the complexes that 
involve β-dystroglycan in skeletal muscle tissue (see Chapter 1, Sections 1.13 and 
1.1.4). In the mdx state Y890F β-dystroglycan is localized to the sarcolemma, 
where it presumably binds the alternative cytoskeletal linker protein plectin 1f 
(Rezniczek et al., 2007 ; Miller et al., 2012). Although plectin 1f binds to actin 
filaments and functionally substitutes dystrophin in mechanical linkage, it does not 
recruit the same accessory proteins that are associated with the DGC. In this 
regard, even the closely homologous protein utrophin does not fully recapitulate 
the functional capacity of dystrophin, as evidenced by the inability to fully cure 
dystrophic pathology with transgenic utrophin overexpression (Rafael et al., 1998). 
Specifically, this could be due to the absence of the nNOS binding site within the 
rod domain of utrophin, which is present in dystrophin (Lai et al., 2009 ; Lai et al., 
2013). Thus, even the replacement of all lost DGCs with UGCs in the dystrophic 
state cannot elicit a full cure. In a similar vein, a DMD patient has been reported 
with a small deletion encompassing the syntrophin binding region of dystrophin 
(exons 72-73), which does not generate a premature stop (Suzuki et al. 1995 ; 
Béroud et al., 2007). As described previously, dystrophin contains various regions 
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that bind accessory proteins, namely the syntrophins and α -dystrobrevins, and 
these in turn recruit adaptors (Grb2  - Oak et al., 2001), channels (SkM1 and 2 – 
Gee et al., 1998), kinases (MAST and SAST – Lumeng et al., 1999) and can even 
control the stoichiometry of the complex (Newey et al., 2000 a). So, blocking Y890 
phosphorylation of β-dystroglycan will not cure DMD or the mdx model, as it does 
not restore all the full DGC. 
Hence, it is unsurprising that to date there is no cure for DMD, as each form of 
therapy carries similar caveats. Returning to gene therapy with truncated utrophins, 
which share a common strategy with the Y890F knock-in mutation, a complete 
amelioration of dystrophic pathology does not occur even with high levels of 
expression (Phelps et al., 1995 ; Wakefield et al., 2000 ; Gregorovic et al., 2006). 
One of the reasons for this is that these proteins do not scaffold the other 
components of the DGC. Therapeutic approaches which generate the re-expression 
of fully functional dystrophin, excepting a minor lesion, such as exon skipping and 
snRNA spliceosome targeting, are not applicable to all DMD patients, and at best 
can only produce a BMD or XDLC phenotype (Béroud et al., 2007). Furthermore, 
exon skipping efficiencies estimated in vitro are not the same as those observed in 
vivo (Aartsma-Rus et al., 2004a ; Aartsma-Rus et al., 2004b ;  Mitrpant et al., 2009 
; Popplewell et al., 2010 ; Kayali et al., 2012). Similarly, the design of small 
molecules or artificial transcription factors is flawed by an incomplete knowledge 
of the factors governing in vivo specificity (Choo et al., 1997 ; Corbi et al., 2000 ; 
Chancellor et al., 2011 ; Tinsley et al., 2011 ; Onori et al., 2013). Therapies are 
also hindered by the route of delivery: for example the delivery of mini  genes 
encapsulated within gutted adenoviral vectors or antisense oligonucleotides only 
transduces fibres near the site of injection (Goyenvalle et al., 2004 ; van Deutekom 
et al., 2007). Whilst the systemic delivery of antisense oligonucleotides is possible 
(Cirak et al., 2011), the efficacy of this route of administration is hard to predict 
(Yin et al., 2010b). 
In spite of these complications and difficulties, one can see evidence for the 
progression towards a functional cure for DMD. The delivery of genes or 
oligonucleotides has been enhanced by conjugation to cell penetrating peptides, 
which permit the specific targeting of skeletal muscle tissue with systemic delivery 
(Yin et al., 2008 ; Yin et al., 2009 ; Goyenvalle et al., 2010 ; Yin et al., 2010a). 
Phage screening and testing within mdx mice, can be used to develop novel 
peptides, with a higher efficacy and specificity (Seow et al., 2010). Furthermore, 
the difficulties with adenoviral vector delivery can be  overcome by selecting 
vectors with a higher tropism for skeletal muscle tissue (Goyenvalle et al., 2012). 
Indeed, the development of exon splicing therapy underscores how knowledge 
from other fields of biology can be used to augment and improve existing t herapies 
(Goyenvalle et al., 2004 ; Goyenvalle et al., 2009 ; Goyenvalle et al., 2012). Dual 
therapy trials, exemplified by the combination of myostatin and micro -utrophin 
 154 
delivery, also highlight the potential of combinatorial therapy (Sonnemann et al., 
2009). Thus, whilst no therapy alone is fully curative, one can envisage how 
combined approaches, or the exchange of knowledge from similar fields, can 
improve therapies so that they accomplish this goal. In this light, one can fully 
evaluate the importance of the Y890F:mdx trial and also the importance of Y890 
phosphorylation and the internalization of β -dystroglycan. 
Although not curative, blocking Y890 phosphorylation and restoring β -
dystroglycan to the sarcolemma does ameliorate dystrophic pathology (Miller et 
al., 2012). Assuming that this effect is caused by blocking the internalization of β -
dystroglycan, as is observed in H2K myoblasts, then this knowledge provides the 
basis for alternative therapies. For example, inhibiting the kinase responsible for 
the phosphorylation of Y890 in dystrophic patients would extend the lifetime of β -
dystroglycan at the sarcolemma, and one would predict this to enhance the 
effectiveness of other therapies. In addition, one could use small peptides which 
bind both the c-terminus of β-dystroglycan and dystrophin/utrophin/plectin 1f to 
block Y890 phosphorylation and maintain a mechanical  link, in a manner similar 
to mini-agrin therapy (Moll et al., 2001). The synergy of combinatorial approaches 
has been used in other research fields, such as HIV treatment, to elicit better 
therapies and one would also expect this to be the case for DMD. Hence, any 
knowledge of the mechanism controlling sarcolemmal β -dystroglycan loss in 
dystrophic pathology can be utilized, in combination with other existing therapies, 
to provide better, or even full, cures for patients.  
One criticism stands between this rose-tinted view of the future and reality and 
that is the heterogeneity of muscular dystrophies and genetic diseases in general. 
Studies of BMD patients with the same genetic lesion, but differing phenotypes, 
indicate the importance of the level of expression as well as the type of mutation 
of the DMD gene in dystrophic pathology (Corrado et al., 1996). Indeed, even 
within the genetic proximity of a family, one observes differences in the phenotype 
of muscular dystrophy presented by the same causative muta tion (McNally et al., 
1996 ; Melis et al., 1998 ; Aartsma-Rus et al., 2006). This genetic variation and the 
importance of other, unknown factors in dystrophic pathology may explain the 
variability of treatment efficacy in clinical trials for DMD (Cirak et al., 2011). 
Exome analyses have been used to identify additional genetic variants that may 
cause the differences in disease severity observed between consanguineous patients 
(McDonald et al., 2012), but how these variations effect disease is currently 
unknown. From the data presented in this thesis, one could predict that the activity 
of the kinase that phosphorylates Y890 may influence the severity of BMD and 
DMD, yet as of writing, the identity of this kinase is unknown. Thus, these 
findings only underscore the current limitation of knowledge regarding the 
processes involved in dystrophic pathology. Can a full cure for every DMD patient 
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be realized before the importance of every factor in dystrophic pathology is 
understood? 
Hence, understanding the cellular biology of proteins such as β-dystroglycan, 
which have a key role in the formation of the DGC, is of paramount importance. 
To return to the model presented earlier, there are still many questions that remain 
unanswered concerning the mechanism of sarcolemmal β-dystroglycan loss. 
However, the research presented in this thesis provides a basis for future study and 
highlights the specific importance of Y890 phosphorylation in other processes, 
such as ubiquitylation. It is through research of this kind that t he importance of 
other factors in dystrophic pathology can be addressed and hence, a full cure for 
DMD may be developed. Thus, future research into the mechanisms controlling β -
dystroglycan, as well as being of scientific interest, is of benefit to the fut ure of 
mankind, and is justified in both regards. 
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